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1 ABSTRACT 
1.1 Zusammenfassung 
Das Ziel der vorliegenden Arbeit ist die Entwicklung bi-spezifischer DNA Aptamere, die den 
auf Tumorzellen überexprimierten Tyrosinkinase-Rezeptor c-Met sowie den auf Natürlichen 
Killerzellen exprimierten Fcγ-Rezeptor IIIα (CD16α) gleichzeitig binden und dadurch eine 
spezifische Lyse von diesen Tumorzellen vermitteln sollen. Vergleichbare Antikörper-
vermittelte zelluläre Zytotoxizität (antibody-dependent cellular cytotoxicity, ADCC) stellt 
einen Wirkungsmechanismus Antiköper-basierter Tumortherapien dar. An Tumorzellen 
gebundene therapeutische Antikörper rekrutieren dabei Natürliche Killerzellen, die eine Lyse 
der Krebszellen auslösen. Vorteile von Aptameren im Vergleich zu therapeutischen 
monoklonalen Antikörpern können eine einfache Selektion, kostengünstige und uniforme 
Synthese sowie geringe oder keine Immunogenität sein.  
 
Es wurden CD16α spezifische DNA Aptamere mittels SELEX (systematic evolution of 
ligands by exponential enrichment) isoliert, die spezifisch und mit hoher Affinität (6 –
 195 nM) an rekombinantes und auf Natürlichen Killerzellen exprimiertes CD16α banden. 
Selektierte c-Met spezifische DNA Aptamere zeigten ebenfalls hohe Spezifität und Affinität 
(91 pM und 11 nM) zu rekombinantem und zellulär präsentiertem Zielprotein. Je zwei 
optimierte CD16α und c-Met spezifische Aptamere wurden mit Linkern unterschiedlicher 
Zusammensetzungen und Längen in 24 Varianten verknüpft. Die Erhaltung der 
ursprünglichen Bindungseigenschaften und eine gleichzeitige Bindung an beide Zielproteine 
konnte in biochemischen Assays belegt werden. Fünf bi-spezifische Aptamere vermittelten 
zelluläre Zytotoxizität, die abhängig von der Aptamerkonzentration und der Menge an 
Effektorzellen war. Verdrängung eines bi-spezifischen Aptamers durch den die CD16α-
Bindung kompetierenden Antikörper 3G8 führte zum Rückgang der Aptamer-vermittelten 
Zelllyse und bestätigte damit den postulierten Wirkmechanismus. Ein bi-spezifisches 
Aptamer vermittelte Lyse von humanen GTL-16 Magen- und EBC-1 Lungen-Tumorzellen.  
 
Die vorliegenden Ergebnisse zeigen zum ersten Mal die Erzeugung einer zusätzlichen 
Effektorfunktion durch Verknüpfung zweier unterschiedlicher Aptamere. Durch Austausch 
des Tumor-spezifischen Aptamers könnte dieses Konzept einfach und schnell zur Therapie 
von unterschiedlichen Tumoren verwendet werden. 
ABSTRACT 
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1.2 Abstract 
The aim of the work presented herein is the development of bi-specific DNA aptamers 
simultaneously binding to tumour cell overexpressed receptor tyrosine kinase c-Met and Fcγ 
receptor IIIα (CD16α) on Natural Killer (NK) cells to mediate specific tumour cell lysis. 
Comparable antibody-dependent cellular cytotoxicity (ADCC) plays a pivotal role in 
antibody-based tumour therapies. Tumour-bound therapeutic antibodies recruit Natural Killer 
cells via their Fc receptors and induce specific lysis of tumour cells. In comparison to 
therapeutic monoclonal antibodies, potential advantages of aptamers are a facile selection, 
cost-effective and uniform synthesis as well as no to low immunogenicity.  
 
CD16α specific DNA aptamers were isolated by SELEX (systematic evolution of ligands by 
exponential enrichment) that bound with both high specificity and affinity (6 – 195 nM) to 
recombinant and NK cell expressed CD16α. Selected c-Met specific DNA aptamers showed 
high affinity (91 pM and 11 nM) and specificity to recombinant and cellular presented target 
protein as well. Two aptamers of each selection were optimised and coupled applying linkers 
of varying compositions and lengths to yield 24 constructs. Bi-specific aptamers that retained 
suitable binding properties and displayed simultaneous binding were applied in functional 
ADCC assays. Five bi-specific aptamers mediated cellular cytotoxicity dependent on aptamer- 
and effector cell concentration. Displacement of a bi-specific aptamer from CD16α by the 
competing antibody 3G8 reduced aptamer-dependent cytotoxicity and hence confirmed the 
proposed mode of action. A bi-specific aptamer mediated specific lysis of human gastric and 
lung tumour cells, GTL-16 and EBC-1, respectively. 
 
These results represent the first gain of an effector function by coupling of two distinct 
aptamers to generate an anti-tumour effective molecule. A facile exchange of the tumour-
specific aptamer to target other surface tumour markers could broaden the concept of 
aptamer-dependent cellular cytotoxicity to therapies of further tumour species. 
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2 INTRODUCTION 
2.1 Aptamers 
Aptamers (derived from aptus, latin: fitting, and meros, greek: area) are single stranded DNA 
or RNA oligonucleotides that bind to molecules of nearly all classes. Their well defined and 
rigid tertiary structure allows both a specific and high affinity molecular recognition (Figure 
1). Reported aptamer targets range from inorganic components and small organic molecules, 
nucleic and amino acids to carbohydrates, peptides, proteins and even complex structures as 
tissues, spores or live parasites (Homann and Goringer, 1999; Stoltenburg et al., 2007). 
Aptamers bind to their targets through a combination of factors including complementarity in 
shape, stacking interactions between aromatic compounds and the nucleobases of the 
aptamers, electrostatic interactions between charged groups, or hydrogen bondings (Patel et 
al., 1997; Hermann and Patel, 2000). These interactions enable aptamers to disrupt protein-
protein-interactions. Since many properties can be compared to their antibody analogues, 
aptamers are also called “chemical antibodies”. They can vary from 15 to over 80 nucleotides 
in length resulting in apparent molecular mass of ca. 5 – 25 kDa. Aptamers can be produced 
by polymerase chain reaction (PCR; Mullis et al., 1986) with subsequent strand separation for 
DNA or transcription for RNA aptamers, respectively, in vivo synthesis (Umekage and 
Kikuchi, 2006; Suzuki et al., 2010) or 
usually by well established and cost-
effective solid phase synthesis. 
 
 
 
Figure 1: Crystal structure of a DNA aptamer 
bound to thrombin. 
A DNA aptamer (backbone orange, nucleobases 
green-blue) is specifically folded and binds to the 
target protein thrombin (green) among others by 
complementarity of shape. Modified from PDB 
entry 1HUT (Padmanabhan et al., 1993). 
 
Aptamers have been selected with high affinities and specificities to their targets, enabling the 
differentiation, for example, between caffeine and theophyllin or between ATP and AMP 
(Jenison et al., 1994; Sazani et al., 2004). Affinities are often comparable to those observed 
for antibodies: most KD values are in the low nanomolar to picomolar range. Aptamers can be 
selected in the SELEX process (systematic evolution of ligands by exponential enrichment, 
described in more detail in chapter  2.4.2), and in contrast to most poly- or monoclonal 
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antibodies selection methods, SELEX is an in vitro process independent of animals or cell 
lines (Tuerk and Gold, 1990). Thus, SELEX can be applied under non-physiological 
conditions and selection of aptamers against toxic target molecules or non-immunogenic 
molecules is possible. Furthermore, SELEX can be successfully applied to the isolation of 
aptamers that address complex structures such as cells or whole tissues without proper 
knowledge of target structures (Shamah et al., 2008). The multitude of different targets used 
in SELEX experiments (Stoltenburg et al., 2007) indicates that the selection of aptamers is 
possible for virtually any target. However, published aptamer work also reveals certain 
limitations of aptamers and some general prerequisites for a potential target to successfully 
select aptamers (Klussmann, 2006). Target molecules should be present in sufficient amount 
and with high purity. Target features that improve chances for successful aptamer selection 
are positively charged groups, the presence of hydrogen bond donors and acceptors and 
aromatic compounds (Rimmele, 2003). The aptamer selection is more difficult for targets 
with largely hydrophobic character and for negatively charged molecules (e.g. containing 
phosphate groups or a low isoelectric point). Aptamers are relatively unstable in biological 
fluids, but different strategies such as chemical modifications (Keefe and Cload, 2008; 
chapters  2.3 and  2.4.1) can lead to significantly improved stabilities. Finally, high-affinity 
aptamers were not, until now, as widely available as antibodies, but taking into account the 
time investment in antibody research as compared to aptamers, it seems as if this area is 
catching up rapidly. 
 
2.2 Bi-valent aptamers 
Aptamers are mainly selected to bind in a monovalent manner to their respective target. 
Applications vary from specific detection of targets for diagnostic purposes (Baldrich et al., 
2004) to molecular alteration of target functions such as competitive or allosteric enzyme 
inhibition (Bock et al., 1992). A few studies have engaged in creation of bi- or oligo-valent 
aptamers mostly to enhance their affinity by avidity. Müller and colleagues fused two 
thrombin aptamers binding different epitopes via a 15dA-nucleotide linker resulting in a ~10-
fold higher affinity and increased enzyme inhibition (Muller et al., 2007; Muller et al., 2008). 
This effect was also independently demonstrated using phosphoramidite spacers (Kim et al., 
2008) or with hybridisation-ligation-based multivalent circular aptamers (Di Giusto and King, 
2004). Similarily, aptamers with up to four binding entities showed improved anticoagulant 
activitiy due to increased stability and avidity (Di Giusto et al., 2006). Moreover, a group of 
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related DNA aptamers inhibiting HIV-1 reverse transcriptase (RT) were combined via either a 
single nucleotide or a hexaethylene glycol linker and inhibited primate RT with low nano-
molar IC50 values (Michalowski et al., 2008). In addition, bi-specific aptamers have been 
developed to capture different ligands in diagnostic applications (Tahiri-Alaoui et al., 2002). 
 
An interesting example of converting a single receptor binding aptamer into a receptor agonist 
by hybridisation of two aptamer copies to a polyethylene glycol linked tandem oligo was 
shown by Dollins (2008). Systemic delivery of this bi-valent aptamer which binds OX40, a 
member of the TNF receptor family, induced various specific cellular activation responses. 
Hybridisation was also used by the same laboratory to create bi-valent aptamers that 
costimulated a CD8+ T cell receptor resulting in tumour growth inhibition in mice 
(McNamara et al., 2008). Even tetrameric aptamers were constructed that showed enhanced 
bioactivity (Santulli-Marotto et al., 2003). While some studies state that constant regions in 
selected aptamers do not contribute to the tertiary structure (Cowperthwaite and Ellington, 
2008) and hence would be available for hybridisation and dimerisation, other examples show 
that any part of the sequence can be critical and also extensions can alter aptamer folding and 
properties (Li et al., 2009). Taken together, coupling approaches require exact 
characterisation of the tolerance of additional or endogenous hybridisation sequences for each 
aptamer. Not only can two aptamers be coupled but Mallikaratchy and colleagues added a 
functional group to a cell-surface specific aptamer for stimulated release of chemical effector 
molecules at the cell surface (Mallikaratchy et al., 2009). 
 
2.3 Aptamers as therapeutic agents 
As the view of regulatory mechanisms in cells has broadened to include not only interactions 
of proteins to proteins but also to nucleic acids, oligonucleotides have emerged as a promising 
class of binding molecules for analytical purposes and as biopharmaceuticals (Burke and 
Nickens, 2002). Some approaches to target a disease at the genetic level are antisense 
technology, RNAi, ribozymes, immunostimulatory nucleotides via CpG-motifs as well as 
aptamers (Kaur and Roy, 2008). For the latter one, several applications can be considered: 
inside the cell, aptamers can affect gene-regulation (Sen, 2008); by binding to cell surfaces, 
they can specifically modulate target activity and trigger activation or inhibition signals, 
making therapeutic applications feasible (Cullen and Greene, 1989; Burmeister et al., 2006; 
Que-Gewirth and Sullenger, 2007; Scherer et al., 2007; McNamara et al., 2008); finally, 
aptamers can be applied in ligand-based targeted therapies to specifically deliver cytotoxic 
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payloads to tumour cells. Several tumour specific aptamers exist that could be utilised in such 
a way (reviewed in Das et al., 2009; Ferreira et al., 2009; Orava et al., 2010). An interesting 
variant of this concept is the aptamer-mediated delivery of nucleotide based effector 
molecules: one folded aptamer domain is coupled to a siRNA in one single oligonucleotide 
strand that can induce internalisation and subsequent downregulation of essential proteins 
(Chu et al., 2006; McNamara et al., 2006; Cerchia et al., 2009; Dassie et al., 2009; Zhou et 
al., 2009b). Since the whole molecule comprises nucleic acids only, no to low 
immunogenicity can be anticipated. Aptamers directed to targets of therapeutic interest are 
reviewed by Keefe et. al., 2010. Another area of research that is being actively pursued and 
decribed in more detail elsewhere is the application of aptamers for in vivo diagnostics and 
imaging (Hicke et al., 2006; Tavitian et al., 2009 ; Kim et al., 2010). 
 
On the therapeutic front, aptamers have made tremendous progress leading to the first 
approved drug Macugen (pegaptanib sodium) in 2007 (Que-Gewirth et al., 2007). Many 
promising approaches are persued in pre-clinical development (Cerchia et al., 2002; Nimjee et 
al., 2005; Burmeister et al., 2006; Lee et al., 2006; Scherer et al., 2007; Ferreira et al., 2008; 
Shaw et al., 2008) and many are already in clinical trials only a few years after the inception 
of the technology (Bates et al., 2009; Keefe et al., 2010). Several characteristics of aptamers 
render them a suitable molecule class for therapeutical approaches, offering specific 
competitive advantages over antibodies and other protein-based formats. One major 
advantage is a high probability of an absence of immunogenicity. Aptamers display low to no 
immunogenicity when administered in preclinical doses 1000-fold greater than doses used in 
animal and human therapeutic applications (White et al., 2000). Microarray studies found 
only mild transcriptional responses of unintended effects upon the cellular innate immune 
response (Di Giusto et al., 2006). Immune responses to oligonucleotide-based therapeutics 
could be triggered intrinsically merely by activation of Toll-like receptor 9 (TLR9) that is 
localised only intracellularly and recognises non-methylated CpG sequences of double-
stranded DNA (Ulevitch, 2004). Other TLRs (such as TLR3, TLR7, and TLR8) are involved 
in recognition of double- and single-stranded RNAs that is putatively decreased when 
modified nucleotides are applied. TLR activation can trigger the release of IFN-α and other 
cytokines that can result in either systemic side effects or an eligible local inflammation 
(Ulevitch, 2004). Whereas the efficacy of many monoclonal antibodies can be severely 
limited by immune responses against the administered antibodies, it is difficult to elicit 
neutralising antibodies to aptamers (Pendergrast et al., 2005). Although the immune response 
to DNA aptamers in humans remains to be determined in more detail major immunogenicity 
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of aptamers is not anticipated. In addition, high affinity and selectivity is achievable; aptamers 
are chemically robust; after denaturing by heat or denaturants, they intrinsically regenerate 
easily within minutes and can be stored for up to one year at room temperature as lyophilized 
powders, thus exhibiting a very long shelf-life.  
 
Natural nucleic acids exhibit poor pharmacokinetics, primarily due to nuclease degradation 
and renal clearance. Both limitations can be overcome by appropriate chemical modifications: 
Unmodified aptamers are degraded in serum by a combination of endonucleases, 5’-3’ and 3’-
5’exonucleases whose activity can be blocked by chemical modifications such as 2’-hydroxy-, 
2’-methoxy- and/or 2’fluoro-substitutions (Zinnen et al., 2002). 3’-3’- (Shaw et al., 1991; 
Kasahara et al., 2010) or 5’-caps such as polyethylene glycol (PEG) as well as cyclisation (Di 
Giusto et al., 2004) prevent exonuclease degradation, but even then aptamers must have 
molecular weights greater than approximately 60 kDa to avoid renal clearance. While several 
strategies such as protein-aptamer complexation, tagging with cholesterol or attachment to 
liposomes have been applied, most work concentrated on PEGylation. When PEG is 
covalently attached the aptamer half-life in animals is extended from minutes to up to 12 
hours in monkeys (Healy et al., 2004; Pendergrast et al., 2005). 
 
Aptamers can be administered by either intravenous or subcutaneous injection. With high 
solubility (>150 mg/ml) and comparatively low molecular weight (aptamer with 5 – 25 kDa to 
antibody with 150 kDa), a weekly dose of aptamer can be delivered by injection in a volume 
of less than 0.5 ml. Aptamer bioavailability via subcutaneous administration is greater than 
80 % in monkey studies (Tucker et al., 1999). There is also evidence that nucleic acid-based 
therapeutics can be dosed topically and via pulmonary administration (Pendergrast et al., 
2005). 
 
Aptamers can be produced by chemical synthesis with high accuracy and reproducibility so 
that no variation between different production batches is anticipated (Kawazoe et al., 1996). 
They are purified by stringent denaturing conditions ensuring very high purity. While the 
capital cost of a large-scale protein production plant is enormous, a single large-scale 
synthesizer can produce upwards of 100 kg of oligonucleotide per year and requires a 
relatively modest initial investment. The cost of goods for DNA aptamer synthesis at the 
kilogram scale is estimated at $500/g, comparable to that for highly optimised antibodies 
(Pendergrast et al., 2005).  
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Finally, folded aptamers can be inactivated by disrupting their structure with the addition of 
short complementary antisense sequences that can be easily produced. When aptamers are 
applied as therapeutic agents these antisense antidotes can safely and selectively control the 
drug activity (Rusconi et al., 2002; Rimmele, 2003; Que-Gewirth et al., 2007). For example, 
since it is important that the effects of anticoagulants be reversible, using aptamers could 
improve the safety of these widely used drugs (Oney et al., 2007; Muller et al., 2008; Chan et 
al., 2008). 
 
Although these factors could be beneficial in drug development, there are potential risks as 
well. Half life extension technology is currently limited to PEGylation, oral application is 
currently not achievable, and there is no experience with slow release formulations in an 
aptamer context. 
 
2.4 Aptamer selection 
The SELEX process (systematic evolution of ligands by exponential enrichment) aims to 
select for rare nucleic acid sequences with unique properties from very large random sequence 
oligonucleotide libraries and was first described in 1990 (Tuerk et al., 1990; Robertson and 
Joyce, 1990; Ellington and Szostak, 1990). SELEX is based upon an iterative process of in 
vitro selection and amplification (Figures 2 and 3).  
 
 
Figure 2: Scheme of the SELEX procedure. 
Aptamers are selected from libraries of up to ~1014 unique sequences targeting essentially all molecule classes up 
to complex samples such as tissues. SELEX is carried out in an iterative process of selection and amplification of 
bound aptamers: A naive pool is allowed to bind target molecules, unbound aptamers are removed and bound 
sequences are amplified by PCR. After reconverting PCR products to single stranded aptamers, the pre-selected 
pool is again used for selection. After several rounds of SELEX, pools are sequenced and enriched aptamers are 
characterised for specific binding and additional criteria of interest. Modified from Shamah et al., 2008. 
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Combinatorial libraries based on replicable biopolymers such as nucleic acids offer the 
convenience of iterative molecules’ amplification, making the screening process fast and easy. 
There are currently hundreds of publications about the selection of aptamers and their 
applications, which reflect the great interest for this research field and its enormous potential 
for pharmaceuticals as well as research and diagnostic tools. 
 
2.4.1 Aptamer pools and compositions  
The SELEX process begins with a random sequence library obtained from combinatorial 
chemical synthesis of DNA. Template molecules typically contain constant 5’- and 3’-
terminal sequences that flank an internal region of 25 - 40 random nucleotides with each 
member in a library being a linear oligomer of a unique sequence. The complexity or the 
molecular diversity of a library is dependent on the number of randomised nucleotide 
positions. Theoretically, a library containing a 40-nucleotide random region is represented by 
440 = 1.2 x 1024 individual sequences. However, in practice, a standard scale (1 µmole) 
synthesis followed by purification and PCR amplification will yield approximately 2 x 1014 
individual template molecules. The success of finding unique and rare molecules that interact 
with a target equals the diversity of the libraries applied. The degree of molecular diversity 
present in random sequence oligonucleotide libraries supersedes that of other combinatorial 
libraries (except for ribosomal display) such as peptide libraries used for phage display, 
indicating that a complexity of 1014 is sufficient for most SELEX experiments (cf. Habicht 
and Siegemund, 2002 and Stoltenburg et al., 2007). 
 
Natural nucleic acids can exhibit short serum half-lives due to nuclease degradation and rapid 
renal clearance that is dependent on their respective molecular masses (chapter  2.3). Nuclease 
degradation varies strongly (half lives were reported to be 0.5 - 42 h, Schmidt et al., 2004; 
Peng and Damha, 2007) and depends on the primary sequence (Choi et al., 2010), a rigid 
compact structure rather than exposed termini (Di Giusto et al., 2004) and on nucleotide 
concentration (Shaw et al., 1995). Degradation can be reduced by modifications to the 2’-
hydroxyl position (Zinnen et al., 2002), the nucleobase or the backbone of potential RNA 
substrates (reviewed in Mayer, 2009). SELEX is performed in this work using pools 
containing nucleotides with modifications at the 2’-position on the ribose (Keefe and Cload, 
2008). In particular, the following pools containing their respective nucleotide chemistries 
could be used (next page): 
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DNA  all 2’-deoxynucleotides 
dCmD  2’-deoxy-C, 2’O-methyl A, U, G 
rRfY  2’-ribo A, G, 2’fluoro-C and U  
rGmH  2’-ribo-G, 2’O-methyl A, U, C 
mRfY  2’O-methyl A, G, 2’fluoro-C and U 
MNA  all 2’-O-methyl 
 
2.4.2 Systematic evolution of ligands by exponential enrichment 
During SELEX, a random oligonucleotide library is incubated with a target of interest at a 
given temperature, usually 37 °C in selections for therapeutical binders. SELEX can be 
carried out against proteins or whole cells, even if the exact target is not exactly known 
(Figure 2). However, it must be noted that the probability of success in selection correlates 
with the quality of the applied target. During incubation of target and SELEX pool, a very 
small fraction of individual sequences interacts with the target and these sequences are 
separated from the rest of the library by means of different physical separation techniques. 
Typically, nitrocellulose filter partitioning is used with protein targets that are retained on 
nitrocellulose which captures the protein-aptamer complexes (Figure 3).  
 
Figure 3: General iterative filter SELEX scheme. 
A RNA or DNA aptamer library pool (top) is incubated with the counter target (red circle) and aptamers that do 
not bind to the counter target are partitioned from the bound molecules on a nitrocellulose filter (white circle). 
Remaining molecules are then incubated with the positive selection target (blue circle). Aptamer : target 
complexes are subsequently partitioned by immobilisation on another nitrocellulose filter following washing off 
non-binding aptamers. Bound molecules are eluted by heat and urea denaturation of target proteins and amplified 
by PCR. Multiple SELEX cycles can result in aptamers that have high affinity and specificity toward the target. 
Modified from Shamah et al., 2008. 
 
This method shares the advantage of selection with soluble target protein and was, for 
example, used in the initial rounds of SELEX against HER3 (Chen et al., 2003). Similarily, 
magnetic beads can be used for separation purposes e.g. when aptamers bound to biotinylated 
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target proteins are removed from the solution applying streptavidin-coated beads that are 
subsequently captured in a magnetic field. In contrast, small molecular targets are generally 
immobilised on a solid support such as a microtiter plate and non-interacting sequences can 
be removed easily by a simple washing step. In addition, methods based on capillary 
electrophoresis, surface plasmon resonance, HPLC, and FACS (Mayer et al., 2010) as well as 
automated processes have been developed for aptamer selections (Mayer, 2009). Plenty of 
SELEX procedure modifications have been developed, one of which is Counter-SELEX that 
generates aptamers that discriminate between closely related structures by introduction of a 
negative selection step to the related target thereby eliminating aptamers unable to distinguish 
between the related structures (Kulbachinskiy, 2007; Table 2 in Stoltenburg et al., 2007; 
Shamah et al., 2008). 
 
If the desired target protein is not available in its soluble or correctly folded form or in the 
case of cancer tissue the target is unknown, SELEX can also be performed directly on whole 
cells (Blank et al., 2001; Huang et al., 2009). Since counterselection is mandatory if specific 
binders need to be enriched, related non-cancer cells or recombinant cell lines can serve for 
pre-selection to deplete unspecific cell binding aptamers. Library pools are initially incubated 
with a sufficient amount of related or parental cells to remove aptamers binding off-target. 
The supernatant is then applied to target-presenting cells and target-specific binders are 
separated by centrifugation of the cells. If cancer cells are applied directly, a related cell line 
has to be chosen for pre-selection (Sefah et al., 2010). Separation of bound aptamers can be 
achieved by simple centrifugation of applied target cells as well as fluorescence-activated cell 
sorting using dye-labelled aptamer pools (Raddatz et al., 2008). Commonly and independent 
of the separation method, bound aptamers are recovered by denaturation of the protein or cell-
aptamer complexes at 95°C releasing conformation-dependent binding aptamers. Different 
partitioning methods can be applied sequentially to benefit from the respective advantages, 
e.g. a few initial rounds of filter selection under defined conditions followed by whole cell 
SELEX in later rounds for enrichment of binders specific to cellular presented target protein 
(Björn Hock, personal communication). 
 
After selection and partitioning, the population of sequences bound to the target is amplified 
to obtain an enriched library to be used for the next selection cycle. Amplification is easily 
performed by PCR and the resulting double stranded DNA (dsDNA) can be reconstituted in 
high amounts with different methodologies for DNA or RNA. A dsDNA PCR product of a 
DNA aptamer already contains the desired aptamer strand, but must be prepared as a single 
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stranded oligonucleotide. Introduction of a pH-labile RNA base 3’ of the 3’-primer enables an 
alkaline induced strand break and the aptamer can be separated by size in a subsequent 
electrophoresis. RNA aptamers can be transcribed from a dsDNA template that was elongated 
5’ by a T7 polymerase recognition site during PCR (Figure 4) (Keefe et al., 2008). 
 
 
Figure 4: Scheme of both, DNA or modified RNA, aptamer production. 
A, DNA aptamers can be amplified by PCR, introducing a pH-labile RNA base in the 3’ primer. Strand 
separation can be accomplished under alkaline conditions followed by PAGE purification. B, RNA aptamers 
(dashed lines) need to be reversely transcribed to DNA templates that are subsequently applied in a PCR 
introducing a T7 binding site within the 5’ primer. This dsDNA template enables RNA aptamer transcription 
finalised by purification via PAGE. Modified from Keefe and Cload (2008). 
 
The progress of the enrichment of high-affinity binders can be determined by monitoring the 
cycle numbers needed to re-amplify applied aptamer pools to a fixed threshold, or by carrying 
out binding analysis in a dot blot assay (chapter  4.3.9). Once affinity saturation or constant 
high amounts of eluted binders are achieved, the enriched library is cloned and sufficient 
clones are sequenced to obtain information on diversity and enrichment of the aptamer pool. 
Individual sequences are further characterised on the basis of their ability to bind to the target 
with high affinity and specificity. 
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2.4.3 Candidate screening 
Usually, between 5 and 20 clones per enriched pool are expected to be characterised. Each 
clone can be synthesised or transcribed and then assayed for target binding using a 
nitrocellulose dot blot assay (chapter  4.3.9)(Yarus and Berg, 1970). Target protein and radio-
labelled aptamers are incubated to allow binding and subsequently partitioned on 
nitrocellulose and PVDF membranes. Complexes of target protein and bound aptamer are 
immobilised on nitrocellulose whereas unbound aptamers are captured by the PVDF 
membrane. The affinity can be calculated using the ratio of bound to unbound aptamer for 
each target protein dilution. Target specific aptamers that meet the affinity criterion (e.g., KD 
of 1 nM – 100 nM determined by dot blots) are then analysed in further cellular and 
functional assays.  
 
2.5 Hepatocyte growth factor receptor (c-Met) 
Receptor tyrosine kinases (RTKs) are key regulators of critical cellular processes such as cell 
growth, differentiation, neovascularisation, and tissue repair. In addition to their importance in 
normal physiology, aberrant expression of RTKs can contribute to the development and 
progression of many types of cancer (Eder et al., 2009).  
 
Hepatocyte growth factor receptor (HGF-R) or mesenchymal epithelial transition factor  
(c-Met) is a membrane RTK that is essential for embryonic development (Bladt et al., 1995; 
Andermarcher et al., 1996; Takayama et al., 1996) and wound healing. It is normally 
expressed by cells of epithelial origin (Tsarfaty et al., 1994; Gentile et al., 2008). The primary 
single chain precursor protein is post-translationally cleaved to produce the alpha and beta 
subunits, which are disulfide linked to form the mature receptor (Figure 5). c-Met is a multi-
domain protein comprised of an extracellular SEMA-domain (of 450 amino acids, a variant of 
semaphorin axon guidance proteins) that consists of two subunits α and β that are present after 
proteolytic cleavage, a cysteine-rich domain and at least four immunglobuline like domains 
(each of 90 amino acids consisting of two β-sheets). A transmembrane domain is followed by 
its intracellular kinase domain that includes several tyrosines and a serine capable of cross-
phosphorylation upon dimerisation (Birchmeier et al., 2003; Eder et al., 2009). Binding of the 
natural ligand hepatocyte growth factor (HGF, or scatter-factor, SF) induces receptor 
dimerisation leading to phosphorylation of the cytoplasmic tyrosine kinase domain at two 
positions (Y1234 and Y1235) and activation of c-Met-mediated signalling (Longati et al., 
1994). In addition to c-Met homodimers, other receptors and cell surface proteins can interact 
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with c-Met that contribute to signal cross talk and oncogenesis (Lai et al., 2009). Aberrant 
c-Met signalling due to dysregulation of the receptor or overexpression of HGF induces 
several biological responses that collectively give rise to „invasive growth“ (Eder et al., 2009; 
Stellrecht and Gandhi, 2009). 
 
 
Figure 5: Domain structure and cellular function of c-Met. 
c-Met (green) consists of two peptide chains, α and β refer to the subunits of the receptor that are present after 
proteolytic cleavage. Two SEMA domains build the receptor surface for binding of the ligand HGF (red), 
followed by one Cys-rich and four Ig-like domains, concluded by an intracellular kinase domain with five 
phosphorylation sites. HGF binding leads to dimerisation that induces kinase auto cross-phosphorylation of 
intracellular domains resulting in docking of activating signal transduction proteins and a variety of growth 
stimulatory responses. 
 
Aberrant c-Met activation or over-expression in cancer correlates with poor prognosis, 
because of c-Met induction of tumour growth, formation of new blood vessels (angiogenesis) 
that supply the tumour with nutrients, and metastasis. c-Met is deregulated in many types of 
human malignancies, including cancers of lung, ovary, kidney, liver, stomach, breast, and 
brain (Birchmeier et al., 2003;Comoglio et al., 2008 ; Cipriani et al., 2009; Eder et al., 2009). 
In many of these tumour types, both receptor and ligand are overexpressed relative to 
surrounding tissue and overexpression of HGF induces tumourigenesis in mice (Takayama et 
al., 1997). Gene amplification (Christensen et al., 2005) or activation of HGF/c-Met 
signalling in vivo promotes cell invasiveness and triggers metastases (Zhang et al., 2003), 
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whereas inhibition of receptor or ligand functions reverses cancer phenotypes such as 
motility, invasion, proliferation and in vivo tumor growth (Toschi and Janne, 2008). 
 
This extensive evidence of a pathological role for c-Met in cancer and understanding of its 
contribution in several diseases generated considerable interest in c-Met and HGF as targets in 
cancer drug development. The three main approaches of c-Met-selective anticancer drug 
development included antagonism of ligand-receptor interaction, inhibition of the intracellular 
kinase activity, as well as blocking the cytoplasmic interaction between the receptor and its 
specific effector molecules. Recently, susceptibility of c-Met overexpressing cell lines to 
antibody-dependent cellular cytotoxicity (ADCC) was shown in vitro by applying two 
antibodies in parallel (van der Horst et al., 2009). Preliminary clinical results of several c-Met 
antagonists such as monoclonal antibodies and small-molecule tyrosine kinase inhibitors have 
been encouraging (Toschi et al., 2008; Eder et al., 2009).  
 
2.6 FcγRIII (CD16) 
Although cellular receptors for immunoglobulins (FcRs) were identified nearly 40 years ago, 
their central role in the immune response was discovered only in the last decade. FcRs are key 
immune regulatory receptors, connecting humoral immune responses to cellular effector 
mechanisms. FcR functions include setting thresholds for B cell activation, regulating the 
maturation of dendritic cells, and coupling the exquisite specificity of the antibody response 
to innate effector pathways, such as phagocytosis, antibody-dependent cellular cytotoxicity 
(ADCC), and the recruitment and activation of inflammatory cells (Nakamura et al., 2008). 
Receptors for all classes of immunoglobulins have been identified, including FcγR (IgG), 
FCεRI (IgE), FcαRI (IgA), FcµR (IgM) and FcδR (IgD) (Powell and Hogarth, 2008). The 
three existing FcγR subclasses, their polymorphisms and respective affinities to all IgGs have 
been studied in detail by Bruhns and colleagues (van Sorge et al., 2003; Bruhns et al., 2008). 
While FcγRI (CD64) is the only high affinity receptor, FcγRIII (CD16, P08637) is the only 
FcR expressed on natural killer cells (NK cells).  
 
CD16α is an intermediate affinity receptor for polyvalent immune-complexed IgG1 and IgG3, 
but not for IgG2 and IgG4 (Vance et al., 1993; Edberg and Kimberly, 1997; Bruhns et al., 
2008). CD16α is involved in phagocytosis, secretion of enzymes and inflammatory mediators, 
antibody-dependent cytotoxicity and clearance of immune complexes (Ravetch and Perussia, 
1989; Nimmerjahn and Ravetch, 2006). Human CD16α is a 50 - 70 kDa type I 
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transmembrane activating receptor expressed by NK cells, δγ-T cells, monocytes, and 
macrophages. NK cell-derived CD16α runs at 50-55 kDa on non-reducing SDS-PAGE, un-
glycosylated at 25 kDa (De et al., 1994), whereas monocyte-derived CD16α runs at 68 kDa. 
The CD16 cDNA encodes 254 amino acids including a 16 amino acid signal sequence, a 
191 amino acid ECD with two C2-type Ig-like domains and five potential N-glycosylation 
sites, a 22 amino acid transmembrane (TM) sequence and a 25 amino acid cytoplasmic 
domain. The isoelectric point (pI) of CD16α is 6.6 (Edberg et al., 1990). CD16 binds the 
lower hinge region of IgG (Figure 6). 
 
 
Figure 6: Scheme, crystal structure and antibody binding of CD16. 
A, the two isoforms of CD16 comprise two extracellular Ig-like domains. CD16β is a glycosylphosphatidyl 
inositol-anchored protein, whereas CD16α as type I integral protein includes transmembrane and cytoplasmic 
domains. Since these domains are not capable of cell signalling, Fcγ or CD3ζ chains in complex with CD16 as 
hetero- or homo-dimers transduce activating signals via an immunoreceptor tyrosine based activating motif 
(ITAM, indicated as green rhombus). CD16 is a glycoprotein that exhibits cell type specific glycosylation 
patterns. B, crystal structure of CD16 (orange) bound to the Fc portion of an IgG1 (green, modified from PDB 
entry 1T83). The two Ig-like domains of CD16 can be distinguished. Amino acids differing between isoforms α 
and β are indicated in blue (with F187S out of structure). CD16α alloforms varying directly at the surface of the 
Fc binding site in position 158 (red) exhibit different affinity to IgG. C, a whole antibody (green and blue) is 
bound by CD16 near the hinge region between Fc and Fab portions (Radaev and Sun, 2001, modified).  
 
Two allotypes exist in human CD16α, V158 and F158, which lead to higher and lower 
affinity, respectively. This can influence susceptibility to autoimmune diseases or response to 
therapeutic IgG antibodies (Wu et al., 1997; chapter  2.8). In addition, glycosylation patterns, 
electrophoretic mobility and binding affinity differ between NK cell and monocyte CD16α 
(Edberg et al., 1997). CD16α surface expression, but not correct folding, requires interaction 
of an accessory chain, either the common Fcγ-chain or CD3ζ (Lanier et al., 1989; Kim et al., 
2003). A fine balance between inhibitory and activating receptors tightly regulates NK cell 
activation (Zompi and Colucci, 2005; Bryceson et al., 2006a). Activation of receptors occurs 
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also through γ or ζ chains that contain immunoreceptor tyrosine-based activation motifs 
(ITAMs). Adapter proteins propagate strong activation signals through recruitment of tyrosine 
kinases Syk and z-associated protein of 70 kDa (ZAP-70), the same signal pathway as in CTL 
activation (Vivier et al., 2004; Bryceson et al., 2006a).  
 
The isoform FcγRIIIβ (CD16β) is highly related to CD16α, sharing 97% amino acid sequence 
identity within the extracellular domain (ECD), but CD16β is a glycosyl-phosphatidyl-
inositol-(GPI)-linked receptor expressed on human neutrophils and eosinophils. The differing 
5 amino acids are found throughout the extracellular domain and result in a low affinity of 
CD16β to Fc (Anderson et al., 1990; Vance et al., 1993). Divergent residues do not occur in 
one specific paratope on CD16, but are located over the whole structure (Figure 6 B).  
 
The ECD of both CD16α and CD16β can be proteolytically cleaved and retain binding 
activity in their soluble forms (Harrison et al., 1991; Li et al., 2007). Soluble FcγRIII (sCD16) 
can be detected in normal plasma and is increased in inflammatory diseases such as 
rheumatoid arthritis and in coronary artery diseases. The prevalent soluble isoform is 
neutrophils-derived sCD16β (Huizinga et al., 1994), and the amount of sCD16α is negligible 
in healthy persons. Upon an immune reaction, sCD16α concentrations increase proportional 
to CRP, although it remains unclear whether this is due to increased cleavage or overall NK 
cell population (De et al., 1994).  
 
The monoclonal mouse antibody 3G8 (targeting both CD16α and CD16β) binds near or in the 
Fc-binding domain (Edberg et al., 1997). Affinities to soluble CD16α were measured for IgGs 
with 560 and 710 nM for IgG3 or IgG1, respectively (Li et al., 2007), 86 nM for 3G8 in a bi-
specific scFv and 5.7 nM for monovalent binding of 3G8 (Bruenke et al., 2004).  
 
2.7 Natural Killer Cells 
Natural Killer cells (NK cells) are unique in their ability to detect changes in tumour cells in 
the absence of stimuli and as such can reject tumours directly. Additionally, they can 
stimulate components of the adaptive immune system to eliminate tumours. 5-20 % of 
peripheral blood mononuclear lymphocytes (PBMCs) are bone marrow derived NK cells 
(Wallace and Smyth, 2005). NK cells are usually defined as CD3–CD56+ cells and can be 
further subdivided based on CD56 expression. Usually, 90 % of peripheral blood NK cells are 
CD56dim, whereas CD56bright NK cells are more abundant in secondary lymphoid tissues 
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(Fauriat et al., 2009). CD56dim NK cells express high levels of CD16 and perforin indicating 
their cytotoxic potential (Lanier et al., 1986; Fauriat et al., 2009). In contrast, CD56bright NK 
cells express low levels of or no CD16, have ten-fold lower perforin expression than CD56dim 
NK cells, and are mainly involved in cytokine-mediated immunoregulation (Fehniger et al., 
1999; Shibuya, 2003; Fauriat et al., 2009). CD16+ NK cells and γδ-cytotoxic T lymphocytes 
(CTLs) are less frequent in plasma than αβ-CD8+ CTLs, but NK cells possess a variety of 
effector mechanisms enabling them to mount a potent anti-tumour response.  
 
NK cell function is regulated by a complex balance of inhibitory and activating signals that 
allow them to selectively target and kill cells that display an abnormal pattern of cell surface 
molecules while leaving normal healthy cells unharmed (Wallace et al., 2005; Terunuma et 
al., 2008). Besides certain ligands for natural cytotoxicity and cell-bound IgG1+3 eliciting 
ADCC as described, NK cells can be activated by TNFα, IFNα, IFNβ, IL-12 secreted by 
activated macrophages (Murphy et al., 2008) and especially IL-2 (Carson et al., 2001). On the 
other hand it is not surprising that NK cells, with their unique role in bridging innate and 
adaptive immunity, are a potent sources of cytokines and chemokines that can among other 
functions can recruit T cells (Roda et al., 2006). Since clinical data has been difficult to assess 
directly, most information is derived from cell-based methods which is then correlated to 
clinical studies. Activated NK cells release lymphotactin (LTN/ATAC; Hedrick et al., 1997), 
regulated on activation normal T cell expressed and secreted (RANTES; Dorner et al., 2004), 
macrophage-inflammatory protein 1 (MIP-1a/b; Taub et al., 1995), interleukin 8 (IL-8; 
Somersalo et al., 1994; Roda et al., 2006), IFN induced protein 10 (IP-10, Murphy et al., 
2008) and macrophage-derived chemokine (MDC; Roda et al., 2006) that can all induce 
T cell and most additional NK cell recruitment. Primarily, direct or monokine induced 
interferon γ (IFNγ or MIG) triggers CD4+ TH1 cell activation, monocyte and neutrophil 
ADCC (Reali et al., 1994; Roda et al., 2007), as well as increased tumour MHC I presentation 
leading to higher immunogenicity and modulation of FcγR towards activating receptors 
(Desjarlais et al., 2007). With this plethora of secondary effects, NK cells could still have 
several, not yet fully understood effects on tumour growth as well as activation of further 
immune effector cells. 
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2.8 ADCC and NK cell recruitment in cancer therapy 
Antibody-dependent cellular cytotoxicity (ADCC) originating from the interaction of Fc 
fragments of antibodies with Fcγ receptors (FcγR) plays a pivotal role in the therapy of 
various tumours (Sliwkowski et al., 1999; Desjarlais et al., 2007; Taylor et al., 2008). 
Antibodies bound to the surface of tumour marker over-expressing cells are recognised by 
CD16 and other Fc receptors on NK cells. This induces a cross-linking of respective receptors 
leading to strong adhesion, granule polarisation, formation of a lytic synapse, and 
degranulation, all of which induce apoptosis of the tumour cell (Figure 7; Zompi et al., 2005). 
NK cells share a common killing mechanism with CD8+ cytotoxic T lymphocytes (Trapani 
and Smyth, 2002; Bossi and Griffiths, 2005) via a lytic synapse and use two major 
mechanisms to induce target cell apoptosis: the granule exocytosis pathway (Trapani et al., 
2002) and the death receptor pathway (Smyth et al., 2003). While the perforin/granzyme 
granule exocytosis pathway has been extensively studied, less is known about NK cell death 
receptor function. The major proteins involved in the granule exocytosis pathway are perforin, 
a membrane-disruption protein, and a family of structurally related serine proteases known as 
granzymes (Smyth and Trapani, 1995). Cytolytic functions of granzyme B include at first 
activation of caspase 3 that cleaves the inhibitor of caspase-activated deoxyribonuclease 
(ICAD) off CAD which triggers this enzyme to induce DNA fragmentation. Secondly, the 
BH3-interacting domain death agonist protein (BID) is cleaved to truncated BID (tBID) 
inducing cytochrome c release from mitochondrial membranes leading to the formation of the 
apoptosom that activates several caspases that finally induce apoptosis (Murphy et al., 2008). 
 
The specific CD16α polymorphism F158 to V158 enhances its affinity for IgG1 and is 
associated with improved clinical outcome in tumour patients treated with therapeutical 
antibodies (Cartron et al., 2002; Desjarlais et al., 2007; Taylor et al., 2008). In particular, 
RTK specific antibody-based therapeutics such as cetuximab (Erbitux) which targets EGF 
receptor or trastuzumab (Herceptin) which binds HER2/neu on cancer cells have been shown 
to elicit ADCC in vivo and in vitro (Roda et al., 2007; Lopez-Albaitero et al., 2009; Mani et 
al., 2009). Several studies revealed ADCC as one major mode of action of antibody-based 
therapeutics and stimulated more interest in how to mobilise, expand and activate NK cells in 
humans (Wallace et al., 2005). The importance of NK cells in anti-tumour immunity was also 
established in tumour models in mice. NK cells can reject a number of tumour cell lines, 
suppress metastasis and stop the outgrowth of tumours (Kim et al., 2000). Tumour resistance 
in these mice was associated with an infiltration of innate leukocytes including NK cells, 
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neutrophils and macrophages into the peritoneum (Cui et al., 2003). Work on insect cells by 
Bryceson and colleagues revealed that surface-bound antibodies induce lysis by both resting 
and IL-2-activated NK cells (Bryceson et al., 2006b) and binding of CD16 can induce contact, 
degranulation and cytotoxicity, but not granule polarisation (Bryceson et al., 2006a). 
Complementing CD16 functions, lymphocyte function-associated antigen 1 (LFA-1) seems to 
be the key player in mediating initially strong adhesion with the intercellular adhesion 
molecule 1 (ICAM-1) on target cells that facilitates polarisation followed by lysis. Taken 
together, engagement of CD16 may be the most applicable and affordable approach to 
harnessing NK cells for immunotherapy.  
 
 
Figure 7: Scheme of antibody-dependent cellular cytotoxicity (ADCC) of NK cells. 
 
The proof of concept for recruitment of NK cells to tumour targets via bi-specific binders was 
achieved in two laboratories in 1999 by McCall as well as Arndt and colleagues (Arndt et al., 
1999; McCall et al., 1999). Scientists of the Fey lab optimised several stabilised bi-specific 
single-chain Fv (scFv) antibody NK cell recruiting constructs, also by introdution of an 
antibody-like third binding arm for increased affinity by avidity (Bruenke et al., 2004; 
Bruenke et al., 2005; Kugler et al., 2010; Singer et al., 2010). Since CD16+ NK cell subsets 
are involved in cytotoxicity, whereas CD16- NK cell populations are responsible for cytokine-
production (chapter  2.7), targeting CD16 should recruit cytotoxic NK cells without extensive 
cytokine-release, which is a major side effect of current antibody-based ADCC approaches 
(Tabrizi and Roskos, 2007). 
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Since NK cells share a common killing mechanism with CD8+ cytotoxic T lymphocytes and 
serial killing of one effector cell to several tumour cells has been reported in CTL recruitment 
(Valitutti and Lanzavecchia, 1997; Bortoletto et al., 2002; Hoffmann et al., 2005). This 
therapeutic advantage could apply putatively also when recruiting NK cells, possibly due to 
high tumour specific antigen (TSA) affinity and lower effector specific antigen (ESA) affinity 
(Bortoletto et al., 2002). On the other hand, as mentioned above, higher affinity could lead to 
enhanced ADCC. NK cells might also enhance adaptive immunity to tumours in a more 
indirect way. NK cell-mediated killing of tumour targets could provide increased access to 
tumour antigens for uptake by dendritic cells (DCs) thereby triggering their maturation. While 
the links between NK cells and adaptive immunity remain poorly defined at a molecular level, 
they are clearly important in the generation of effective anti-tumour responses (Wallace et al., 
2005).  
 
Transgenic mouse models are available that reproduce the unique pattern of human gene 
expression for CD16α and β (as well as CD32α and β and CD64α), making in vivo studies for 
proof of concept possible (Li et al., 1996; Nimmerjahn and Ravetch, 2008). 
 
2.9 Further bi-specific therapeutic approaches 
 
 
Besides efforts at NK cell recruitment, therapeutic approaches to engage the intact immune 
system via bi-specific molecules were broadened to include other effector cell populations. 
Constructs consisted mostly of an anti-tumour scFv linked to a second scFv-fragment specific 
for surface proteins expressed on effector cells such as Bispecific T-cell Engager molecules 
(BiTEs) (Loffler et al., 2000; Wolf et al., 2005; Baeuerle and Reinhardt, 2009) or triomabs 
like catumaxomab, a T cell retargeting agent that was approved in the European Union in 
April 2009 (Chames and Baty, 2009). Potent effector specific antigens (ESAs) besides CD16 
are CD3ε on Cytotoxic T-Lymphocytes (CTLs), CD89 (FcαRI) on neutrophils, CD64 (FcγRI) 
on activated neutrophils, monocytes and macrophages as well as DEC-205 on dendritic cells 
(Kontermann, 2005; Kellner et al., 2008). Surface proteins that have been chosen as tumour 
specific antigens (TSAs) so far are recapitulated among others by Das, Kontermann and 
Schrama (Kontermann, 2005; Schrama et al., 2006; Das et al., 2009).  
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2.10  Aptamer-dependent cellular cytotoxicity 
 
Enabling ADCC in an aptamer-format could yield therapeutic effects similar to those of 
antibodies while at the same time sharing the advantages of aptamers such as potentially low 
or no immunogenicity, uniform and cost-effective production by chemical synthesis, as well 
as excellent shelf life stability. Since highly related soluble CD16β circulates in plasma and 
acts as decoy receptor without triggering activation (chapter  2.6), the high selectivity of 
aptamers to molecules with even very minor differences (Jenison et al., 1994) could be of 
great advantage in this context: CD16α-specific aptamers would prevent interception of 
effector molecules by soluble CD16β-decoys. Additionally, therapeutical whole antibodies 
could support RTK activation by dimerisation upon simultaneous binding of both CDRs, thus 
acting as agonists (Stellrecht et al., 2009). Bi-specific aptamers on the other hand can only 
bind in a mono-valent manner to tumour targets, exclusively acting as an antagonist in 
addition to potential ADCC activity. The adoption of the bi-specific format with aptamers 
might combine these advantages with the successful strategy of approved antibody-based 
therapeutics or the BiTE format in clinical trials.  
 
So far, neither CD16α or c-Met specific aptamers nor bi-specific aptamers targeting different 
proteins for the introduction of additional tumour-effective functions have been published.  
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2.11  Aim of the work 
 
The work presented herein aims to be a proof of concept for the specific re-localisation of NK 
cells to tumours by aptamers bi-specific for CD16α and c-Met to elicit “aptamer-dependent 
cellular cytotoxicity” (Figure 8). 
 
 
Figure 8: Concept of bi-specific aptamers mediating tumour cell lysis. 
Bi-specific aptamers mimick ADCC by recruitment of NK cells via FcγRIIIα / CD16α to tumour cells with 
c-Met overexpression. A high density of effector molecules at the surface of tumour cells leads to cross-linking 
of CD16α on NK cells inducing polarisation, formation of a lytic synapse, degranulation and finally specific 
lysis of the target cells. 
 
Hence, main objectives are the selection of aptamers with high affinity and specificity for 
cellular expressed CD16α and c-Met via SELEX as well as their characterisation and 
minimisation. Furthermore, suitable linkers need to be designed that bridge the required 
distance between both binding entities to elicit target cell lysis, but do not alter aptamer 
binding characteristics. Finally, functionality of the bi-specific aptamer approach has to be 
demonstrated in cellular ADCC assays. 
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3 MATERIAL 
3.1 Bacterial strains and cell lines 
Bacterial strains 
E. coli One Shot TOP10 Competent Cells, C4040-10  Invitrogen, Karlsruhe, Germany 
Genotype: F- mcrA ∆(mrr-hsdRMS-mcrBC) φ80lacZ∆M15 ∆lacX74 recA1 araD139 
∆(araleu) 7697 galU galK rpsL (StrR) endA1 nupG 
 
Cell lines 
Jurkat E6.1   Human leukemic T cell lymphoblast  
Origin: ECACC 88042803 / ATCC No. TIB-152 
Cultivation at 37°C, 5 % CO2 
 
Jurkat V158   Recombinant transformation of Jurkat E 6.1  
with CD16α(V158) at Merck; origin and cultivation as above 
 
Jurkat F158   Recombinant transformation of Jurkat E 6.1  
with CD16α(F158) at Merck; origin and cultivation as above 
 
GTL-16    Human gastric adenocarcinoma 
    Origin: Paolo Porporato Novara, Merck KGaA 
    Cultivation at 37°C, 10 % CO2 
 
MKN-45   Human gastric adenocarcinoma 
Origin: DMSZ No. ACC 409 
Cultivation at 37°C, 5 % CO2 
 
EBC-1    Human lung squamous cell carcinoma 
    Origin: Health Sc. Res. Resources Bank, JCRB0820 
Cultivation at 37°C, 5 % CO2 
 
NIH-3T3   Mouse embryonic fibroblasts 
    Origin: ATCC No. CRL-1658 
    Cultivation at 37°C, 10 % CO2 
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3.2 Enzymes and proteins 
3G8       BioLegend / Biozol, Eching, Germany 
3G8-biotin      BioLegend / Biozol, Eching, Germany 
3G8-FITC      Jürgen Schmidt, Merck, Darmstadt 
3,3’,5,5’-Tetramethylbenzidine (1step Ultra TMB) Pierce/Thermo Scientific, Schwerte, Ger. 
aCella-TOX ADCC assay kit    Cell Technol., Mountain View, CA, USA 
Antarctic Phosphatase (AP)    New England Biolabs, Beverly, USA 
Benzonase      Novagen, Nottingham, UK 
Bovine serum albumin (BSA)   Merck, Darmstadt, Germany 
Cetuximab (Erbitux)     Merck, Darmstadt, Germany 
CD16α(V158)-6His (rhFcγR IIIα-6His)  R&D Systems, Minneapolis, MN, USA 
CD16β-6His (rhFcγR IIIβ-6His)   R&D Systems, Minneapolis, MN, USA 
c-Met-Fc (rhHGF-R-Fc)    R&D Systems, Minneapolis, MN, USA 
cynoCD16α-8His     Merck, Darmstadt, Germany 
DNA-dependent T7 RNA polymerase Y639L PCS DA, Merck, Darmstadt 
Fc-CD16α(V158)     PCS Boston, Merck, Rockland, USA 
Fc-CD16α(F158)     PCS Boston, Merck, Rockland, USA 
Goat anti mouse F(ab’)
 2 PE conjugate  Jackson ImmunoResearch, Suffolk, GB 
Goat anti mouse peroxidase conjugate  Jackson ImmunoResearch, Suffolk, GB 
Goat anti rabbit peroxidase conjugate  Jackson ImmunoResearch, Suffolk, GB 
Goat anti hIgG F(ab’)2 FITC conjugate  Jackson ImmunoResearch, Suffolk, GB 
Goat anti hIgG F(ab’)2 PE conjugate   Jackson ImmunoResearch, Suffolk, GB 
MACS BSA stock solution    Miltenyi, Bergisch-Gladbach, Germany 
MACS NK cell isolation kit, human   Miltenyi, Bergisch-Gladbach, Germany 
muCD16α-Fc (huFc-muFcGRIV-ECD)  Merck, Darmstadt, Germany 
Mouse anti penta His antibody   Qiagen, Hilden, Germany 
Mouse anti rhHGF-R mAb (c-Met mAb)  R&D Systems, Minneapolis, MN, USA 
Ni-NTA-peroxidase conjugate   Qiagen, Hilden, Germany 
Rabbit anti human-Fc antibody   Epitomics, San Francisco, CA, USA 
Reverse transcriptase (Thermoscript RT)  Invitrogen, Karlsruhe, Germany 
Streptavidin-R-phycoerythrin conjugate (SA-PE) Sigma-Aldrich, Steinheim, Germany 
T4 polynucleotide kinase (T4 PNK)   New England Biolabs, Beverly, USA 
T7 RNA polymerase Y639L mutant   Merck, Darmstadt, Germany,  
Taq DNA polymerase (5 U/µl)   New England Biolabs, Beverly, USA 
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Trypsin-EDTA     Gibco (Invitrogen), Karlsruhe, Germany 
TOPO-TA cloning kit    Invitrogen, Karlsruhe, Germany 
 
Enzymes and proteins originating from Merck, Darmstadt, were produced inhouse at Merck. 
 
 
 
3.3 Oligonucleotides 
primer M13_for  CCCAGTCACGACGTTGTAAAACG  
primer M13_rev  AGCGGATAACAATTTCACACAGG  
oligo 5978   GGAGGGAAAAGTTATCAGGC (c.f. Tsang and Joyce, 1996) 
oligo 5979   GGAGCGAGTACTCCAAAACTAAT/RiboC 
oligo 5980   GACTGTAATACGACTCACTATAGGAGGGAAAAGTTATCAGGC 
oligo 5981  GGAGCGAGTACTCCAAAACTAATC 
oligo 5977  GGAGGGAAAAGTTATCAGGC(N)40GATTAGTTTTGGAGTACTCGCTCC 
oligo CLNX  5978-ATGCGCTAGCCGATCGAATCCCGTAGACATTCCGATCGAC-5981 
oligo CLNC  AATGAAGGGGCAACTATCGTTAAACAGAACACTCGTCAGCTA 
CTCGAGGATATTAGCTCCGAACGAACTGCCACAATTCAGAAC
GCCTGTCACATTATG 
 
All oligonucleotides were purchased from Eurofins MWG Operon, Ebersberg, Germany, 
except for CLNC produced at IDT, Leuven, Belgium. 
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3.4 Chemicals 
5x cDNA synthesis buffer    Invitrogen, Karlsruhe, Germany 
6x DNA gel loading buffer    Novagen, Nottingham, UK 
10x Taq polymerase buffer    NEB, Beverly, New England, USA 
100 bp DNA ladder     NEB, Beverly, New England, USA 
Ammonium persulfate (APS)   Merck, Darmstadt, Germany 
Chloroform:isoamylalcohol 24:1 solution  Sigma-Aldrich, Steinheim, Germany 
CleanGel IEF Ultra      Sigma-Aldrich, Steinheim, Germany 
Coomassie plus protein assay reagent  Pierce/Thermo Scientific, Schwerte, Ger. 
Coomassie R250 tablets    Serva, Heidelberg, Germany 
Desoxy ribonucleotide triphosphates (dNTPs) Novagen, Nottingham, UK 
dH2O       Merck, Darmstadt, Germany 
Dithiotreitol (DTT)     Invitrogen, Karlsruhe, Germany 
DMEM medium     Gibco (Invitrogen), Karlsruhe, Germany 
Dulbecco’s PBS (DPBS)    Gibco (Invitrogen), Karlsruhe, Germany 
EDTA       Gibco (Invitrogen), Karlsruhe, Germany 
Ethanol      Merck, Darmstadt, Germany 
Ethanolamine       Sigma-Aldrich, Steinheim, Germany 
Fetal calf serum (FCS)    Invitrogen, Karlsruhe, Germany 
Fluoro- ribonucleotide triphosphates (fYTPs) MP Biomedicals, Illkirch, France 
Formamide      Merck, Darmstadt, Germany 
γ − 32P ATP      Perkin Elmer Life Sciences, MA, USA 
Gel concentrate and diluent     National Diagnostic, Hessle Hull, England 
Glacial acetic acid     Merck, Darmstadt, Germany 
Glutamine      Invitrogen, Karlsruhe, Germany 
Glycerine      Merck, Darmstadt, Germany 
Glycogen      Roche, Mannheim, Germany 
GMP       Sigma-Aldrich, Steinheim, Germany 
Goat anti mouse IgG Dynabeads   Invitrogen/Dynal AS, Oslo, Norway 
Isoelectric Focussing Calibration KIT   GE Healthcare, München, Germany 
Inorganic pyrophosphate (400x ppi)   Sigma-Aldrich, Steinheim, Germany 
Horse serum       Gibco (Invitrogen), Karlsruhe, Germany 
Human serum albumin (HSA)   Sigma-Aldrich, Steinheim, Germany 
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Hydrochloric acid (HCl) mol. biology grade  Sigma-Aldrich, Steinheim, Germany 
LDS sample buffer     Invitrogen, Karlsruhe, Germany 
Magnesium chloride     Sigma-Aldrich, Steinheim, Germany 
MEM Eagle medium      Sigma-Aldrich, Steinheim, Germany 
MES hydrate      Sigma-Aldrich, Steinheim, Germany 
Methanol      Merck, Darmstadt, Germany 
Methotrexate (MTX)     Sigma-Aldrich, Steinheim, Germany 
N-Hydroxysuccinimide (NHS)   Sigma-Aldrich, Steinheim, Germany 
N-(3-dimethylaminopropyl)- 
N’-ethylcarbodiimide hydrochloride (EDC)  Sigma-Aldrich, Steinheim, Germany 
Pharmalyte pH3-10      GE Healthcare, München, Germany 
Phenol solution     Sigma-Aldrich, Steinheim, Germany 
PKH2/6 fluorescent cell linker kits   Sigma-Aldrich, Steinheim, Germany 
Potassium hydroxide pellets (KOH)   Sigma-Aldrich, Steinheim, Germany 
Propidium iodide (PI)    Invitrogen, Karlsruhe, Germany 
RPMI 1640       Invitrogen, Karlsruhe, Germany 
Sample reducing agent    Invitrogen, Karlsruhe, Germany 
SeeBlue Plus 2 prestained protein standard  Invitrogen, Karlsruhe, Germany 
Sodium acetate (NaOAc, pH 5.2)   Merck, Darmstadt, Germany 
Sodium azide      VWR International, Darmstadt, Germany 
Sodium hydroxide (NaOH)    VWR International, Darmstadt, Germany 
Sodium pyrovate     Invitrogen, Karlsruhe, Germany 
Taq polymerase and 10x buffer   NEB, Beverly, New England, USA 
TE buffer pH 8.0     Invitrogen, Karlsruhe, Germany 
TEMED      VWR International, Darmstadt, Germany 
tRNA from baker's yeast     Sigma (Fluka), Steinheim, Germany 
Tween-20      Merck, Darmstadt, Germany 
Ultra low IgG FCS     Gibco (Invitrogen), Karlsruhe, Germany 
Urea       VWR (OmniPur), Darmstadt, Germany 
Western blot diluent A    Invitrogen, Karlsruhe, Germany 
Western blot diluent B    Invitrogen, Karlsruhe, Germany 
Western blot wash solution    Invitrogen, Karlsruhe, Germany 
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3.5 Cell culture media 
 
Jurkat E6.1       RPMI 1640  
2 mM glutamine 
1 mM sodium pyruvate 
10 % (v/v) FCS  
 
Recombinant Jurkat V158 and F158   RPMI 1640 
2 mM glutamine  
1 mM sodium pyruvate  
10 % (v/v) FCS 
100 nM MTX 
 
GTL-16      DMEM 
10 % (v/v) FCS 
 
MKN-45      RPMI 1640 
2 mM glutamine 
1 mM sodium pyruvate 
20 % (v/v) FCS  
 
EBC-1       MEM Eagle   
2mM glutamine 
10 % (v/v) FCS 
 
NIH-3T3      DMEM 
10 % (v/v) FCS 
2.5 % (v/v) horse serum  
 
ADCC Assay medium    RPMI1640 
10 % (v/v) ultra low IgG FCS 
(heat-inactivated 56°C 30 min) 
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3.6 Solutions and buffer 
1x gel loading buffer     40 % formamide 
2.5 mM EDTA 
 
1x TC buffer      40 mM Tris-HCl (pH 7.5) 
6 mM MgCl2 
10 mM NaCl 
2 mM spermidine 
 
2x gel loading buffer     80 % (v/v) formamide 
5 mM EDTA 
 
5x RT buffer      1 M Tris-acetate pH 8.4 
2 M potassium acetate 
100 mM magnesium acetate 
 
10x TBE buffer     890 mM Tris 
890 mM boric acid 
20 mM EDTA 
 
ADCC assay medium     RPMI 1640 
10 % (v/v) ultra low IgG FCS 
(heat-inactivated 56°C 30 min) 
 
Cell SELEX binding buffer    0.05 % (w/v) BSA 
0.03 % (w/v) sodium azide in DPBS 
 
Coomassie staining solution    40 % (v/v) methanol 
10 % (v/v) glacial acetic acid 
16 tablets/l Coomassie R250 
 
Coomassie destaining solution    35 % (v/v) ethanol  
10 % (v/v) glacial acetic acid 
 
DNA SELEX PCR mix    1x Taq buffer (for 200 µl final volume) 
4 mM dNTPs (each) 
1 µM primer 5978, 1 µM primer 5979 
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FACS binding buffer     1 % (w/v) BSA in DPBS 
 
Filter elution buffer     7 M Urea 
100 mM NaOAc pH 5 
3 mM EDTA (pH 5.7 final) 
 
IEF rehydration buffer    890 µl Pharmalyte pH3-10 
       1.22 g glycerine in 12 ml dH2O 
 
MACS buffer      4.9 ml MACS BSA stock solution 
       95.1 ml DPBS 
 
Passive elution buffer     300 mM NaOAc 
20 mM EDTA 
 
Reverse transcription (RT) mix   1x cDNA synthesis buffer (50 µl final vol.) 
       4 mM dNTPs (each) 
       2 µM 3’primer 5981 
       5 mM DTT 
 
TBE buffer      89 mM Tris 
89 mM boric acid 
2 mM EDTA 
 
TC reaction composition    1x TC buffer 
2 mM MgCl2 
1.5 mM of each ATP, GTP, fCTP, fUTP 
40 mM DTT 
5x ppi 
3.2 µg T7 RNA polymerase Y639L (1 µl) 
 
Western blot antibody solution   2 ml western blot diluent A 
       1 ml western blot diluent B in 7 ml dH2O 
 
Western blot blocking solution   2 ml western blot diluent A 
       3 ml western blot diluent B in 5 ml dH2O 
 
Western blot wash solution    10 ml western blot wash in 150 ml dH2O 
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3.7 Laboratory materials 
 
4-20 % TBE gels      Biostep, Jahnsdorf, Germany 
4-20 % Tris-glycine gels    Invitrogen, Karlsruhe, Germany 
10 % TBE gels      Invitrogen, Karlsruhe, Germany 
10 % TBE-Urea gels      Invitrogen, Karlsruhe, Germany 
Abgene PCR plates     Thermo Scientific, Langenselbold, Ger. 
Airpore tape sheets     Qiagen, Hilden, Germany 
E gel 4 % agarose (HR)    Invitrogen, Karlsruhe, Germany 
FortéBio tips      FortéBio, Menlo Park, California, USA 
Gel blot paper      Whatman, Dassel, Germany 
Glas pasteur pipettes     VWR, Darmstadt, Germany 
Glas plates for electrophoresis   Whatman, Maidstone, UK 
iBlot dry blotting components   Invitrogen, Karlsruhe, Germany 
Lymphoprep tubes (Ficoll)     Axis-Shield, Heidelberg, Germany 
Maxisorp microtiter plates    Nunc, Langenselbold, Germany 
Micro Bio-Spin columns P-30 Tris, RNase-free Bio-Rad, Munich, Germany 
Nitrocellulose Centrex columns (0.45 µm)  Schleicher & Schuell, Dassel, Germany 
Nitrocellulose membrane Protran BA85 (0.45 µm) Schleicher & Schuell, Dassel, Germany 
NuPAGE 4-12 % Bis-Tris gels   Invitrogen, Karlsruhe, Germany 
Optiplate microtiter plates    Perkin Elmer Life Sciences, MA, USA 
Plastic spacer for electrophoresis gels  Whatman, Maidstone, UK 
Polypropylene round-bottom tubes for FACS BS Biosciences, Massachusetts, USA 
Polypropylene microtiter plates, black  Greiner Bio-one, Frickenhausen, Germany 
PVDF filter membrane Hybond P   GE Healthcare, München, Germany 
Thin layer chromatography plate   Merck, Darmstadt, Germany 
Thermoscript RT-PCR system   Invitrogen, Karlsruhe, Germany 
Tissue culture flasks “Cellstar”, 75 cm2  Greiner Bio-one, Frickenhausen, Germany 
Ultrafree-MC 0.22 µm pore size spin filters  Millipore, Schwalbach, Germany 
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3.8 Equipment 
 
AlphaImager 12-bit dynamic range CCD camera Alpha Innotech, Santa Clara, CA, USA 
BioMek Synergy4 fluorescence reader  BioMek/BeckmanCoulter, Brea, CA, USA 
CEDEX cell counter MS20C    Roche Innovatis, Mannheim, Germany 
Centrifuge Megafuge 1.0 R    Kendro, Langenselbold, Germany 
Dot blot S&S Minifold I Dot-Blot system  Schleicher & Schuell, Dassel, Germany 
E gel PowerBase Ver.4    Invitrogen, Karlsruhe, Germany 
Electrophoresis chambers    Invitrogen, Karlsruhe, Germany 
FACScan cytometer     Beckton Dickinson, Heidelberg, Germany 
FortéBio octet red     FortéBio, Menlo Park, California, USA 
Geiger counter     Mini Instruments Ltd., Burnham, UK 
iBlot dry blotting system    Invitrogen, Karlsruhe, Germany 
Luminometer Varioskan Flash   Thermo Scientific, Schwerte, Germany 
MACS autoMACS separator    Miltenyi, Bergisch-Gladbach, Germany 
Magnet separators     Invitrogen/Dynal, Oslo, Norway 
Nanodrop ND-1000 spectrophotometer  Peqlab, Erlangen, Germany 
PCR machine/ Peltier Thermal cycler, Tetrad2 Bio-Rad, Munich, Germany 
PhosphorImager Storm 860    GE healthcare, München, Germany 
Power supply Power-Pak 300   Bio-Rad, Munich, Germany 
Storage phosphor screen and cassette  GE healthcare, München, Germany 
Table-top centrifuge Eppendorf 5415  Eppendorf, Hamburg, Germany 
Tecan Washer HydroFlex    Tecan, Crailsheim, Germany 
Thermomixer comfort    Eppendorf, Hamburg, Germany 
UVS-26 EL Lamp, 115V, 254NM, 6W  VWR International, Darmstadt, Germany 
Vacuum centrifuge Vacuum Concentrator 5301 Eppendorf, Hamburg, Germany 
Vertical gel electrophoresis system   Whatman, Maidstone, UK 
 
Further equipment comprised common laboratory instrumentation. 
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3.9 Software 
BD CellQuest      Becton Dickinson, Heidelberg, Germany 
BioEdit ver. 7.0.9.0     Ibis Therapeutics, Carlsbad, CA, USA 
DNA Star ver. 7.2.1 SeqMan and EditSeq  DNA Star Inc., Wisconsin, USA 
FortéBio octet data analysis ver. 6.2.1.1  FortéBio, Menlo Park, California, USA 
Gen5 fluorenscence reader analysis ver. 1.04.5 BioMek/BeckmanCoulter, Brea, CA, USA 
ImageQuant ver. 5.2     Mol. Dynamics/GE, München, Germany 
Mfold ver. 3.2 by Zuker and Turner  http://mfold.bioinfo.rpi.edu/cgi-bin/dna-
form1.cgi (Zuker, 2003) 
Microsoft Office 2003    Microsoft Corp., Redmond, WA, USA 
Origin  ver. 8.1     OriginLabs, Northampton, MA, USA 
Phoretix      Totallab, Newcastle upon Tyne, UK 
Python       Python Software Foundation 
SkanIt Software ver. 2.4.3    Thermo Scientific, Schwerte, Germany 
XL fit ver. 2.1.1     IDBS, Surrey, UK 
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4 METHODS 
4.1 Molecular biological methods 
4.1.1 DNA aptamer production 
4.1.1.1 Polymerase chain reaction 
For specific amplification of DNA fragments or aptamer production, a polymerase chain 
reaction (PCR) was applied (Mullis et al., 1986). Generally, a total volume of 200 µl for an 
initial small scale PCR (ssPCR) and 1 ml for a large scale PCR (lsPCR) was used to assemble 
50 – 100 pmol, but also larger volumes could be applied to yield higher amounts of aptamers. 
The same PCR mix was applied in all DNA aptamer amplifications and contained up to 
10 ng/ml template (pool or single aptamer); 1 µM forward and reverse primer 5978 and 5979, 
respectively (chapter  3.3); deoxyribonucleoside triphosphates at 0.2 mM of each nucleotide; 
appropriate amount of 10x NEB Taq buffer and 0.025 U/µl Taq DNA polymerase (native 
form, chapters  3.2 and  3.6).  
 
10 rounds of amplification were performed for 30 sec each at 94°C for denaturing, at 50°C for 
annealing, at 72°C for extension and pausing at 4°C in a thermocycler (chapter  3.7). After 10 
cycles, 5 µl of PCR reaction were added to 5 µl dH2O on an 4 % agarose ethidium bromide E-
Gel (chapter  3.7) and run for 7 min along with 0.5 µg NEB 100 bp marker (which includes 50 
ng as 100 bp band, chapter  3.7). The PCR product was visually quantified compared to the 
reference marker band applying a trans-illuminator (AlphaImager, chapter  3.7). Additional 
PCR cycles were carried out to yield at least 10 ng/µl of the specific aptamer PCR product 
(sample is at the same intensity as the 100 bp band). Resulting PCR products were 
precipitated (chapter  4.1.5) and a strand separation was carried out (chapter  4.1.1.2). Aliquots 
of PCRs could be stored at -20°C for several months as a resource for additional aptamer 
productions. 
 
4.1.1.2 Alkaline induced DNA strand break 
PCR products were double stranded, but aptamers need to be single stranded DNA to adapt a 
correct conformation. The reverse primer 5979 used in DNA aptamer amplification contained 
a 3’ terminal ribo-dCTP to enable an alkaline induced antisense strand break with subsequent 
PAGE (chapter  4.1.3.2) size exclusion strand separation to finally yield single stranded DNA 
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aptamers. To perform a strand separation on a pool or single aptamer in aqueous solution, 
0.5 volumes 1M NaOH were added and incubated for 15 min at 90°C. Then, 0.5 volumes 1M 
HCl for neutralisation and 1 volume of 2X gel loading buffer (chapter  3.6) were added and 
boiled for further 5 min at 90°C. Samples were run on a TBE-polyacrylamide gel (chapter 
 4.1.3.2) and the desired 84 nt aptamer sense strand could be well separated from 24 nt and 
60 nt antisense strand fragments. The aptamer band was extracted (chapter  4.1.4), precipitated 
(chapter  4.1.5), re-constituted in DPBS and the final concentration was determined (chapter 
 4.1.6). Figure 4 gives a short overview of DNA aptamer production. 
 
4.1.1.3 DNA aptamer synthesis  
DNA aptamers can be obtained in higher quantity (more than 100 pmol) simply by oligo 
synthesis. Single sequence aptamers were purchased in 200 nmol or 1 µmol synthesis scale 
from Eurofins MWG Operon (Ebersberg, Germany) or invitrogen (Karlsruhe, Germany). 
Aptamers with nucleotide lengths over 100 were synthesised as “ultramers” by IDT (Leuven, 
Belgium). A subsequent PAGE purification (chapter  4.1.3.2) ensured high quality. The 
appropriate aptamer band was extracted (chapter  4.1.4), precipitated (chapter  4.1.5), re-
constituted in DPBS and the final concentration was determined (chapter  4.1.6). 
 
4.1.1.4 Production of labelled aptamers 
5’ Fluorescein (FLO) labelling as well as both, 5’ or 3’ biotinylation of DNA aptamers were 
accomplished by coupling during synthesis and purchased PAGE-purified in a 200 nmol scale 
from Invitrogen (Karlsruhe, Germany). 
 
4.1.2 Modified RNA aptamer production 
Modified RNA aptamers can be synthesised at higher costs or transcribed from a double 
stranded DNA template applying a modification tolerating mutant DNA-dependent T7 RNA 
polymerase Y639L (chapter  3.2). The first steps of amplifying a reverse-transcribed pool or 
single aptamers are similar to DNA aptamer production and comprise ssPCR and lsPCR using 
a DNA template (chapter  4.1.1.1). The applied forward primer 5980 (chapter  3.3) elongates 
the original 20 nt 5’ PCR flanking sequence by a T7 transcription start site. The resulting 
106 nt dsDNA PCR product can serve as transcription template for an 84 nt RNA aptamer 
production.  
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The dsDNA fragments obtained by PCR were precipitated (chapter  4.1.5) and resuspended in 
nuclease-free H2O to a concentration of 1.5 µM (0.1 volume of PCR, 100 ng/µl). Since high 
concentrations of dNTPs could inhibit the transcription reaction, the precipitated PCR 
reaction was additionally desalted using Biospin columns according to manufacturer’s 
protocol. 20 µl of the desalted PCR template were applied in a total volume of 100 µl 
transcription reaction yielding a final concentration of 300 nM dsDNA template. The work 
presented herein was carried out with the rRfY pool comprising 2’-hydroxy-purines and 2’-
fluoro-pyrimidines (chapter  2.4.1), the transcription composition is shown in chapter  3.6. The 
transcription reaction was incubated for 18 h at 32°C and yielded modified ssRNA aptamers. 
For transcription verification and purification, 1 volume of 2X gel loading buffer (chapter  3.6) 
was added and incubated for 5 min at 90°C. Samples were run on a TBE-polyacrylamide gel 
(chapter  4.1.3.2) and the desired 84 nt RNA aptamer could be separated from the longer 
dsDNA template. The aptamer band was extracted (chapter  4.1.4), precipitated (chapter 
 4.1.5), resuspended in usually 100 µl DPBS and the final concentration was determined 
(chapter  4.1.6). Figure 4 in the introduction shows a scheme of RNA aptamer production and 
purification. 
 
4.1.3 DNA gel electrophoresis 
4.1.3.1 Agarose gel electrophoresis 
For analytical purpose, agarose gel electrophoresis was carried out applying the E-Gel system 
of invitrogen (Karlsruhe, Germany). For this, usually 5 µl of DNA sample solution were 
added to 5 µl dH2O on a 4 % agarose ethidium bromide E-Gel and run for 7 min along with 
0.5 µg NEB 100 bp marker (which includes 50 ng as 100 bp band, chapter  3.7). The PCR 
product was visually evaluated or quantified to the reference marker band for size and 
concentration applying a trans-illuminator (AlphaImager, chapter  3.7). 
 
4.1.3.2 TBE polyacrylamide gel electrophoresis 
For aptamer purification and analyses requiring precise resolution, polyacrylamide gel 
electrophoresis was applied. Analytical 4-20 % or 10 % TBE gels were run according to the 
manufacturer’s suggestions (chapter  3.7). Preparative gels were made by adding 20 ml Gel 
Concentrate, 25 ml Gel Diluent, 5 ml 10x TBE, 200 µl 10 % APS and 100 µl TEMED 
(chapter  3.7, the two latter substances immediately before use) in a 50 ml falcon tube. The 
solution was inverted for complete mixing and poured between two glass plates blocked on 
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three sides by 1.5 mm plastic spacers. A comb was placed on top and the solution was 
allowed to polymerise at ambient temperature for at least 10 min before the gel was 
suspended into the running device.  
 
Samples were loaded usually along with 10 µl of 6x DNA loading buffer (chapter  3.4) in a 
separate lane for visualization of the PAGE-progress. The gel was run at a constant voltage of 
350 V for 1 h, or until the bromophenol blue dye marker was at the bottom of the gel. The 
glass plates were taken apart, the gel covered in plastic wrap and transferred onto a thin layer 
chromatography plate including a fluorescent dye. For visualisation, the DNA shadowing 
technique was applied: When excited with UV light (at 254 nm applying a hand lamp or the 
“epi short wave uv” function of the AlphaImager, chapter  3.7) the dye’s fluorescence was 
quenched by oligonucleotide bands in the gel and could be imaged and marked.  
 
4.1.4 Gel extraction 
Desired bands were excised out of TBE polyacrylamide gels with a clean razor or scalpel and 
placed into a 1.5 ml tube. The gel piece was sheared using a pipette tip. Usually 400 µl 
passive elution buffer (chapter  3.6) were added, quickly homogenised by vortexing and 
incubated over night at 37°C to allow passive elution of aptamers into the solution. On the 
next day, the liquid containing the eluted sample was removed from the gel remnants and 
purified using a Millipore spin column (chapter  3.7), spinning for 1 minute at 13000 rpm. 
Finally, the aptamer solution had to be purified by ethanol precipitation (chapter  4.1.5). 
 
4.1.5 DNA precipitation 
Precipitation provided a basis to concentrate DNA and remove undesired proteins, salts and 
free nucleotides. The ladder ones are not removed completely, but sufficiently in many cases. 
If complete removal was critical, Biospin columns were applied in addition (chapter  3.7). 
Addition of mono-valent cations diminishing rejection of its negatively charged backbone 
with simultaneous solvent deprivation by ethanol addition leads to precipitation of DNA out 
of the solution. Glycogen applied as a carrier can further improve the recovery.  
 
PAGE-eluted DNA and RNA aptamers were already in acidified solution containing 0.3 M 
sodium acetate and could be ethanol precipitated by the addition of 2 µl (40 µg) glycogen and 
2.5 volumes ice cold 100 % ethanol p.a. to the aqueous solution into a 1.5 ml tube. This was 
followed by vigorous vortexing to ensure complete mixing and centrifugation for 30 – 60 min 
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at 13000 rpm and 4°C. The supernatant was decanted and discarded, and pellets were allowed 
to completely dry in open tubes for 1 h at ambient temperature or at 37°C for shorter time 
spans. The DNA usually was resuspended in 40 – 100 µl DPBS. Ethanol precipitation of PCR 
reactions was carried out essentially as described above, only differing in the addition of 
0.1 volume of 3 M sodium acetate pH 5.0 (not yet included in the solution) instead of 
glycogen.  
 
Isopropanol precipitation can reduce the amount of co-precipitated salts. It was carried out 
similar to the ethanol precipitation including glycogen as described above, but only 1 volume 
of isopropanol was applied. Complete drying of pellets was assured to avoid residual 
isopropanol that could interfere with subsequent reactions. 
 
4.1.6 Determination of DNA concentration  
The nucleic acid concentration of aqueous solutions can either be measured applying the law 
of Lambert-Beer via absorption of aromatic nucleobases at 260 nm or comparing the intensity 
of electrophoresis gel bands with quantitative marker bands run simultaneously.  
 
In general, the concentration of purified DNA or RNA samples was determined with the UV 
spectrophotometer Nanodrop ND1000 (chapter  3.7) by adding 1.5 µl sample solution and 
measuring the 260/280-ratio as well as the absorption at 260 nm. 1 OD260 equates to a 
concentration of 50 µg/ml dsDNA, 35 µg/ml RNA or 33 µg/ml ssDNA. Evaluation of protein 
contents by measuring absorption at 280 nm allows for determination of purity of the sample: a 
protein-free nucleic acid solution should have a OD260/OD280  ratio of about 2 : 1. Aptamers 
purified by gel electrophoresis were already examined for the correct size to exclude the 
possibility that absorption at 260 nm was caused by single nucleotides or degradation 
products that would decrease the concentration of the actual aptamer in solution. Sample that 
were measured but had not been analysed in this way were evaluated on a 4 % E-Gel (chapter 
 4.1.3.1) to ascertain their identity. 
 
During PCR monitoring, PCR progress evaluation could not be carried out using the method 
described above due to free dNTPs and primers in the PCR solution. Here, a comparative 
agarose gel electrophoresis was carried out applying a quantitative marker along with the 
samples run on 4 % agarose E-Gels. This method is described in more detail in chapter 
 4.1.1.1. 
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4.1.7 Separation of pools into single aptamers 
The analysis of single aptamers out of a library or selection required the separation of a pool 
into single entities representing one aptamer only. For this, double stranded PCR fragments 
containing a Taq polymerase derived adenine overlap were cloned into the TOPO-TA pCR4.0 
cloning vector (chapter  3.7). This vector contained a death (CCD) gene and utilised a 
life/death screen: only in the presence of a vector with insert exchanged for the CCD gene a 
clone was able to grow. 1 µl of a 1 : 100 dilution of PCR product (generally at 10 ng/µl) was 
combined with 1 µl water, 0.5 µl salt solution and 0.5 µl TOPO TA pCR 4.0 vector (all 
provided in the cloning kit), mixed by gently flicking tube with a finger, centrifuged down for 
10 sec in a microcentrifuge and incubated at ambient temperature for 30 min. Topo-cloning 
vectors were transformed into E. coli (chapter  4.4.1.). Single clones representing one single 
aptamer were analysed further by sequencing, since they were carrying one vector containing 
one single aptamer sequence as insert only. 
 
4.1.8 Sequence analysis of single aptamer containing E. coli clones 
Analysis of aptamers in a selected pool was carried out by sequence comparison of usually 96 
aptamers to evaluate potential enrichment of single or similar aptamers. Single aptamers 
represented by E. coli clones transformed with a dsDNA-aptamer-Topo-vector were 
sequenced by MWG, Ebersberg, Germany. For this, a DNA preparation and sequencing with 
both M13_for and M13_rev primers (chapter  3.3) were carried out. Resulting sequences were 
obtained as ab1-files and processed in Python. Aptamers were brought in the correct 
orientation on the basis of known 5’ and 3’ flanking sequences, vector and invariant flanking 
sequences were clipped to leave only the 39 or 40 nt long variant fragment and these were 
stored in a multiple fasta file. The single sequences were grouped applying DNA Star SeqMan 
to sequence families of 90 % sequence identity, e.g. four bases in 40 were allowed to be 
altered. A unique identifier was assigned to the most prevalent aptamer in each sequence 
family. Sequence variants were listed for each aptamer and characterised later on as well, if 
the most prevalent sequence exhibited desired properties.  
 
4.1.9 5’ radioactive oligonucleotide labelling 
Radioactive labelling represents an effective and sensitive method that does not alter initial 
aptamer characteristics. DNA aptamers and synthetic RNA can be labelled directly due to the 
lack of a 5’ phosphorylation; RNA transcripts have to undergo a dephosphorylation step at 
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first. For this, 10 pmol of an aptamer clone or pool, 1 µl 10x AP buffer, 1 µl (5 U) antarctic 
phosphatase (chapter  3.2) and a respective volume of water were incubated in a total volume 
of 10 µl at 37°C for 15 – 45 min. Subsequently, the phosphatase was heat inactivated by 
incubation at 65°C for 10 minutes. 
 
Either dephosphorylated RNA or DNA was then employed in a kinase reaction applying the 
T4 Poly Nucleotide Kinase (PNK, chapter  3.2). 10 pmol of aptamer, 2 µl 10x T4 PNK buffer, 
0.5 µl (5 U) T4 PNK, 3 µl 32P γ-ATP (30 µCi, chapter  3.4) and the respective volume of water 
in a total volume of 20 µl were incubated for 15 – 45 min at 37°C. 
 
For removal of unincorporated ATP by non-interactive separation by size, Bio-Spin columns 
were used following the manufacturer’s protocol (chapter  3.4). In brief, column bottom caps 
were removed and the columns placed in waste collection tubes, then top caps were removed 
and the initial flow-through liquid was removed by decanting. Tubes were centrifuged at 
1,000 g (3,300 rpm) for 2 min. Columns were placed in new 1.5 ml tubes, 20 µl kinase 
reactions were added to the top of the resin and centrifuged at 1,000 g (3,300 rpm) for 4 min 
in the same centrifuge. The columns were discarded in 32P radiation waste and the flow 
through was evaluated using a Geiger counter (chapter  3.8) to ensure a successful labelling 
reaction when samples registered high on the 100x setting. 
 
To obtain an applicable working concentration, the obtained labelled aptamer solution was 
diluted 1 : 500 by adding 2 µl of labelled aptamer to 998 µl DPBS (chapter  3.4). The resulting 
solution was applicable for dot blots (chapter  4.3.9) with 1 nM for the respective aptamer, 
hence containing 5 fmol aptamer in 5 µl. 
 
4.2 Systematic evolution of ligands by exponential enrichment 
Systematic evolution of ligands by exponential enrichment (SELEX) is a method for selection 
of single aptamers that bind to a target of interest out of a pool of nucleic acid sequences. 
Aptamers are enriched by iterative steps of selection and amplification by PCR in 5 to 15 
rounds. DNA SELEX consists of selection by aptamer binding, separation and washing 
followed directly by amplification via PCR, strand separation and PAGE purification of the 
new aptamer pool. RNA SELEX shares a similar selection route, but comprises amplification 
by reverse transcription, PCR, transcription of the respective composition and PAGE 
purification to yield a potentially enriched pool.  
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In order for SELEX to be successful, aptamer-target molecule complexes must be efficiently 
captured. The following paragraph describes three procedures for separation of binding from 
non-binding nucleic acids by immobilisation of nucleic acid : protein complexes on a 
nitrocellulose filter (filter SELEX, chapter  4.2.1), on the hydrophobic surface of a microtiter 
plate (hydrophobic plate SELEX, chapter  4.2.2) or whole cells (cell SELEX, chapter  4.2.3). 
For all selections, a DNA or rRfY oligonucleotide library containing a 40-base random 
sequence flanked by complementary priming regions on either end (chapter  3.3) was used as 
the starting point for an aptamer SELEX.  
 
4.2.1 Filter SELEX 
Filter SELEX was based on the immobilisation of the target protein to a nitrocellulose 
membrane after incubation of aptamer with target protein in solution, enabling separation of 
target-bound aptamers and washing off non-binding sequences.  
 
4.2.1.1 Nitrocellulose filter capacity test 
Since target molecules must be efficiently captured to not loose bound aptamers of interest, an 
initial nitrocellulose filter capacity test has to prove 100 % target protein binding to the 
applied filter. Nitrocellulose Centrex columns (chapter  3.7) were incubated at ambient 
temperature for 15 min with 1 ml of 0.5 M KOH solution to reduce non-specific binding of 
aptamers to the nitrocellulose. Filters were centrifuged at 2000 rpm for 1 min, flow-through 
material was removed from the bottom of the tubes, and columns were incubated with 1 ml 
dH2O at ambient temperature for 3 min. Centrifugation and incubation were repeated two 
times with DPBS (chapter  3.4) to equilibrate the filter with the appropriate buffer. 200 µl 
target protein solution with the concentration maximally applied in SELEX rounds (usually 
1 µM) were prepared and divided: 100 µl were applied to a pre-treated Centrex column 
collecting the flow-through, 100 µl were stored at ambient temperature. Equivalent volumes 
(20 µl) of both filter flow-through and original sample were directly compared by gel 
electrophoresis (chapter  4.3.2) and coomassie staining (chapter  4.3.4). Complete depletion of 
protein in the flow-through indicated sufficient filter capacity. 
 
4.2.1.2 DNA SELEX 
Carrying out DNA filter SELEX, desired target-bound aptamers were separated by 
immobilisation of target protein on a nitrocellulose filter and washing away unbound 
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aptamers that were discarded in the flow-through. Selection was carried out in a total volume 
of 100 µl in Dulbecco’s PBS (DPBS) with increasing concentration of the non-specific 
competitor tRNA and washing volume as well as decreasing amounts of target protein to 
enhance stringency over the course of selection (all chapter  3.4). For round 1, 
1 x 1014 molecules of the starting pool were used (with a final concentration of 1.66 µM) and 
in subsequent rounds, the output pool from the previous round were adjusted to 1 µM. The 
filters were pre-treated with KOH to reduce non-specific binding of the DNA pools to the 
filter as described in chapter  4.2.1.1, and filters were kept wet during the last washing step 
until selection.  
 
For removal of filter-binding aptamers in a negative pre-selection (skipped in round 1), 50 µl 
pool/DPBS solution were added to pre-treated filters and centrifuged at 2000 rpm for 1 min. 
The flow-through was collected for use in subsequent positive / negative selection steps. A 
counterselection was applied if desired to remove aptamers against components not to be 
targeted (e.g. His-tags or Fc-fusion portions of applied recombinant target proteins; skipped in 
round 1) by adding protein and DPBS to the flow-through of negative selection to a final 
concentration of 1 µM protein in 90 µl total volume. After incubation for 1 h at 37°C, the 
pool/DPBS solution was added to pre-treated filters, centrifuged at 2000 rpm for 1 min and 
the flow-through was collected for use in a positive selection step. 
 
Positive selection was carried out in case of a previous counterselection by adding target 
protein and competitor amount to 90 µl pool/DPBS flow-through to yield 1 µM protein in 
100 µl total volume. In case of no counterselection, 50 µl target protein and competitor 
mixture were added to 50 µl flow-through solution from negative pre-selection. Positive 
selection mixtures were incubated 1 h at 37°C, then added to pre-treated Centrex columns and 
centrifuged at 2000 rpm for 1 min discarding the flow-through. Filters thereby caught desired 
protein:pool complexes. These were washed two times with pre-warmed 1000 µl DPBS 
(500 µl in round 1) and centrifugation discarding flow-through as before, and eluted with two 
times 200 µl 90°C pre-heated elution buffer (chapter  3.6) by incubation for 1 min and 
centrifugation as above combining both flow-through elution fractions (400 µl total). During 
this step, heat and urea denatured target proteins lost their correct folding releasing 
conformational epitope-binding aptamers that were collected in the flow-through. These 
aptamers were purified for subsequent PCR via isopropanol precipitation (chapter  4.1.5) and 
resuspended in 10 µl dH2O. 
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Amplification of aptamer pools was achieved in a two-step PCR setup. Initial small scale 
PCRs (ssPCR) were carried out to adjust DNA concentrations to a standard concentration of 
10 ng/µl, at the same time investigating indirectly the amount of selected aptamers by PCR 
cycle monitoring. The more aptamers were enriched, the less PCR cycles were needed to 
yield the desired concentration. In the next step, large scale PCRs (lsPCR) followed to yield 
sufficient aptamer material for subsequent selection rounds. PCRs were performed as 
described in chapter  4.1.1.1. A 50 µl aliquot of each ssPCR was stored at -20°C as stock 
sample for the respective selection round. lsPCR was carried out for 11 cycles under ssPCR 
conditions and confirmed by E-gel electrophoresis as described in chapter  4.1.1.1. Residual 
ssPCR- and lsPCR-volumes were combined in 15 ml tubes and precipitated (chapter  4.1.5). 
After removal of supernatant and drying as above, pellets were resuspended in 30 µl TE 
buffer pH 8.0 (chapter  3.4) and transferred to 1.5 ml tubes. 
 
Single stranded aptamers had to be obtained via strand separation of the double stranded PCR 
products. The use of 3’ ribo-modified reverse primers (oligo 5979, chapter  3.3) enabled 
alkaline induced strand breaks of the anti-sense strand (chapter  4.1.1.2) leading to one larger 
sense strand aptamer and two smaller anti-sense fragments that were separated by 
polyacrylamide gel electrophoresis (PAGE, chapter  4.1.3.2). Passive gel elution (chapter 
 4.1.4), DNA precipitation (chapter  4.1.5), and resuspension in 40 µl DPBS were completed by 
concentration determination (chapter  4.1.6) to yield an enriched aptamer pool ready for the 
next SELEX round. 
 
4.2.1.3 rRfY SELEX 
Filter SELEX of 2’-modified RNA aptamers comprised the same selection work-flow as 
DNA filter SELEX (chapter  4.2.1.2), but differed in two main aspects of amplification: 
Firstly, filter-eluted aptamers needed to be reversely transcribed to DNA to be amplified via 
PCR. For this, eluate precipitation was followed directly by resuspension in 50 µl of RT mix 
(chapter  3.6) and addition of 0.5 µl of Thermoscript Reverse Transcriptase (chapter  3.2). 
Reverse transcription was carried out at 65°C for 30 min. Subsequently, DNA aptamers in 
50 µl RT samples were amplified in 400 µl total volume ssPCR as described in DNA filter 
SELEX (chapter  4.2.1.2). Application of oligos 5980 and 5981 (chapter  3.3) introduced a T7 
transcription site 5’ of the resulting DNA aptamer template for transcription back into rRfY 
composition in the next step. Since high concentrations of residual free dNTPs could inhibit 
the transcription, the PCR solution was ethanol precipitated (chapter  4.1.5) and desalted via 
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Biospin columns (as in chapter  4.1.9), yielding 40 µl of purified DNA aptamer templates. 
20 µl were stored as aliquot at -20°C, 20 µl were combined with 80 µl transcription reaction 
mix (chapter  3.6) and rRfY aptamers were transcribed from DNA templates at 32°C for 18 h. 
Resulting modified RNA aptamers could be separated by PAGE from larger DNA templates 
carrying the T7 transcription site (as in chapter  4.2.1.2). In this manner purified rRfY 
aptamers were applicable for following SELEX rounds. 
 
4.2.2 Hydrophobic plate SELEX 
If target proteins could not be captured sufficiently to nitrocellulose filters, immobilisation 
onto the well of a hydrophobic plate and subsequent capture of binders to that surface 
displayed another opportunity for aptamer selection to recombinant proteins. A further 
advantage was the facile competition elution of pre-bound aptamers by addition of a potential 
competitor that bound to the immobilised target protein replacing aptamers bound to the same 
epitope. These desired aptamers found in the supernatant could be amplified by PCR.  
 
Immobilisation was carried out with 100 nM protein target in 100 µl DPBS per Nunc 
Maxisorp plate well (chapter  3.7) for 30 min at ambient temperature, followed by 3 washes 
with 200 µl DPBS to remove unbound target. Target wells were further blocked with 200 µl 
5 % HSA of DPBS and washed as above. For negative or counterselection steps (skipped in 
round 1), empty or counter protein wells, respectively, were blocked in the same way. 
Aptamer and competitor concentrations and volumes were applied analogue to DNA filter 
SELEX (chapter  4.2.1.2). For negative, counter and positive selection steps, 100 µl aptamer 
pools were incubated for 1 h at 37°C and transferred consecutively to all particular wells. The 
positive selection supernatant was discarded and wells washed 5 times with 100 µl 37°C pre-
warmed DPBS. Elution was carried out analogue to filter SELEX with pre-heated urea elution 
buffer (chapters  3.6 and  4.2.1.2) yielding 400 µl eluted aptamer solution. For an alternative 
competition elution, the competitor (in this work antibodies 3G8 or cetuximab, chapter  3.2) 
was added to the fifth washing solution in high excess to target protein of 1 µM final 
concentration and incubated for 1 h at 37°C. The supernatant contained displaced aptamers 
and was removed as eluate. Aptamers in eluates were precitipated, amplified and purified as 
described for filter SELEX (chapter  4.2.1.2). 
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4.2.3 Cell SELEX 
Since aptamers have been shown to be highly selective to the tertiary structure of their target 
proteins and folding could vary between cellular-bound and recombinant produced target 
proteins, SELEX directly on whole cells could yield better cell-targeting aptamers. To avoid 
enrichment of unspecific sequences, pre-selected but still diverse pools, e.g. from early filter 
SELEX rounds to the same target protein offer a promising base for cell SELEX. For the 
selection, high target expressing cell lines were preferred (~105 receptors/cell). Recombinant 
cell lines positive for the target protein („(+) cells“) were used that enable optimal negative 
selection when applying parental cells („(-) cells“). Adherent cells were detached from culture 
dishes, whereas suspension cells were used directly; cell density was determined via CEDEX 
(all as in chapter  4.4.2). Selection was initiated with 2 x 107 cells for positive selection with 
decreasing cell amount in later rounds, a negative selection was carried out from round 2-3 
on. (+) as well as (-) cells were pelleted at 250 g (~1300 rpm) for 10 min at 21°C and the 
supernatant was removed applying a Pasteur pipette on vacuum (chapter  3.8). Cells were 
resuspended by screeding without medium followed by addition of 14 ml Cell SELEX 
binding buffer (chapter  3.6) and this washing step was repeated once. For negative selection, 
(-) cells were resuspended in an appropriate volume of binding buffer to yield 200 µl total 
volume after aptamer pool addition. Aptamers were incubated in 1 µM final concentration 
with parental (-) cells for 30 min at 37°C with gentle shaking of 300 rpm. For positive 
selection, (-) and (+) cells were pelleted at 1000 g for 2 min, (+) cell supernatant was 
discarded only and supernatant containing unbound aptamers was used to resuspend (+) cells. 
From round 2-3 on, 0.1 mg/ml tRNA competitor was added to the positive selection step, with 
increasing amounts up to 1 mg/ml in later rounds. Aptamers were allowed to bind during 
incubation for 30 min at 37°C with gentle shaking of 300 rpm. Cells were then washed three 
times with 1 ml (500 µl in round 1) of 37°C pre-warmed binding buffer and pelletisation as 
before. Subsequently, 500 µl DPBS (chapter  3.4) were added and cells were resuspended by 
trituration. To purify cell bound aptamers from cell debris and proteins, a phenol/chloroform 
extraction was carried out by adding 1 volume phenol (500 µl, chapter  3.4) and vigorous 
vortexing followed by centrifugation at top speed for 5 min. The top aqueous layer was 
transferred to a new microcentrifuge tube and 1 volume chloroform : isoamylalcohol (chapter 
 3.4) was added, followed by vortexing and centrifugation as before. The top aqueous layer 
was again transferred to a new microcentrifuge tube and purified aptamers were isopropanol 
precipitated (chapter  4.1.5). Purified Cell SELEX selected aptamers were resuspended in 
30 µl DPBS and amplified via PCR as described in DNA filter SELEX (chapter  4.2.1.2).  
METHODS 
 
 - 52 - 
4.3 Biochemical methods 
4.3.1 Protein concentration determination 
Protein concentration determination was carried out as described by Bradford (1976). BSA 
(chapter  3.4) served as standard reference protein in dilutions from 25 – 2000 µg/ml. 5 µl of 
each sample or standard dilution were combined with 150 µl of Coomasie Plus Protein Assay 
Reagent (chapter  3.4) in a microtiter plate well, incubated for 5 min in the dark and the 
extinction was measured at 595 nm. Comparison of samples with the calibration curve yielded 
the protein concentration. 
 
4.3.2 SDS polyacrylamide gel electrophoresis 
Separation of proteins due to their molecular mass was achieved by SDS polyacrylamide gel 
electrophoresis (PAGE) as described by Laemmli (1970). Protein samples were added to 
0.1 volume of sample reducing agent and 0.25 volume of LDS sample buffer (both 
chapter  3.4), boiled at 90°C for 10 min and run along with 5 µl SeeBlue Plus 2 prestained 
protein standard marker (chapter  3.4) on 4-20 % Tris-glycine or NuPAGE 4-12 % Bis-Tris 
gels (chapter  3.7) at 200 V for 35 min. Subsequently, protein bands were visualised by 
coomassie staining (chapter  4.3.4). 
 
4.3.3 Isoelectric focussing 
Since an iso-electric point (pI) of lower than 5.5 can indicate improbable selection success, 
the pI of target proteins was evaluated before SELEX was started. Isoelectric focussing uses 
the fact that a protein in a gel with applied voltage and pH lower than its pI is positively 
charged and thus migrates through a gradient of increasing pH towards the cathode until the 
pH region that corresponds to its pI. At this point it has no net charge, hence migration stops 
and the protein becomes focussed into a sharp band at the pH corresponding to its pI.  
For focussing, 20 µg target proteins were analysed on a CleanGel IEF Ultra rehydrated in IEF 
rehydration buffer for 60 min at ambient temperature in comparison to the Isoelectric 
Focussing Calibration KIT as reference. Samples were applied anodic and separated at 10°C 
in 4 steps: pre-focussing 30 min at 700 V, 6 mA and 4 W; sample entry 30 min at 500 V, 
4 mA and 4 W; separation 90 min at 2000 V, 7 mA and 7 W and band sharpening 10 min at 
2500 V, 7 mA and 9 W. The gel was coomassie-stained (chapter  4.3.4) and analysed using 
Phoretix by comparison to reference proteins. 
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4.3.4 Coomassie staining of proteins 
PAGE-separated proteins could be visualised with coomassie staining solution (chapter  3.6) 
for at least 30 min followed by incubation with destaining solution (chapter  3.6) for 2 – 18 h 
and additionally in dH2O if desired until background was totally discoloured. 
 
4.3.5 Transfer of proteins to PVDF membranes 
For subsequent immunological analyses, PAGE-separated proteins could be transferred to 
PVDF membranes (Towbin et al., 1989) using the iBlot dry blotting system following the 
manufacturer’s instructions (chapter  3.8).  
 
4.3.6 Immunodetection of proteins 
Detection and quantification of particular protein species on PVDF membranes ( 4.3.5) were 
carried out by immunodetection applying specific antibodies. Unspecific binding of detection 
antibodies was prevented by blocking PVDF membranes with 10 ml western blot blocking 
solution (chapter  3.6) for at least 30 min with gentle shaking at ambient temperature. In 
between blocking and antibody incubations, membranes were washed 4 times with 15 ml 
western blot washing solution (chapter  3.6) for 1 min under gentle shaking. Penta His or other 
protein specific antibodies (chapter  3.2) were allowed to bind the target typically in a 1 : 1000 
dilution in 10 ml western blot antibody solution (chapter  3.6) for 1 h at ambient temperature 
and gentle shaking. After washing, secondary goat anti mouse peroxidase-conjugated 
detection antibodies (chapter  3.2) were incubated usually in a 1 : 5000 dilution at same 
conditions. An aminobenzidine tablet was dissolved in the dark in 10 ml 1x TBE buffer and 
12 µl 10 % hydrogen peroxide solution (added freshly). After repeated washing, antibody-
decorated proteins of interest were visualised by enzymatic conversion of aminobenzidine to a 
colourful precipitation at the location of the respective protein. Detection was stopped by 
washing PVDF membranes with dH2O.  
 
4.3.7 Immunoprecipitation of proteins 
Correct folding of proteins applied in SELEX could be confirmed by immunoprecipitation. 
Conformation sensitive mouse antibodies (e.g. 3G8 for CD16α, chapter  3.2) were allowed to 
bind to correctly folded protein of interest, subsequently self bound by magnetic bead coupled 
goat anti mouse antibodies and pulled out of solution by magnetic separators. Quantitative 
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capturing of target protein indicated thus eligible conformational folding. Initial antibody-
protein binding was performed in each case applying 1 µg protein and/or antibody in a final 
volume of 100 µl DPBS + 2 % (w/v) BSA (chapter  3.4) for 20 min at ambient temperature. 
Simultaneously, magnetic goat anti mouse IgG Dynabeads (chapter  3.4) were prepared by 
2 min vortexing, 50 µl aliquotation for each sample into a 1.5 ml tube, separation of beads for 
20 sec on magnet separators (chapter  3.8) discarding the supernatant. Beads were washed for 
1 min in first 250 µl DPBS + 0.01 % Tween-20 (chapter  3.4) and secondly DPBS as described 
above. For capturing of protein:antibody complexes, pre-incubated 100 µl samples were 
added to prepared beads and incubated for 20 min at ambient temperature rotating or shaking 
to avoid sedimentation of beads. After 1 sec centrifugation assuring the complete volume at 
bottom of tubes, the liquid was separated from beads as above and discarded. Samples were 
washed once with 250 µl DPBS + 0.01 % Tween-20 and two times with 250 µl DPBS as 
before, ensuring complete removal of supernatant in the last step. Captured proteins were 
resuspended in 19.5 µl DPBS and prepared by adding sample buffer to a total volume of 30 µl 
for PAGE and western blot, in which an equal amount of 15 µl was applied per each gel (as 
described in chapter  4.3.2). The original amounts of protein or antibody applied were loaded 
along the samples to enable quantitative comparison. 
 
4.3.8 Enzyme-linked immunosorbent assay 
Confirmation of specific interaction of two proteins was determined as well by an enzyme-
linked immunosorbent assay (ELISA). All steps were conducted at ambient temperature in 
100 µl total volume, except for blocking and washing with 300 µl. Usually, 1 µg 3G8 (chapter 
 3.2) or cetuximab (chapter  3.2) were immobilised in duplicate in DPBS (chapter  3.4) on a 
Maxisorp microtiter plate well (chapter  3.7) for 18 h at 4°C. The liquid was aspirated off with 
a Tecan washer (chapter  3.8) and wells were blocked for at least 1 h with freshly prepared 
2 % BSA in DPBS (DPBS + BSA, chapter  3.2) to render free adsorbing surface inert to 
further protein binding. After washing with DPBS, target proteins were allowed to bind for 
1 h; 2.5 µg or 1 µg CD16α-6His (chapter  3.2) were applied in DPBS + BSA for 3G8 or 
cetuximab samples, respectively. Unbound proteins were removed by washing once with 
DPBS + 0.05 % Tween-20 (chapter  3.4) and twice with DPBS. Specific labelling of bound 
target proteins was accomplished by addition of Ni-NTA-peroxidase conjugate (chapter  3.2, 
1:500 in 100 µl) and incubation for 1 h. Washing as before was followed by addition of 
100 µl TMB substrate (chapter  3.2), incubation for 1 – 10 min until sufficient colour 
development and termination of the enzymatic reaction by addition of 100 µl 0.5 M HCl 
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solution. Fluorescence was determined at 450 nm with a Synergy4 reader (chapter  3.8) and 
Gen5 software (chapter  3.9). Raw values were exported to Microsoft Excel (chapter  3.9), the 
mean background of the medium only reference was subtracted from each well; finally, mean 
and standard deviation were calculated. 
 
4.3.9 Aptamer affinity determination by dot blot 
Dot blots were applied to measure the binding affinity (i.e. the dissociation constant, KD) of a 
nucleic acid pool or aptamer to a specific protein. Aptamer : protein complexes were captured 
by a nitrocellulose filter and unbound aptamers immobilised on a PVDF membrane; a 
sandwich assembly of both filters in combination with target protein dilutions allowed 
calculation of bound aptamer percentage and thus binding affinity determination.  
 
Binding reactions were performed in 30 µl total volume, with 5 µl 32P-labelled aptamers 
(chapter  4.1.9) in constant final concentrations of 200 pM lower than proteins at 1000 – 
0.1 nM. Binding buffer was generally DPBS + 0.1 mg/ml BSA + 0.1 mg/ml tRNA (all 
chapter  3.4). Target proteins were typically 4-fold diluted serially from 1 µM in 8 point 
curves, sparing the last well with buffer only as negative reference. Aptamer and protein were 
combined in PCR plates, sealed by a plastic foil and incubated for 30 min at 37°C. In the 
meantime, adequately cut nitrocellulose filters were pre-treated with 0.5 M KOH solution for 
15 min at ambient temperature to reduce non-specific aptamer sticking to the filter, and 
subsequently washed 5 min with dH2O and DPBS. PVDF filters were pre-wet with methanol, 
washed with dH2O and DPBS. Gel blot paper was soaked in DPBS for 1 min (all reagents 
chapter  3.4). Membranes were transferred to the lower dot blot manifold unit in the order 
from bottom to top: blot paper, PVDF membrane, and nitrocellulose filter. The top manifold 
unit was added and secured, and attached to vacuum.  
 
Dot blot capture was performed by transferring solutions quantitatively from PCR plates to 
the dot blot manifold and allow the reactions to be pulled through the filters. After turning off 
the vacuum, each well was washed with 37°C pre-warmed 100 µl DPBS two times. Finally, 
vacuum was applied for further 2 – 5 min to dry filters, the manifold was disassembled, 
nitrocellulose and PVDF filters were covered with plastic wrap, placed in a phosphorimager 
cassette (chapter  3.8), and a screen was positioned on top of the filters. Filters were exposed 
to acquire an image usually 2 h (up to 18 h depending on label signal strength) and scanned 
on a storm phosphorimager (chapter  3.8).  
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Data analysis comprised quantitation of each dot on nitrocellulose and PVDF filters via 
ImageQuant 5.2 software (chapter  3.9), calculation of percentage of bound aptamer at each 
protein concentration using the equation:  
 
PVDFcpmlosenitrocellucpm
losenitrocellucpm
xboundaptamer
+
= 100%  
 
Background was defined as % aptamer bound to buffer only sample in dot 8 of each dilution 
and % aptamer bound values were normalised according to the following equation: 
 
)(%)(%% onlybufferboundaptamersampleboundaptamerboundaptameradjusted −=  
 
Values of adjusted % aptamer bound were plotted against protein concentration in MS Excel 
(chapter  3.9) and KD values were calculated by non-linear fitting of a sigmoid binding curve 
with XL fit (chapter  3.9), using the equation: 
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4.3.10 Epitope mapping by competition dot blot 
Competition of antibodies or aptamers to selected aptamers of interest was evaluated applying 
the dot blot method: Displacement of radio-labelled aptamers by added non-radioactive 
competitors indicated a similar addressed epitope on the target protein. The experimental 
setup was equal to the dot blot procedure (chapter  4.3.9) including amounts (5 fmol in 30 µl) 
of radio-labelled aptamers. Target protein concentration was held constant near aptamer 
binding saturation, usually at 50 nM (1.5 pmol in 30 µl). Antibody or aptamer competitors 
were added in a dilution series with maximally 100-fold molar excess to target protein 
(150 pmol). All samples were referenced to wells containing target protein and analysed 
aptamer only. Negative controls included addition of non-binding control proteins or aptamers 
at the same highest amount as competitor molecules to exclude the possibility of unspecific 
displacement. Amounts of bound or displaced aptamers were calculated by: 
 
PVDFcpmlosenitrocellucpm
losenitrocellucpm
xboundaptamer
+
= 100%  
 
Further, the amount of bound aptamer without competitor was set to 100 % and all associated 
measured values were normalised accordingly. A significant, titrated decrease of labelled, 
bound aptamers upon high molar excess addition of competitor indicated displacement, thus 
binding to the same or a similar epitope.  
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4.3.11 Bio-layer interferometry 
Label-free determination of single or simultaneous binding of aptamers to proteins was 
carried out by bio-layer interferometry (BLI) on a fortéBio octet red device (chapter  3.8). BLI 
applied the fact that any change in the number of molecules bound to a biosensor tip caused a 
shift in the interference pattern of reflected white light that was measured in real-time and 
could be translated back to the amount of applied binders. For determination of simultaneous 
target protein binding of bi-specific aptamers, c-Met-Fc fusion protein (chapter  3.2) was 
immobilised, aptamers were allowed to bind and subsequent binding of the second target 
protein CD16α was monitored. Target protein was immobilised on amino reactive sensor tips 
(AR tips, chapter  3.7) after activation of sensor tips with EDC/NHS. Fc-fusions were used for 
coupling since it was hypothesised that a sufficient amount would only be coupled via the Fc-
portion leaving the target protein free of conformational changes. All measurements were 
conducted in 200 µl total volume in black polypropylene microtiter plates (chapter  3.7) with a 
„flow rate“ of 1000 rpm at 37°C. 
 
AR tips were rehydrated for at least 1 h in DPBS (chapter  3.4) and put into the octet red 
device (chapter  3.8). Tips were further equilibrated for baseline measurements in DPBS for 
60 sec, followed by activation for 600 sec with freshly prepared activation solution (0.1 M 
NHS / 0.4 M EDC in dH2O, mixed 1:1, chapter  3.4) and coupling of 25 µg/ml C-Met-Fc 
fusion protein for 900 sec in 0.1 M MES buffer pH 6. Quenching was achieved with 0.4 M 
ethanolamine pH 8.5 (chapter  3.4) for 450 sec and tips were then equilibrated for 300 sec in 
DPBS pH 7.4. Bi-specific aptamers were bound to immobilised protein in 100 nM 
concentration for 600 sec, followed by a short washing step in DPBS of only 10 sec to avoid 
major dissociation. Binding of 2 µM Fc-CD16α(V158) (chapter  3.2) was monitored for 
300 sec and dissociation in DPBS as well for 600 sec. A reference of the same setup but 
lacking bi-specific aptamer and a negative control of a single c-Met specific aptamer (usually 
CLN0003) were measured in parallel. The reference signal was subtracted from each sample 
and negative control to exclude false-positive signal of unspecific Fc-CD16α binding. A clear 
association and dissociation of Fc-CD16α higher than the negative control indicated 
simultaneous binding of the respective bi-specific aptamer to both target proteins. 
 
4.3.12 Electrophoretic migration shift assay 
An electrophoretic migration shift assay (EMSA) was applied based on a lower migrating 
distance of larger molecules in gel electrophoresis, e.g. if target proteins were bound by 
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aptamers. Both single- and bi-valent target binding could be monitored by an aptamer band 
shift when target protein was added. 5 pmol of bi-specific aptamer were incubated with 
40 pmol (2 µg) CD16a-6His (chapter  3.2) and/or 15 pmol (2 µg) c-Met-Fc (chapter  3.2) in 
DPBS of 10 µl total volume for 30 min at 37°C. Subsequently, 2 µl 6x DNA gel loading 
buffer (chapter  3.4) were added, mixed and the total sample volume of 12 µl was run on a 
4-20% TBE-gel for 120 min at 150 V (as in chapter  4.3.2, but additionally cooled with water 
of 17°C). Gels were incubated for 15 min in ethidium bromide solution ( 4.1.3.2) and bands 
were detected with a trans-illuminator (AlphaImager, chapter  3.7). 
 
4.3.13 Determination of aptamer serum stability 
DNA aptamer serum stability was tested for 2 days at 37°C with 10 pmol aptamer in 100 µl 
PBS-buffered fetal bovine serum (90 µl FBS + 10 µl 10x PBS, chapter  3.4). 2 pmol aptamer 
were radio-labelled ( 4.1.9) for detection purposes and combined with 8 pmol unmarked 
aptamer. For each measurement, 10 µl sample were transferred to a new 1.5 ml tube, 
combined with 90 µl 2x gel loading buffer (chapter  3.6) + 0.01 % SDS (chapter  3.4) and 
boiled for 10 min at 90°C to linearise serum proteins and detach them from aptamers to be 
analysed. Degraded aptamers were separated from intact molecules via PAGE (chapter  4.3.2) 
by loading 10 µl of each sample onto a 10 % TBE-Urea gel (chapter  3.7) skipping one lane at 
a time and running gels for 15 min at 200 V. Gels were disassembled, wrapped in plastic foil 
and aptamer bands were visualised by exposing the gels to phosphorimager screens in 
appropriate cassettes (chapter  3.8) for 2 h before scanning on a storm scanner (chapter  3.8). 
Intensities of lower degraded and upper intact aptamer bands were extracted applying 
ImageQuant 5.2 software (chapter  3.9) and the percentage of undegraded aptamer for a given 
time point was calculated by the following equation: 
 
bandslowerallcpmbanduppercpm
banduppercpm
x100aptamerundegraded
+
=%  
 
Resulting values were used as a basis for curve fitting with Origin (chapter  3.9) applying least 
squares optimisation and the formula )(0
xkeAyy ⋅−⋅+=  with A = 100 as starting point as well 
as fittable parameters k and y0 < 5 as residual background signal of analysed gels . Finally, 
half lives were calculated as 
kk
T 693.0)2ln(2/1 == . Resulting data points and graphs were 
plotted using Microsoft Office Excel (chapter  3.9). 
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4.4 Cell-biological methods 
4.4.1 Chemical transformation of E. coli 
Plasmids were inserted into E. coli by heat shock transformation. One Shot Top 10 competent 
cells (chapter  3.1) were thawed on ice, 1 – 3 µl of plasmid solution was added to 50 ml cells, 
mixed gently by flicking tubes with a finger and incubated on ice for 20 min to allow 
adsorption of DNA to the bacterial surface. Cells were then immediately transferred to 42°C 
for 45 sec, placed on ice again for 2 min, 250 µl SOC medium (provided in cloning kit) was 
added to each tube and tranformants were allowed to recover for at 37°C for 30 min at 
450 rpm in a shaking incubator. The transformation reaction was split to 30 and 270 µl and 
transferred to 2 pre-warmed LB agar plates including the respective selection antibiotics and 
plated out with a sterilised Drigalski spatula. For aptamer pool TOPO-cloning 
transformations, 75 µl cell solution were plated on each of 4 agar plates. Transformed clones 
were allowed to grow for 18 h in a 37°C incubator or 70 h at ambient temperature. 
 
4.4.2 Culturing of cell lines 
All human and mammalian cell lines were cultured under sterile conditions in Cellstar tissue 
culture flasks (chapter  3.7) using the appropriate media (chapter  3.5) at conditions described 
in chapter  3.1. Cell amount, viability and aggregation rates were determined with a CEDEX 
cell counter (chapter  3.8) by averaging countings from 20 images.  
Adherent cell lines were detached for passaging or experiments applying trypsin-EDTA 
(chapter  3.2). Medium supernatants were transferred into 50 ml tubes and stored at ambient 
temperature whilst cells were washed two times with 10 ml 37°C pre-warmed DPBS without 
calcium and magnesium to deplete these trypsin-inhibiting bivalent cations. 5 ml trypsin-
EDTA solution were added and cells fully detached at 37°C for 2 – 5 min. The enzymatic 
reaction was terminated by adding the original culture medium before transferring the 
complete suspension to a 50 ml tube for pelletisation at 250 g (1200 rpm) for 10 min at 21°C. 
The supernatant was discarded and cells resuspended in an appropriate amount of either fresh 
culture or respective assay medium.  
 
4.4.3 Flow cytometry of antibodies and aptamers 
Aptamer binding to cellular target antigen was evaluated by flow cytometry on human cell 
lines applying biotinylated aptamers detected via streptavidin-phycoerythrin (SA-PE). 
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Adherent cell lines were detached (chapter  4.4.2) or suspension cells used directly, the cell 
count was determined with a CEDEX cell counter (chapter  3.8) and 1 x 106 cells were used 
per sample. All washing and sample incubation steps were performed in FACS binding buffer 
(chapter  3.6). Cells were pelleted at 250 g and 4°C for 10 min, washed with 10 ml binding 
buffer, pelleted as before and resuspended in the appropriate volume to yield 1 x 106 cells in 
90 µl binding buffer. Aptamer or antibody samples were prepared in 10 µl binding buffer in 
separate polypropylene round-bottom tubes (chapter  3.7). Initially 100 pmol aptamer or 10 µg 
(66 pmol) antibody were applied, in subsequent experiments this amount could be optimised 
by decreasing the concentration. 90 µl cell suspension were added to 10 µl sample solution, 
mixed well by flicking the tubes and incubated for 30 min at 21°C upon repeated mixing. 
Incubation was carried out at 21°C to find a balance between keeping cells in their original 
state (best at 4°C) and allowing sufficient aptamer binding (usually at 37°C). Each tube 
represented a separate binding reaction, including cells alone, SA-PE only, a biotinylated non-
binding aptamer as negative controls as well as a respective aptamer or antibody positive 
control, usually 3G8 and cetuximab (chapter  3.2). The binding reaction was washed once with 
1.5 ml binding buffer as described before, but only 5 min centrifugation to keep the duration 
of cells at ambient temperature as short as possible. Cells were resuspended in 90 µl binding 
buffer + 10 µl SA-PE solution (chapter  3.2) and streptavidin-phycoerythrin was allowed to 
anneal to cell-bound, biotinylated aptamers for 10 - 15 min at 21°C under repeated mixing. 
Two washing steps with 1.5 ml binding buffer as before were followed by resuspension in 
995 µl binding buffer  + 5 µl propidium iodide (chapter  3.4), allowing the exclusion of dead 
cells in later analyses. Samples were immediately measured via Fluorescence-activated cell 
sorting (FACS) using a FACScan device (chapter  3.8). For each binding reaction, 15.000 
events were collected and analysed using CellQuest Pro software (chapter  3.9). Intact cells 
were identified by using a plot of FSC-H against SSC-H, fluorescein-labelled samples 
recorded using the FL1-H detector, PE-labelling with the FL2-H detector and propidium 
iodide-based dead cell exclusion in the FL3-H channel. A significant increase of respective 
histogram mean fluorenscence in comparison to all negative controls indicated evidence of 
cellular binding. 
 
4.4.4 Preparation of peripheral blood mononuclear cells 
Ficoll as the most common technique for separating peripheral blood mononuclear cells 
(PBMCs) was applied. Whole EDTA-stabilised blood from healthy donors (distributed by 
Merck’s medical department) was mixed with a compound aggregating erythrocytes, thereby 
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increasing their sedimentation rate. The sedimentation of PBMCs was only slightly affected; 
they could be collected from a distinct layer between serum of the upper part and settled 
erythrocytes and granulocytes at the bottom of the tube.  
 
For the separation of PBMCs, Lymphoprep tubes (chapter  3.7) were applied utilising one-step 
density gradient centrifugation with sodium metrizoate (Isopaque) and Ficoll (Boyum, 1968). 
15 ml DPBS and 18 ml EDTA-blood were poured freely into Lymphoprep-tubes, mixed by 
inverting the tube and centrifuged for 25 min at 800 g and precisely 21°C. Serum was 
removed using a Pasteur pipette and the PBMC-layer was decanted into a fresh 50 ml tube. 
PBMCs were washed two times in respective medium by centrifugation for 10 min at 250 g 
and 21°C. Cells were rigorously resuspended in 1 ml of the same medium using a pipette to 
yield single cell suspensions and counted in a CEDEX cell counter in 1:100 dilution (10 µl 
cells + 990 µl medium).  
 
4.4.5 Preparation of Natural Killer cells 
Natural Killer cells (NK cells) were isolated from PBMC preparations of healthy donors 
(chapter  4.4.4) with a NK cell isolation kit (chapter  3.2) applying the MACS technique: 
Non-NK cells were depleted by indirect labelling with lineage-specific, biotinylated 
antibodies that were later coupled to streptavidin-coated magnetic beads enabling removal of 
these cells with a magnet. NK cells were not marked, hence enriched in the flow-through.  
 
The procedure was carried out following the manufacturer’s instructions. Briefly, all steps 
were carried out on ice, samples volumes are described for 1 x 107 PBMCs; cells were 
pelleted for 10 min at 250 g and 4°C, each 1 x 107 PBMCs were resuspended in 40 µl MACS 
buffer (chapter  3.6), 10 µl NK cell biotin-antibody cocktail were added, mixed well and 
antibodies were allowed to bind non-NK cells for 10 min. Then, 30 µl buffer and 20 µl NK 
cell microbead cocktail were added, mixed well and beads could bind to biotinylated 
antibodies during 15 min incubation. Cells were washed with 2 ml buffer, centrifuged as 
before, the supernatant was removed completely and cells were resuspended in 500 µl buffer. 
Separation was carried out using the autoMACS separator running program “depletes”. The 
NK cell containing flow-through was collected in a fresh 50 ml tube and cells were counted in 
a CEDEX cell counter in 1 : 100 dilution (10 µl cells + 990 µl medium). 
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4.4.6 ADCC assay 
The cytotoxic function of bi-specific aptamers or reference antibodies was determined by 
assaying Aptamer/Antibody Dependent Cellular Cytotoxcitiy (ADCC) in vitro. For this, 
tumour cell lines (GTL-16 or EBC-1, chapter  3.1) were exposed to isolated PBMCs (chapter 
 4.4.4) in absence or presence of effector molecules. The specific cell lysis was measured via 
release of Glyceraldehyd-3-Phosphate Dehydrogenase (GAPDH) in a coupled enzyme 
reaction with Luciferase (aCella-TOX kit, chapter  3.2). GAPDH was found to be abundantly 
present in all known living cells, catalysing the oxidative phosphorylation of D-
glyceraldehyde-3-phosphate to 1,3-diphosphoglycerate. This served as substrate for 3-
Phosphoglyceric Phosphokinase (PGK) to produce ATP which was further used by added 
Luciferase/luciferin yielding bioluminescence that was measured. More dead or dying cells 
lead to higher GAPDH release, increased ATP levels and thus a higher bioluminescence 
signal.  
 
All ADCC measurements were conducted in Optiplate microtiter plates (later sealed with 
airpore tape sheets, chapter  3.7) at least in triplicates in 100 µl total volume ADCC medium 
(chapter  3.6) for 4 h at 37°C and 5 % CO2. 104 tumour cells (of >90 % viability) were 
combined with PBMCs in a ratio of 80:1. This ratio was varied in later experiments from 80:1 
to 5:1. Cetuximab (chapter  3.2) as positive antibody reference was applied in high 
concentrations of 50 nM (7.5 ng/µl) and bi-specific aptamers in serial dilutions from 500 nM 
to 1 pM. Aptamers and antibodies were pre-incubated for 15 min at 37°C before adding 
effector cells. Negative controls comprised mono-valent aptamers at comparable 
concentrations and samples lacking any additional molecules. Reference triplicate 
measurements were medium, target cells (spontaneous target cell lysis), effector cells 
(spontaneous effector cell lysis) and target cells for detergence-induced maximal lysis. The 
outer rows and columns of each microtiter plate were left out to avoid boundary effects in 
luminescence readings.  
 
ADCC assay enzyme reactions were performed as suggested by the manufacturer. Briefly, 
15 min prior to full incubation time 10 µl lytic agent were added to wells containing target 
cells for maximal lysis readout and microtiter plates further incubated at 37°C. For 
preparation of enzyme solutions, 4 ml green label enzyme assay reagent and 4 ml enzyme 
assay diluent A were combined as well as 700 µl magenta label detection assay diluent B with 
3.15 ml dH2O. Following steps were carried out uninterrupted: 28 µl green label G3P vial C 
solution were added to tube A, mixed and 100 µl dispensed in each microtiter plate well with 
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a multipette. Then, 77 µl magenta label vial B were added to tube B, mixed and exactly 50 µl 
were pipetted in each well. Microtiter plates were mixed by gentle shaking, transferred in the 
dark to a Varioskan luminometer (chapter  3.8) and bioluminescence was measured for 100 ms 
every minute for 10 min. Raw data was exported to Microsoft Office Excel (chapter  3.9), and 
the mean background luminescence of „medium only“ samples was calculated and subtracted 
from each individual well. Specific target cell lysis was calculated applying the formula  
 
lysiscelltargetspont.lysismaximal
lysiscelleffectorspontlysiscelltargetspont.lysissample
x100lysisspecific
−
−−
=
.%  
 
Based on resulting values, specific target cell lysis mean and standard deviation were 
calculated and blotted for each aptamer concentration. Cetuximab-mediated tumour cell lysis 
of more than 30 % indicated the success of the respective ADCC assay measurement.  
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5 RESULTS 
5.1 Determination of target protein quality 
Since high target protein quality is crucial for the success of aptamer SELEX, several target 
protein quality controls were conducted before starting the selection of CD16α specific 
aptamers. 
5.1.1 Assessment of purity and glycosylation 
SDS-PAGE (chapter  4.3.2) with subsequent coomassie staining (chapter  4.3.4) demonstrated 
purity higher than 90 % of all His-tagged CD16 isoforms and the monoclonal antibody 3G8 
(Figure 9, A, lanes 2-4). Electrophoretic migration at 50 kDa or 75 kDa indicated 
glycosylation similar to NK cell-presented CD16 for His-tagged or Fc-fusion proteins, 
respectively (Figure 9). Both CD16-HisTag fusion proteins could be pulled out of solution 
quantitatively by 3G8 (Figure 9, A, lanes 7 and 8), but not in its absence (Figure 9, A, lanes 5 
and 6). CD16 allotype Fc-fusions exhibited high purity but partly aggregation (Figure 9, B, 
additional bands in lanes 2 and 3). Small fractions of applied Fc-fusion proteins could be 
pulled out of solution by 3G8 (Figure 9, B, lanes 7 and 8 in comparison to lanes 2). 
Unspecific binding of Fc-CD16α(V158) to beads (Figure 9, B, lane 5) was much weaker than 
specific signals via 3G8 (lane 7), leaving the validity of this sample unaffected.  
 
5.1.2 Validation of correct target protein folding  
Since aptamers could exhibit high selectivity for minor conformational changes in target 
proteins, validation of correct folding was crucial for success of SELEX and carried out by 
immunoprecipitation (IP) and enzyme-linked immunosorbent assay (ELISA) measurements. 
Immunoprecipitated samples (chapter  4.3.7) were analysed by SDS-PAGE (chapter  4.3.2) and 
coomassie stained (chapter  4.3.4) as well as detected by a western blot (chapters  4.3.5 and 
 4.3.6). For the specific detection of CD16α-6His and CD16β-10His fusion proteins, a mouse 
penta His antibody (1:2000) and a goat anti-mouse peroxidase conjugate (1:3000) were 
applied. For CD16 Fc-fucion proteins, a rabbit anti-human-Fc antibody (1:2000) and a goat 
anti-rabbit peroxidase conjugate (1:3000) were used (all described in chapter  3.2). The 
conformation-specific antibody 3G8 immunoprecipitated equivalent amounts of His-tagged 
CD16 proteins (Figure 9, A), thereby verifying correct folding of these recombinant soluble 
proteins. Fc-fusions of both CD16α allotypes were captured from solution by 3G8 more so 
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than in negative control samples, but in a clearly smaller portion than His-tagged proteins 
(Figure 9, B). This indicates a partly incorrect conformation or sterical hindrance by the Fc-
fusion. 
 
 
 
Figure 9: SDS-PAGE and immunoprecipitation of several recombinant CD16 proteins. 
A, His-tagged CD16 isoforms and the monoclonal antibody 3G8 exhibited high purity (lanes 2-4). Both CD16 
proteins were immunoprecipitated by 3G8 (lanes 7 and 8), but not in its absence (lanes 5 and 6). B, CD16 Fc-
fusions were of similar purity but partly aggregated (lanes 2 and 3) and a small portion was immunoprecipitated 
by 3G8 (lanes 7 and 8). V158, Fc-CD16α(V158); F158, Fc-CD16α(F158); SDS-PAGE bands of IP samples in 
lanes 5 – 9 at 25 and 50 kDa represented the secondary goat-anti-mouse antibody detached from magnetic beads. 
 
 
 
In ELISA measurements (chapter  4.3.8), binding of all recombinant CD16 proteins to 3G8 as 
well as cetuximab - CD16α-6His interaction confirmed functionality and hence correct 
folding of CD16 target proteins (Figure 10). 
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Figure 10: ELISA of all CD16 target proteins to conformation-sensitive antibodies 3G8 and cetuximab. 
3G8, BSA or cetuximab were coated to microtiter plates and binding of CD16 His- and Fc-fusion proteins were 
analysed in triplicate. All recombinant CD16 fusion proteins were bound by 3G8 or cetuximab, while BSA 
negative controls exhibit only minor background binding. Bars represent mean values with standard deviation as 
error bars. 
 
5.1.3 Determination of isoelectric properties 
Since a low pI (<5.5) could impede aptamer selection due to repulsion between negatively 
charged groups of the nucleotide 
backbone and the target protein at 
physiological pH, the pI of 
CD16α-6His was determined via 
isoelectrical focussing (chapter 
 4.3.3). Differently charged His-
tag residues lead to several bands 
for one CD16α molecule. 
However, the experimentally 
calculated mean pI of 6.6 ± 0.2 
agreed with the in silico 
predicted value of 6.7 as 
determined by DNA Star Edit 
Seq software (chapter  3.9). This 
pI indicated that it is feasible to raise aptamers against CD16α. 
 
 
Figure 11: Isoelectric focussing of CD16α-6His. 
Several protein bands were recognisable in the coomassie stained 
IEF gel (left) that resemble the same His-tagged CD16 protein in 
differently charged states. Comparison of CD16 bands to marker 
proteins lead to the calculation of a mean pI of 6.6 (right). 
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5.1.4 Nitrocellulose filter capacity test 
To ascertain if there was a complete separation of all target protein bound from non-binding 
aptamers in SELEX, the CD16 
binding capacity of 
nitrocellulose filter membranes 
was determined by a capacity 
test (chapter  4.2.1.1). The full 
amount of CD16α or CD16β 
used in initial SELEX rounds 
was captured quantitatively by 
nitrocellulose filters (Figure 12). 
 
5.2 Aptamer selection 
With high quality target protein available, several SELEX approaches (Figure 13) were 
conducted applying both DNA and modified rRfY RNA aptamer pools for selection of 
specific and high affinity CD16α binders.  
 
Figure 13: SELEX scheme of different CD16 DNA selection approaches. 
Nine rounds of filter SELEX were conducted in parallel, only differing in the lack of counterselection in filter 
SELEX 01.09 (left). Additional rounds were performed using CD16 immobilised on microtiter plates and elution 
selection with monoclonal antibody 3G8 to enrich aptamers specific for the Fc binding domain of CD16. Filter 
SELEX R3 and R5 were used as pre-selected starting pools for two parallel selections targeting recombinant 
Jurkat cells in a cell SELEX (right). Filter, nitrocellulose filter; MTP, microtiter plate; CD16α, CD16α-6His; 
CD16β, CD16β-10His.  
Figure 12: Nitrocellulose filter capacity test. 
The full amount of CD16α (lane 2) or CD16β (lane 4) fusion proteins 
was absent in the flow-through (lanes 3 or 5, respectively), hence 
target proteins were captured completely by the filter. 
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5.2.1 CD16 DNA filter SELEX 
SELEX for DNA CD16 specific aptamers was initiated with nine rounds of filter SELEX 
(chapter  4.2.1.2) in parallel with both positive selection against CD16α-6His only (Figure 13, 
filter SELEX 01.09) and an additional counter-selection against CD16β-10His 
(filter SELEX 02.09). With each successive round, the target protein concentration was 
decreased while the amount of tRNA competitor was increased and PCR cycles were 
monitored (appendix, Table 4). Fewer numbers of PCR cycles from round 6 on indicated 
enrichment of aptamers, therefore radioactive labelling (chapter  4.1.9) of aliquots from both 
round 9 pools was used to determine the pool affinities towards CD16α and CD16β by dot 
blot measurements (chapter  4.3.9). Both round 9 pools bound with KD values of 62 nM (filter 
SELEX 01.09) and 41 nM (filter SELEX 02.09) to CD16α, but not at all to CD16β. The naive 
R0 library exhibited minimal affinity to both target proteins that was repressed by addition of 
the unspecific competitor tRNA (Figure 14). 
 
To specifically select for aptamers binding in the Fc binding domain of CD16 with a two-digit 
nanomolar affinity, two additional SELEX rounds were performed on microtiter plates 
(chapter  4.2.2) followed by one final filter SELEX round (chapter  4.2.1.2): Pre-selected R9 
pools of both selections were allowed to bind MTP-immobilised CD16α, non-binders were 
washed off and then Fc-domain specific aptamers were eluted by addition of 3G8 in 100-fold 
molar excess. 3G8 was reported to bind in or near the Fc-binding domain of CD16 with at 
least 5.7 nM affinity and was used to potentially displace aptamers that bound this epitope. 
Finally, these aptamers were applied in a filter SELEX round 12 offering a CD16α - 
cetuximab complex with a reference affinity of 710 nM; only aptamers of higher affinities 
than that should bind to the target complex. Hence, aptamers enriched in such a way should 
bind near or in the Fc-binding domain of CD16α with low nanomolar affinity. PCR cycle 
monitoring revealed fewer cycles in round 12 were needed, which indicated an increased 
enrichment (Figure 14). 
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Figure 14: PCR cycle monitoring and determination of SELEX pool affinity via dot blot. 
A and B, PCR cycle monitoring of aptamer SELEX 01.09 and 02.09, respectively. Filter SELEX was performed 
until round 9 and MTP SELEX in rounds 10 - 12. In later stages of both selections (rounds 6 – 9 and round 12), 
low numbers of PCR cycles needed for aptamer re-amplification indicated enrichment. C, Dot blot raw data 
readout of bound aptamers on the NC membrane or unbound molecules on PVDF. D, Processed dot blot data 
revealed that both round 9 pools exhibited two-digit nanomolar CD16α affinities (red and blue), but did not bind 
to CD16β (orange and green). Magnified circles indicate the calculated KD values of 62 nM (filter SELEX 
01.09) and 41 nM (filter SELEX 02.09). 
 
Assessment of aptamer enrichment during filter and MTP SELEX steps was achieved by 
separation of pools into single aptamers by TOPO-cloning (chapter  4.1.7) and subsequent 
single sequence analysis (chapter  4.1.8) of rounds 9 and 12 for both selections. Both 
selections yielded similar sequences and were thus jointly analysed. 192 sequences of 
rounds 9 were sequenced, 185 of which were analysable (97 %). 86 % of all sequences were 
grouped in 13 main families of 90 % sequence identity (designated CLN0015 - CLN0027) 
and single aptamers were enriched up to 31 % of the whole pool (CLN0015, Figure 16). 
Sequencing of round 12 yielded five new aptamers (CLN0028 – CLN0032) with a prevalence 
of 1 - 11 % in the pool. Several motifs were found througout many aptamers, but also unique 
sequences were found. Figure 16 displays sequences of all selected DNA CD16 aptamers.  
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5.2.2 CD16 DNA cell SELEX 
Since the aim of this work was the selection of aptamers binding to NK cell-expressed 
CD16α, SELEX was also performed directly on CD16α-overexpressing cell lines. To avoid 
massive enrichment of unspecific aptamers, two cell SELEX approaches were initiated with 
pre-selected but still variable libraries from filter SELEX 02.09 round 3 (cell SELEX 01.09) 
and round 5 (cell SELEX 02.09). Six additional rounds were performed (chapter  4.2.3) with 
alternating cross-selection using Jurkat cells that express recombinant CD16αV158 or 
CD16αF158 proteins to select for aptamers binding to both allotypes. PCR cycle monitoring 
exhibited a slight decrease in cycle numbers upon increased stringency (Figure 15, A and B). 
Direct affinity assessment of cell SELEX pools was achieved by 5’ radioactive labelling of 
initial filter SELEX rounds 0, 3, and 5, cell SELEX 01.09 rounds 7 and 9 as well as cell 
SELEX 02.09 rounds 9 and 11 (chapter  4.1.9) followed by dot blot measurements of all these 
pools (chapter  4.3.9). In both selections, CD16α-6His pool affinity increased from no binding 
to 103 nM or 175 nM in round 9 (01.09) or round 11 (02.09), respectively. Binding to both 
allotypes was observed in both selections, while CD16β-10His was not bound at all (Figure 
15, C - F). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
RESULTS 
 
 - 71 - 
 
 
 
 
 
Figure 15: PCR cycle monitoring and pool dot blots for affinity determination. 
A and B, PCR cycle monitoring of cell SELEX 01.09 and 02.09, respectively. Target protein concentration in 
form of applied cell amount was decreased over time, fewer cells were used in third rounds due to a lack of 
availability. PCR cycles decreased slightly indicating a putative enrichment. Cell SELEX 01.09 dot blot raw (C) 
and processed (D) data revealed an increasing pool affinity towards CD16α when comparing rounds 0, 3, 7 and 9 
(red, orange, blue to green). Raw data (E) and calculated graphs (F) of cell SELEX 02.09 exhibited a similar 
pattern. CD16α, CD16α-6His; CD16β, CD16β-10His; CD16α V/F158, Fc-CD16α(V/F158). 
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Since pool affinity determination indicated enrichment of CD16α specific aptamers, cell 
SELEX pools 01.09 R7 and R9 as well as 02.09 R9 and R11 were applied to single aptamer 
separation by TOPO-cloning (chapter  4.1.7) and subsequent analyses of 96 single sequences 
(chapter  4.1.8). All pools were found to be highly enriched, containing only 3 – 19 % single 
sequences, but up to a 40 % occurrence of single aptamers (Figure 17). Eleven new aptamer 
sequence families (of 90 % sequence identity) were found in cell SELEX and designated 
CLN0118 – CLN0128 (Figure 16), but also 6 sequences already known from filter SELEX 
were enriched (CLN0015, 20, 21, 22, 28, 32). Unlike in filter selection, unique sequences to 
either SELEX approach indicated the essential impact of the composition of a starting pool 
for the outcome of a selection (Figure 17 and Table 6, appendix).  
 
 
Figure 16: Alignment and frequencies of all selected DNA CD16 aptamers. 
Sequence comparison of CD16 aptamers from different selections revealed several motif blocks (orange mark) 
that mostly contained both filter and cell SELEX derived sequences. CLN0015, 21 and 22 were found 
throughout all selections. Randomised regions are shown without invariant flanking sequences. Two-digit codes 
indicate filter SELEX derived aptamers, three-digit codes cell SELEX sequences. 
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Figure 17: Variation of the aptamer pool composition during all DNA selections. 
The initially totally variable pool of round 3 exhibited enrichment of several aptamers upon progression of each 
particular SELEX approach. Major filter SELEX sequences (blue and green colours) were found to some extent 
as well in cell SELEX pools, intermittent even highly enriched (green colours). Cell SELEX 02.09 yielded many 
aptamers not found in other selections (yellow and red colours). Filter and MTP SELEX approaches 01.09 and 
02.09 were analysed jointly. R3, round 3 et cetera. Two-digit codes indicated filter SELEX, three-digit codes 
cell SELEX derived aptamers. Associated exact values can be found in Table 6, appendix. 
 
5.2.3 CD16 rRfY filter SELEX 
Since DNA aptamers are prone to low serum stability, putatively more stable aptamers of the 
rRfY composition were additionally applied for selection of specific and high affinity CD16α 
binders. rRfY SELEX ( 4.2.1.3) was performed for nine rounds with cross-selection of 
CD16α-6His(V158) and Fc-CD16α(F158) to select for aptamers binding to both allotypes 
while avoiding Fc- or His-tag-binders. Negative selection against filter was carried out from 
round 2 on and counterselection against CD16β-10His started in round 3 (Figure 18, panel A). 
PCR cycle monitoring showed a clear decrease in the required re-amplification cycles 
indicating enrichment of rRfY CD16 specific aptamers, even upon lowered target protein and 
increased tRNA competitor concentrations (Figure 18, B). R7 and R9 pools were 5’ 
radioactive labelled (chapter  4.1.9) and the pool affinities were determined via dot blot 
(chapter  4.3.9). The naive R0 library exhibited desired low level CD16 affinity that could be 
repressed by tRNA competitor addition. Differences in labelling strength (e.g. last two lines) 
did not affect calculations since only relative values were used. Both selected pools showed 
strong binding (10 nM) to CD16α, but no binding to CD16β, as desired (Figure 18, D).  
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Figure 18: rRfY SELEX. 
A, Specifications of rRfY SELEX approach. V158, CD16α-6His(V158); F158, Fc-CD16α(F158); 
counterselection target protein was CD16β-10His. B, PCR cycle monitoring indicated enrichement due to 
decreasing PCR cycles needed for re-amplification. C, Pool dot blot raw data showed strong binding of R7 and 
R9 pools (blue and black) as well as weak and reversible signals of R0 library (orange vs. red). D, Processed dot 
blot data revealed high affinity and specific binding of R7 and R9 rRfY pools to CD16α, but no binding to 
CD16β. Magnified symbols indicate calculated KD values. 
 
 
Since both PCR cycle monitoring and pool affinity measurements indicated enrichment of 
rRfY aptamers, 96 samples of round 7 and 9 pools were sequenced by separation of the 
respective ssPCR samples to single aptamers by TOPO-cloning (chapter  4.1.7) and 
subsequent single sequence analysis (chapter  4.1.8). 13 unique sequence families of 90 % 
sequence identity were found in round 7 and additional 4 aptamers in the round 9 pool (Figure 
19). These rRfY CD16 aptamers were designated CLN0047 – CLN0063. 
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Figure 19: Overview of CD16 specific rRfY aptamer sequences. 
rRfY aptamer families (of 90 % sequence identity) were enriched to 2 – 21 % in R7 and R9 pools. Several motif 
blocks (marked orange) as well as unique sequences were found. Randomised regions are shown without 
invariant flanking sequences. 
 
5.3 Characterisation of aptamer hits 
5.3.1 Affinity and specificity determination 
Affinity determination for all filter and cell SELEX derived DNA CD16 specific aptamers 
towards all iso- and alloforms of CD16 was biochemically performed using dot blot assays. 
The three most abundant rRfY CD16 aptamer sequences were analysed in the same manner. 
Additionally, c-Met specific DNA aptamers CLN0003, CLN0004 and CLN0008 were kindly 
provided by Angelika-Nicole Helfrich (MerckSerono) and characterised towards c-Met 
specificity and affinity. CD16 and c-Met specific DNA aptamers selected by filter SELEX 
were synthesised (chapter  4.1.1.3) and PAGE-purified (chapters  4.1.3.2 -  4.1.5), whereas 
CD16 specific, cell SELEX derived aptamers were synthesised with a 3’ biotin label and then 
purified by PAGE (chapter  4.1.1.4). rRfY aptamers were produced by PCR (chapter  4.1.1.1) 
using primers 5980 and 5981 (chapter  3.3), and 10 ng of sequence verified plasmid template, 
followed by transcription (chapter  4.1.2) and PAGE-purification (chapters  4.1.3.2 -  4.1.5). In 
all cases, the final concentration was determined (chapter  4.1.6). 10 pmol of each aptamer 
were then individually 5’ radioactively labelled (chapter  4.1.9) and applied in a dot blot with 
their respective target proteins (chapter  4.3.9). Possible causes for wide variation in KD values 
could be high sensitivity of the assay to deviation in protein batch, conformation and 
concentration as well as possible temperature variation (cf. chapter  5.3.2). 
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Most filter SELEX derived CD16 specific DNA aptamers exhibited low nanomolar affinities 
of 6 – 154 nM towards CD16α-6His, but no binding at all to CD16β-10His (Table 1). The 
four aptamers CLN0020, 21, 23 and 30 bound to both CD16α allotypes (example CLN0020 in 
Figure 20) and did not belong to the major motif block but comprised unique sequences 
(Figure 16). All other aptamers were allotype specific binders for the high affinity binding 
form CD16α(V158) (example CLN0015 in Figure 20 and Table 1). The negative control 
oligonucleotide CLNC (chapter  3.3) did not bind to any protein (data not shown, cf. Figure 
30). As a representative aptamer, CLN0020 exhibited only minor binding to cynoCD16α with 
high three-digit nanomolar affinity as well as no binding at all to murine CD16α (data not 
shown). Nine aptamers were selected for further analyses and these included the five aptamers 
CLN0015, 18, 19, 28 and 30 with the highest affinities and the four sequences CLN0020, 21, 
23 and 30 binding both CD16α allotypes.  
 
 
Figure 20: Examples of affinity determination by dot blot. 
A, Dot blot raw data of three DNA aptamers from filter and cell SELEX. B, CLN0015, as representative of a 
large motif block, bound with two-digit nM affinity to CD16α V158 allotype (red and orange), much weaker to 
CD16α F158 (blue) and not at all to CD16β (green). C, CLN0020 exhibited high affinity to both CD16α 
allotypes whilst only very weakly binding CD16β. D, Cell SELEX derived CLN0123 bound with moderate 
affinity to CD16α-6His but less to the Fc-fusion of the same allotype. In comparion to Fc-CD16α(V158), 
binding to Fc-CD16α(F158) was weaker and CD16β was nearly not bound. Enlarged symbols represent 
calculated KD values. NC, nitrocellulose membrane readout; PVDF, polyvinylidenfluoride membrane readout. 
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CD16 specific DNA aptamers isolated in cell SELEX were analysed in biotinylated form and 
exhibited intermittent no to low affinity of approximately 1000 nM to recombinant CD16α-
6His (Table 1). The two abundant sequences CLN0118 and CLN0126 bound with 31 nM and 
46 nM, respectively, to CD16α of both alloforms (dot blot data not shown). CLN0123 
exhibited a KD of 193 nM to CD16α-6His, preferentially binding the V158 allotype (Figure 
20). Binding to CD16β-10His again was not observed as predicted when pre-selected pools 
were used. Already present in biotinylated form, all cell SELEX aptamers were further 
characterised for cellular binding. 
 
Out of eleven selected CD16 specific rRfY aptamers, the three most prevalent sequences 
CLN0047, 48 and 49 were analysed and exhibited high affinity to CD16α-6His with 44 nM, 
20 nM and 49 nM, respectively, whilst no binding to CD16β was detected (data not shown). 
In addition to these effector cell-specific aptamers, tumour-specific aptamers of rRfY 
composition were not selected or available. Additionally, for the design of bi-specific 
aptamers linkage by full synthesis was favoured over hybridisation (chapter  5.4.1) that would 
have enabled the use of diverse compositions. Thus, the rRfY aptamers were not characterised 
or applied any further. 
 
Table 1: Dot blot determined affinities to CD16α-6His or C-Met-Fc fusion protein of all applied aptamers. 
CLN 
code KD (nM) n   
CLN 
code KD (nM) n   
CLN 
code KD (nM) n 
              
CD16 DNA filter SELEX   CD16 DNA cell SELEX   CD16 rRfY filter SELEX  
              
15 24 ± 18 7  15 24 ± 18 7  47 44 1 
16 48 ± 26 4  20 45 ± 28 10  48 20 1 
17 42 ± 33 4  21 25 ± 19 5  49 49 1 
18 38 ± 26 4  22 401 ± 79 2      
19 29 ± 11 4  28 76 ± 42 4      
20 45 ± 28 10  32 429 ± 8 2  c-Met DNA filter SELEX  
21 25 ± 19 5  118 31 ± 20 2      
22 401 ± 79 2  119 no binding 2  3 0.091 ± 0.040 3 
23 18 ± 14 5  120 >1000 2  4 11 ± 5 6 
24 61 ± 30 4  121 no binding 2  8 10 ± 9 2 
25 105 ± 25 4  122 >1000 2      
26 154 ± 95 4  123 193 ± 29 4      
28 76 ± 42 4  124 1000 2      
30 6 ± 5 6  125 >1000 2      
31 81 ± 102 4  126 46 ± 11 2      
32 429 ± 8 2  127 no binding 2      
     128 1000 2      
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Three c-Met specific DNA aptamers (designated CLN0003, CLN0004 and CLN0008) were 
kindly provided by Angelika-Nicole Helfrich. All sequences shared certain motifs (Figure 21) 
that in part included 3’ flanking region of CLN0004 and CLN0008. The latter aptamer was 
excluded from further analyses due to a highly related sequence and affinity (Figure 21 and 
Table 1), only CLN0003 and CLN0004 were characterised further. Dot blots revealed high 
affinity binding to c-Met, but not to Fc, for CLN0003 and CLN0004 with averaged KD values 
of 91 pM and 11 nM, respectively (Figure 21 and Table 1).  
 
Figure 21: Sequence comparison and dot blot affinity determination of DNA c-Met aptamers. 
A, Three analysed c-Met specific DNA aptamers shared certain sequence motifs (orange boxes) that included 
G61 in the 3’ flanking region of CLN0004 and CLN0008. B, Representative dot blot raw data and C, fitted 
binding curves revealed high affinity binding to c-Met, but not to Fc, for CLN0003 and CLN0004. Enlarged 
symbols represent the respective KD as aptamer concentration at half-maximal binding in fitted curves. 
 
5.3.2 Temperature dependency of aptamer affinity 
Since aptamer selection and dot blots had been performed at 37°C, but following 
characterisation could require binding evaluation at other temperatures, the affinity of six 
different 5’ radioactive labelled (chapter  4.1.9) aptamers was determined via dot blot (chapter 
 4.3.9) at 4°C, 21°C and 37°C. The same aptamers, target protein dilutions and membranes 
were applied in parallel, altering only the temperature during incubation and of the used 
washing buffer. Affinity and binding properties were generally dependent on temperature, but 
varied from aptamer to aptamer (Figure 22, other data not shown). Less binding or lower 
affinity were observed in all cases at 4°C, while incubation at 21°C yielded similar or 
enhanced affinity in comparison to 37°C. Especially CLN0004 and CLN0020 showed 
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significantly less binding at 4°C. These aptamer-specific properties had to be taken into 
account when conducting subsequent binding assays, e.g. FACS measurements. 
 
 
Figure 22: Temperature dependency of four selected DNA aptamers. 
All aptamers exhibited high affinity at 21°C, clearly less binding at 4°C and varying behaviour at 37°C. A, 
CLN0004 clearly exhibited less binding and lower affinity upon temperature decrease. B, The optimal 
temperature for CLN0018 appeared to be in the range of 21°C, although it was selected at 37°C. C, CLN0003 
showed less binding at 4°C while the overall affinity was only slightly altered. D, CLN0020 bound with clearly 
higher affinity at 21°C compared to 37°C, and less at 4°C. Small dots indicate dot blot-measured values, whereas 
lines and enlarged symbols represent a fitted binding curve including the derived KD. 
 
5.3.3 First minimisation 
A first minimisation was performed to enable synthesis of shorter biotinylated aptamers in 
higher quantities. Cropped sequences for two c-Met and nine CD16α specific aptamers 
(chapter  5.3.1 and Figure 23) were synthesised in 25 nmol-scale at Invitrogen (chapter 
 4.1.1.3), followed by PAGE-purification (chapter  4.1.3.2), gel-extraction (chapter  4.1.4), 
precipitation (chapter  4.1.5) and determination of aptamer concentration (chapter  4.1.6). 
Minimisation constructs lacking five nucleotides or the full PCR flanking sequence on either 
the 5’ or 3’ end were then radioactively labelled (chapter  4.1.9) and the affinity was compared 
to the full length aptamer biochemically in a dot blot (chapter  4.3.9). Nine of eleven aptamers 
could be minimised to 40mers – 74mers, only CLN0003 and CLN0018 had to be applied at 
RESULTS 
 
 - 80 - 
full length (Figure 23). All cell SELEX derived aptamers were characterised further without 
minimisation. 5’ or 3’ truncations were denoted using a prefix or suffix, such as -20 nt.  
 
 
Figure 23: First minimisation via dot blot affinity change assessment. 
A, Dot blot binding curves of four differently cropped aptamer variants (here examplarily CLN0030) were 
compared in parallel in one measurement. Loss of binding properties (green) or significant affinity shifts (not 
shown) indicated undesired removal of essential sequence elements. B, Based on dot blot data, two c-Met and 
nine CD16α specific aptamers were minimised to lengths of 40 – 84 nt. A prefix “-20 nt” indicates a 5’ fully 
flanking-cropped sequence, whereas a suffix “-5 nt” denotes removal of 5 bases on the aptamer 3’ end. 
 
5.3.4 Determination of cellular binding  
Most aptamers exhibited affinities in the low nano-molar range in biochemical dot blot 
measurements, but since binding to cellular presented target protein was the essential 
property, cellular binding was analysed by flow cytometry. Two c-Met and nine filter SELEX 
derived CD16α specific aptamers were synthesised in minimised form (chapter  5.3.3), cell 
SELEX derived CD16α specific sequences as full length aptamers, all directly including 3’ 
biotinylation (chapter  4.1.1.4). This approach enabled additional 5’ radiolabelling (chapter 
 4.1.9) needed for dot blot analysis (chapter  4.3.9) to confirm unaltered binding properties of 
biotinylated aptamers. All analysed biotinylated aptamers had affinities similar to unlabelled 
original references (data not shown).  
 
5.3.4.1 Binding analysis to cellular CD16α 
 
In CD16 flow cytometry binding analyses (chapter  4.4.3), two antibody positive controls were 
applied to characterise all cell lines: the CD16-specific monoclonal mouse antibody 3G8 and 
the chimeric EGFR-antibody cetuximab that bound via its Fc-portion (Figure 24, chapter  3.2). 
Binding was assessed using freshly ficoll-isolated and MACS-enriched NK cells (chapters 
 4.4.4 and  4.4.5), recombinant Jurkat cells over-expressing either the V158 or F158 alloform 
of CD16α as well as maternal CD16α negative Jurkat E6.1 cells as negative control 
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(Figure 24, chapters  4.4.2 and  3.1). Cetuximab was detected with a goat anti hIgG F(ab’)2 
specific, F(ab’)2 PE conjugated antibody that did not compete with Fc binding to CD16. 3G8 
was applied as all aptamers in biotinylated form and detected via SA-PE (all in chapter  3.2).  
 
 
Figure 24: Binding of selected aptamers and reference antibodies to cellular CD16α by flow cytometry. 
A, The CD16 specific antibody 3G8 bound to all CD16 positive cells, but not to negative reference Jurkat E6.1. 
Broadened histogram peaks might be due to internalisation during incubation at 21°C. B, Cetuximab bound to 
both over-expressing Jurkat cell lines, with stronger binding to CD16α(V158) cells reflecting the higher affinity 
of this Fc receptor alloform. NK cell binding was not evaluated. C, CLN0015 as representative did not bind to 
both NK or Jurkat CD16α(V158) cells. D, As expected, CLN0018 bound to NK and Jurkat CD16α(V158) cells 
and weaker to the CD16α(F158) allotype. Unspecific binding was also observed to CD16 negative Jurkat E6.1 
cells (orange line). E, Unique sequence CLN0020 bound specifically to NK cells as well as to both alloforms of 
CD16α presented on Jurkat cells, as expected from dot blot characterisation. F, Cell SELEX derived CLN0123 
exhibited weak but measurable binding to NK and CD16α(V158) positive Jurkat cells, weaker to CD16α(F158) 
positive Jurkat cells, but not to CD16 negative Jurkat E6.1 cells.  
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Both anti-CD16 antibody references exhibited expected specific binding to NK cells, 
recombinant Jurkat CD16α V158 and F158 cells and no binding to the maternal Jurkat E6.1 
cell line. In contrast, binding to either of the cell lines could not be measured for most of both 
filter- and cell-SELEX derived aptamers. This included sequences with high affinity (for 
instance CLN0015, 19, 30) some of which were highly enriched in both selection screens 
(i.e. CLN0015, 21, 22, 118, 126). Additional 5’ biotinylation or 5’ fluorescein-labelling did 
not alter this result (data not shown). CLN0015 as a representative of a major sequence motif 
block is displayed in Figure 24 (cf. Figure 16). CLN0020 was the only filter SELEX derived 
aptamer found to bind cellular CD16α with high specificity and similar affinity for both 
allotypes on all tested CD16 positive cells (Figure 24, E). CLN0018 bound to NK and 
recombinant CD16 positive Jurkat cells as well, but also unspecifically to CD16 negative 
Jurkat E6.1 cells (Figure 24, D) and nearly all fractions of peripheral blood mononuclear cells 
(PBMCs, data not shown). Unexpectedly, most aptamers enriched in cell SELEX on Jurkat 
CD16α V158 and F158 cells did not exhibit binding to these cell lines in biotinylated form 
(data not shown). CLN0022 and CLN0128 exhibited very weak intensity shifts in FACS 
measurements (data not shown), but were not characterised further due to their low affinities 
in dot blot assays (see also chapter  5.3.1). CLN0123 was the only cell SELEX derived 
sequence to show specific and reasonable cellular binding that was in accordance with a 
relatively low affinity to CD16α-6His of 193 nM in dot blots. As expected, CLN0123 bound 
to NK and Jurkat CD16α(V158) positive cells better than to CD16α(F158) positive and did 
not bind to CD16α negative Jurkat E6.1 cells (Figure 24, F). Direct comparison of 
fluorescence intensities between antibody and aptamer measurements were not feasible due to 
on average four biotins per antibody to exactly only one per aptamer. All results were 
confirmed in two to eight independent measurements.  
 
5.3.4.2 Binding analysis to cellular c-Met 
 
The c-Met specific aptamers CLN003 and CLN0004 were analogously characterised by flow 
cytometry (chapter  4.4.3) along with a monoclonal anti c-Met mouse antibody as positive 
control (c-Met mAb, chapter  3.2) on different c-Met positive human cancer cell lines (GTL-
16, MKN-45, EBC-1) and Jurkat E6.1 cells as a negative control. These cells were also 
characterised towards EGFR surface expression with cetuximab (chapter  3.2) to assess the use 
of this antibody as a positive control in ADCC assays. The c-Met mAb was detected with a 
goat anti mouse F(ab’)2 specific, F(ab’)2 PE conjugated antibody (chapter  3.2) and cetuximab 
as decribed above.  
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The three human cancer cell lines GTL-16, MKN-45 and EBC-1 were confirmed as both 
c-Met and EGFR positive, whereas Jurkat E6.1 provided an appropriate c-Met negative 
control cell line (Figure 25, A and B). Both c-Met specific aptamers bound to all three human 
cancer c-Met cell lines in a very distinct manner, but exhibited no unspecific binding to Jurkat 
E6.1 cells (Figure 25, C and D).  
 
 
Figure 25: FACS determination of cellular binding of c-Met aptamers and antibody references. 
A, The monoclonal mouse antibody c-Met mAb revealed that human cancer cell lines GTL-16, MKN-45 and 
EBC-1 were c-Met positive, while Jurkat E6.1 cells were c-Met negative, hence a suitable control. B, Cetuximab 
binding indicated additional strong EGFR surface expression on GTL-16, MKN-45 and EBC-1. C, CLN0003 
bound clearly with high specificity to all c-Met positive cells, but not to the negative control Jurkat E6.1. D, 
CLN0004 exhibited specific cellular c-Met binding as well.  
 
Taken together, two CD16α aptamers (CLN0020 and CLN0123) and two c-Met aptamers 
(CLN0003 and CLN0004) were found to bind with high specificity to the cellularly presented 
target proteins. 
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5.3.5 Structure prediction 
Structure prediction for the remaining four 
DNA aptamers, calculated for physiological 
conditions of 150 mM Na+ concentration 
without Mg++at 37°C using mfold (Zuker, 
2003 and chapter  3.9), yielded only one 
proper structure suggestion for CLN0020 
that predicted the last base of the 5’ flanking 
sequence (C20) to be essential for structure 
formation (Figure 26). Other predictions 
included only minimal secondary structure 
interactions of less than 6 bases and were 
ignored. For both c-Met aptamers, a primary 
sequence comparison indicated two identical motifs instead (cf. Figure 21).  
 
5.3.6 Epitope mapping 
Since binding multiple epitopes on CD16 could be valuable for bi-specific aptamer 
development, the binding sites of CLN0020 and CLN0123 were characterised in competition 
dot blots with antibodies 3G8 and cetuximab that bind near or in the Fc-binding domain. 
5 fmol radiolabelled CLN0020 (chapter  4.1.9) was used in a competition dot blot 
(chapter  4.3.10) with 50 nM CD16α-6His and a dilution series of 3G8, cetuximab, or 
CLN0123. Additionally, CLN0020 itself was used as positive control as well as a non-binding 
antibody fragment BMP2-7 as negative control (Habicht and Siegemund, 2002). CLN0020 
was clearly displaced by 3G8 and cetuximab, while similar amounts of BMP2-7 did not alter 
binding properties (Figure 27, A and B). Higher amounts of cetuximab were needed to replace 
CLN0020 as opposed to 3G8, which was in line with 3G8’s higher affinity to CD16. Non-
labelled CLN0020 replaced radiolabelled CLN0020 as expected, whereas CLN0123 and 
negative control CLNX did not compete with CLN0020 (Figure 27, C). Thus, CLN0020 was 
found to bind in or near the Fc binding domain.  
 
Direct competition studies of CLN0123 with cetuximab could not be performed in a dot blot 
assay because low CD16α affinities of both CLN0123 and the IgG1 cetuximab enforced the 
use of too high protein amounts that could not be captured quantitatively on the nitrocellulose 
membrane. Competition studies by flow cytometry and bio-layer interferometry indicated 
Figure 26: Structure predition for CLN0020. 
Nucleotides from base 20 - 53 are predicted to be 
essential for structure formation. Orange 
numbering indicated base numbers of the full 
length aptamer. 
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reduced binding of CLN0123 to CD16α in the presence of cetuximab (data not shown). Thus, 
CLN0123 bound to an epitope near or in the Fc binding domain different than the site 
recognised by CLN0020. 
 
Similar sequence motifs of c-Met specific aptamers CLN0003 and CLN0004 (cf. Figure 21) 
suggested a putative specificity for the same epitope on c-Met. This assumption was 
confirmed by competition dot blots with 5 fmol radiolabelled aptamers (chapters  4.1.9 and 
 4.3.10) binding to 10 nM c-Met-Fc fusion protein (chapter  3.2). Radiolabelled CLN0003 was 
replaced by non-labelled CLN0004 and in the reverse assay labelled CLN0004 competed with 
unmarked CLN0003 (Figure 27, D). Higher amounts needed for CLN0003 competition by 
CLN0004 were in line with the lower c-Met affinity of CLN0004. This mutual replacement 
provided clear evidence that both aptamers recognise the same epitope on c-Met. 
 
 
Figure 27: Competition dot blots of CD16α and c-Met aptamers. 
A – C, Competition dot blots applying CD16α-6His and specific aptamers CLN0020 or CLN0123 in the 
presence or absence of putative competitors for epitope mapping. X-axes represent the molar excess of 
competitor over CD16α. A, Radiolabelled CLN0020 was rapidly replaced in a concentration dependent manner 
by the anti-CD16 monoclonal antibody 3G8, while the negative control antibody fragment BMP2-7 (orange) did 
not affect aptamer binding. B, Competition of the Fc-portion of cetuximab with CLN0020 binding on CD16α 
could be titrated as well, while addition of BMP2-7 did not alter aptamer binding. C, Radiolabelled and CD16α-
bound CLN0020 was replaced by non-labelled CLN0020 as positive control (blue bars), but not by CLN0123 
(green bars) or the negative control aptamer CLNX (orange, chapter  3.3). D, Mutual replacement of 
radiolabelled CLN0003 by non-labelled CLN0004 (blue bars) or radiolabelled CLN0004 by CLN0003 (green 
bars) indicated binding the same epitope. Addition of non-binding CLNX (orange) had no effect. X-axis, molar 
excess of unlabelled competitor aptamer over labelled aptamer bound to c-Met. For all experiments n = 1. 
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5.3.7 Second minimisation and sequence analyses 
A prerequisite for the establishment of bi-specific aptamers was knowledge of the core 
sequences necessary for aptamer binding to assemble bi-specific constructs with well defined 
linker lengths. In addition to initial minimisations (chapter  5.3.3), further and more defined 
minimised aptamer constructs were screened based on mfold structure prediction of CLN0020 
(chapter  5.3.5) and sequence analysis of CLN0003 and CLN0004 (Figure 21). Cropped 
sequences were synthesised in 200 nmol scale (chapter  4.1.1.3), PAGE-purified (chapter 
 4.1.3.2) and -eluted (chapter  4.1.4), precipitated (chapter  4.1.5) and the concentration was 
determined (chapter  4.1.6). Pure aptamers were then 5’ radiolabelled (chapter  4.1.9) and the 
affinity was determined in a dot blot (chapter  4.3.9), directly comparing cropped sequences to 
the original 84 nt aptamer. Additionally, two sequence variants of CLN0004 found in the 
analysed SELEX pools were produced and their affinity determined in the same way. 
Generally, dot blot derived KD values were prone to variation due to a high sensitivity 
towards changes in temperature and protein preparation; hence minimisation evaluation was 
based on direct comparison of parallel samples of one experiment. 
 
While the c-Met specific aptamer CLN0003 generally exhibited a decrease in affinity upon 
truncation, CLN0004 could be minimised to a 41mer with a KD of 83 nM or a 46mer with an 
affinity comparable to the full length aptamer (Figure 28, C and D). Interestingly, the base 
G61 of CLN0004 was suggested as an essential component by sequence comparison (to 
CLN0003, cf. Figure 21) and this was confirmed by dot blot minimisation (Figure 28, A). 
Removal of nearly all flanking bases of the CD16α specific aptamer CLN0020 led to a 41mer 
and further structure prediction based minimisation to a 34mer. Both minimised aptamers 
displayed unaltered affinity to CD16α-6His (Figure 28, B and E). The importance of the 5’ 
flanking base C20, as suggested by structure prediction (Figure 26), was confirmed by testing 
two constructs differing only in this base (Figure 28, B, blue vs. red graphs). Flanking 
sequences of CLN0123 could be removed without major loss of binding properties, but 
CD16α affinity remained relatively low in all CLN0123 constructs, as expected (Figure 28, 
F).  
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Figure 28: Dot blot based minimisation of c-Met and CD16α specific aptamers. 
A, Removal of full flanking sequences of CLN0004 resulted in complete loss of binding in dot blot experiments 
(red), whereas addition of only G61 (orange) recovered nearly similar affinity as the original clone (green, cf. D 
and Figure 21, A). B, Removal of C20 in CLN0020 altered low nanomolar affinity (blue) to hardly any binding 
(red) as determined in a dot blot. C, Minimisation of CLN0003 generally led to decrease of affinity, however still 
remaining in a low nano-molar range. D, Sequence variants of CLN0004 (blue bases) and 3’ truncations 
exhibited lower affinities, while the 5’ flanking sequence was not essential for c-Met binding. E, CD16α aptamer 
CLN0020 was minimised to a 34mer core sequence while retaining a high affinity. F, Truncated CLN0123 
constructs bound expectedly weak but with similar or improved affinities to CD16α. Intermittent, binding curves 
shifted due to temperature and protein batch variations; hence only direct, qualitative comparison to the original 
aptamer was feasible (indicated as ~11 nM in D). Binding was categorised as similar (green), altered but 
reasonable (orange) or severely shifted (red) in comparison to the original sequence (black). 
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Two sequence variants of CLN0004 found in the original SELEX pool exhibited weaker 
affinity to c-Met than the major sequence and were ignored (Figure 28, D, blue bases). 
Variants of CLN0003, CLN0020 and CLN0123 did not occur; several sequence variants of 
CLN0018 were not evaluated due to unspecific binding of the most prevalent aptamer.  
 
Aptamers against c-Met and CD16α specifically binding to their respective cellular antigens 
were fully characterised and minimised and therefore suitable for linkage into bi-specific 
constructs. 
 
5.4 Bi-specific aptamers 
5.4.1 Design of bi-specific aptamers 
With the goal of developing bi-specific aptamers featuring high affinities to c-Met and CD16α 
as well as an optimal linker length to mediate cytotoxicity, 24 different bi-specific aptamer 
constructs (bsA1 – bsA32) were designed (Table 2). CLN0020 was used as the effector 
specific portion in most constructs, and CLN0123 which bound with lower affinity to CD16α, 
was used in the construction of bsA15 and bsA16. As target specific aptamers, both CLN0003 
and CLN0004 were applied. All aptamers were synthesised as one oligonucleotide chain. 
These constructs varied in orientation of the effector and target cell specific aptamer. 
Differently minimised aptamers were used to screen for a suitable linker length while 
retaining high affinities at the same time, and several kinds of linker were applied: A 15 dA 
linker (Muller et al., 2007), up to 44 nucleotides as “original” linker derived from flanking 
regions of the full length sequence as well as shorter flanking region sequences known to not 
interact with the aptamer (c.f. Figure 28). Polyethylene glycol (PEG) linkers were applied as 
PEG(3) and PEG(6) bridging 9 or 18 C- and O-atoms, respectively. bsA14 incorporating a 
PEG(24) linker was planned but not produced due to positive progress with nucleotide linker 
constructs. 
 
The core aptamer sequence was defined as those that retained similar binding properties in 
minimisations (green sequences in Figure 28). CLN0020 structure predition suggested a core 
sequence of C20 – G53 essential for structure formation (cf. Figure 26), yielding the exact 
borders that were essential for target binding. For example, all nucleotides downstream from 
G54 were defined as linker sequence.  
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Assuming an optimal bsA linker should bridge approximately the distance spanning from 
CDRs to the Fc binding domain in the hinge region of an antibody, this distance was 
estimated from measurement of PDB entry 1T83 (Radaev et al., 2001) to be ~65 Å. The 
nucleotide to nucleotide distance in single stranded portions of DNA aptamers was 
determined by measuring 4 distances in PDB entries 1HUT and 1OOA, resulting in a mean 
distance of 7 Å. Hence, the putative linker lengths ranged from 20 Å of PEG(3) over 105 Å of 
a 15 dA linker to 357 Å of the 51 nt linker applied in bsA12. Although these values were a 
rough approximation, they could serve as a first estimation for the range of the desired linker 
length.  
 
Table 2: Overview of bi-specific aptamer constructs.  
CLN0004-5 denotes a 5 nt truncation 3’ of CLN0004 and so forth. Bi-specific constructs bsA31 and bsA32 are 
direct derivatives of bsA3. 
Construct 5' aptamer Linker sequence 3' aptamer Putative linker length ( Å) M W 
bsA1 -19CLN0020-24 GCAGGTC -20CLN0004-23 49 25800
bsA2 -20CLN0004-23 none -19CLN0020-24 0 25800
bsA3 -19CLN0020-24 GCAGGTCAAAAAAAAAAAAAAA -20CLN0004-23 154 30500
bsA31 -19CLN0020-24 GCAGGTCAAAAAAAAAAAAAAA -20CLN0004 154 37600
bsA32 -19CLN0020-31 AAAAAAAAAAAAAAA -20CLN0004 105 35400
bsA4 -20CLN0004-23 GCAGGTCAAAAAAAAAAAAAAA -19CLN0020-24 154 30500
bsA5 -19CLN0020-24 GCAGGTC + PEG (3)  = C 9 -20CLN0004-23 69 26000
bsA6 -20CLN0004-23 PEG (3)  = C 9 -19CLN0020-24 20 26000
bsA7 -19CLN0020-24 GCAGGTC + PEG (6)  = C 18 -20CLN0004-23 82 26100
bsA8 -20CLN0004-23 PEG (6)  = C 18 -19CLN0020-24 33 26100
bsA9 CLN0020 GCAGGTCGATTAGTTTTGGAGTACTCGCTCC CLN0003 217 52700
bsA10 CLN0003 GGAGGGAAAAGTTATCAGG CLN0020 133 52700
bsA11 -19CLN0020 GCAGGTCGATTAGTTTTGGAGTACTCGCTCC CLN0003 217 46600
bsA12 -19CLN0020 GCAGGTCGATTAGTTTTGGAGTACTCGCTCCGGAGGGAAAAGTTATCAGGC CLN0004-5 357 45100
bsA13 -20CLN0004 GCTCCGGAGGGAAAAGTTATCAGG CLN0020-31 168 36700
bsA14 -10CLN0020-24 GCAGGTC + PEG (24)  = C 72 CLN0003 144 42800
bsA15 CLN0123 GATTAGTTTTGGAGTACTC CLN0003 140 52700
bsA16 -20CLN0004 ATTAGTTTTGGAGTACTCGCTCCGGAGGGAAAAGTTATCAGGC CLN0123 308 46400
bsA17 -19CLN0020-24 GCAGGTC CLN0003 49 39200
bsA18 -19CLN0020-31 ATCAGGC -13CLN0004-5 49 33500
bsA19 -19CLN0020-24 GCAGGTCAAAAAAAAAAAAAAA CLN0003-24 154 36400
bsA20 -19CLN0020-24 GCAGGTC CLN0003-24 49 31700
bsA21 -19CLN0020-24 GCAGGTCAAAAAAAAAAAAAAA CLN0003 154 43800
bsA22 -19CLN0020-31 AAAAAAAAAAAAAAA CLN0003 105 41700
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5.4.2 Affinity confirmation  
High affinities to CD16α and especially to c-Met were expected to be crucial for the 
mediation of a cytolytic function of bi-specific aptamers and thus determined in dot blot 
measurements (Figure 29). All bi-specific aptamers were synthesised by IDT, Leuven, 
Belgium, and purified by PAGE (chapter  4.1.3.2), followed by gel extraction, precipitation 
and concentration determination (chapters  4.1.4 -  4.1.6). 10 pmol of each aptamer were then 
labelled with 32P (chapter  4.1.9) and a dot blot (chapter  4.3.9) was performed 1 – 10 times to 
evaluate affinities to CD16α-6His and C-Met-Fc fusion protein (chapter  3.2). Resulting KD 
values were compared to those of the corresponding parental minimised single aptamers (c.f. 
Figure 28). 
 
 
Figure 29: Dot blot affinity determination of all bi-specific aptamers. 
A and C, Dot blot binding curves of bi-specific aptamers bsA17 and bsA31, respectively. Affinities to CD16 
were comparable (19 and 24 nM) and in accordance with the parental -19ntCLN0020-31nt (47 nM). In contrast, 
CLN0003-derived bsA17 exhibited picomolar c-Met affinity (A) whereas CLN0004-derived bsA31 bound with 
92 nM Kd to c-Met (C), reflecting the different affinities of parental aptamers CLN0003 and CLN0004 (91 pM 
and 57 nM, respectively). B, Dot blot derived affinities to CD16α and c-Met for all bi-specific aptamers (except 
of bsA14 that was not produced). Generally, CLN0020 retained original affinity when used 5‘, whereas c-Met 
aptamers performed best fused to the 3‘ end (bsA3, 5, 7 17 – 22). Linked full length aptamers yielded affinities 
similar to parental single aptamers (CLN0003: picomolar Kd of bsA9-11, 17, 21, 22; CLN0004: 18 nM of 
bsA12, 13; CLN0123: 174 nM and 178 nM of bsA15 and 16, respectively). bsA1 and bsA2 without linker 
exhibited a c-Met affinity decrease. KD values are shown as mean values and standard deviation of independent 
dot blot experiments. 
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Generally, most bi-specific aptamers exhibited high affinities to both target proteins similar to 
their respective parental single aptamers. Especially CLN0003-derived bsAs retained 
picomolar affinities to c-Met (bsA9, 10, 11, 15, 17, 21, 22) or low nanomolar KD values when 
truncated (cf. 5 nM of bsA20 to 3 nM of CLN0003-24nt in Figure 28). CLN0004 was 
generally more suitable to linkage at the 3’ end of bsAs (cf. Figure 28, D) and with a longer 
linker (bsA12 and bsA13) exhibited a similar affinity of 18 nM as the original aptamer. 
Further truncated derivatives and shorter linkers led to decreased but still reasonable c-Met 
affinities of 92 – 160 nM (bsA3, 31, 32, 4, 5, 7, 16, 18). CLN0020 performed best when fused 
5’ to a bi-specific aptamer, but not when applied 3’ (as in bsA4, 6, 13). When CLN0020 
constituted the 5’ end of a bi-specific aptamer, mostly including the 7 nt linker sequence 
GCAGGTC that originated from the parental sequence, original affinities of low two-digit 
nanomolar KD were generally retained (cf. Figure 28, E). CLN0123-derived bsA15 and bsA16 
bound to CD16α-6His with 173 nM and 178 nM, respectively. These affinities were lower 
than those of CLN0020-containing bi-specific aptamers, but as high as the parental single 
aptamer CLN0123 (cf. Figure 20 and Table 1). Bi-specific constructs bsA1 and bsA2 lacking 
a linker, as well as bsA6 and bsA8 exhibited clear c-Met affinity decreases with KD values of 
220 – 370 nM. These bi-specific aptamers were not analysed further. All other bi-specific 
aptamers (bsA3 - 5, 7, 9- 22) were further evaluated for simultaneous binding to both target 
proteins. 
 
5.4.3 Determination of simultaneous binding  
Suitable affinities to CD16α or c-Met were confirmed for most bi-specific aptamers, but 
simultaneous binding to both target proteins had to be determined as prerequisite for a 
potential mediation of cytotoxicity as well. Electrophoretic motility shift assays (EMSAs) 
were primarily performed for all remaining bsAs, and positive results for major candidates 
were confirmed with bio-layer interferometry. 
 
5.4.3.1 Electrophoretic motility shift assay 
 
An EMSA was performed with 19 remaining bi-specific aptamers (bsA3-5, 7, 9-22; 
chapter  4.3.12). Sole binding to either CD16α-6His or c-Met-Fc fusion proteins was indicated 
by an additional slower migrating aptamer band. Simultaneous binding to both target proteins 
could be detected by a further shift in the migration distance upon addition of c-Met-Fc and 
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CD16α-6His in comparison to c-Met-Fc alone. A migration shift indicated a larger size of the 
bi-specific aptamer and hence simultaneous binding of both target proteins. Figure 30 shows 
representative results for CLN0003- and CLN0004- derived bi-specific aptamers. All 
constructs yielded similar results (data not shown).  
 
 
Figure 30: Electrophoretic migration shift assay proving simultaneous binding to CD16α and c-Met. 
A – C, CLN0003-derived bsA17, bsA22 and bsA11 all exhibited binding to CD16α-6His (additional band in 
lane 2) or c-Met-Fc fusion proteins (additional band in lane 3). This c-Met-Fc bound aptamer band shifted again 
upon addition of CD16α-6His (lane 4). D, Negative control parental single aptamer CLN0003, in contrast, did 
not show this migration shift. E and F, bsA31 and original single c-Met specific aptamer CLN0004 exhibited the 
same pattern, while non-binding negative control aptamer CLNC did not bind to any protein, as expected. 
Application of a gradient gel and size differences between CD16α-6His and c-Met-Fc fusion protein led to 
differently extended migration (lanes 2 and 3) and an expectedly minor but clearly present migration shift upon 
addition of both target proteins (from lane 3 to 4). Arrows indicate the lowest migration frontier of specific 
aptamer bands. Weak additional bands in lanes 1 and 2 in A, B, C as well as all lanes in D could be due to 
unspecific aggregation.  
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5.4.3.2 Bio-layer interferometry 
 
Four bi-specific aptamers with high affinities and different potentially suitable linkers were 
selected for additional confirmation of simultaneous binding via bio-layer interferometry 
using a fortéBio Octet Red device (chapter  4.3.11). Briefly, c-Met-Fc fusion protein was 
immobilised on amino reactive tips, bi-specific aptamers and suitable controls were allowed 
to bind and finally CD16α association and dissociation was monitored. In addition to 
c-Met-Fc binding, bsA17 clearly yielded simlutaneous Fc-CD16α binding, whereas c-Met 
specific single aptamer CLN0003 did not (Figure 31). Bi-specific aptamers bsA22 and bsA11 
exhibited similarly strong bi-specific binding, whereas bsA31 bound weaker but measureable 
to both proteins (data not shown).  
 
 
Figure 31: Proof of simultaneous binding of bsA17 to both target proteins via fortéBio Octet Red. 
A, Raw data of applied AR sensor tips. c-Met-Fc fusion protein is immobilised on the tip surface (step 2), then 
bsA17 and CLN0003 bound to c-Met-Fc (blue and red curves in step 5), followed by Fc-CD16α association to 
bsA17 (blue curve in step 6). To exclude unspecific Fc-CD16α binding, the reference measurement lacking 
aptamer in step 5 (green) was subtracted from bsA17 and CLN0003 raw data, yielding the signal of specific 
simultaneous binding displayed by Fc-CD16α association and dissociation (B). c-Met-bound bsA17 exhibited 
additional Fc-CD16α binding (blue curve), while CLN0003 did not (red curve).  
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5.4.4 Serum stability 
Since further functional assays demanded measurements in the presence of serum and 
stability was of interest for potential later applications of this therapeutic concept, serum 
stability was determined for CLN0004 and CLN0020 as well as for bi-specific aptamers 
bsA17 and bsA3 (chapter  4.3.13). DNA aptamers exhibited serum half lives of 9.8 h 
(CLN0004), 14.5 h (CLN0020), 6.4 h (bsA3) and 20.3 h (bsA17) in freshly thawed ultra low 
IgG FCS (also used for ADCC assay medium, chapter  3.2). bsA17 remained stable in DPBS 
for 48 h, indicating the long shelf-life of aptamers in general (Figure 32).  
 
 
Figure 32: Serum stability of major DNA aptamers. 
A and B, PAGE of CLN0020 or bsA17, respectively, after incubation in fetal calf serum at different time points. 
Bands at the migration level of the 0 h sample represented intact aptamer, while increasing signals at lower 
positions depicted breakdown products. C, bsA17 was stable in PBS over the whole time course, as debris could 
not be observed even after 48 h. D, Intensity values were extracted from gels as in A – C, the percentage of intact 
aptamer calculated and a curve fitted to the resulting time course. Half lives were determined as 6.4 h – 20.3 h. 
Enlarged symbols indicate the half life fit of each aptamer. 
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5.5 Functional screening of bi-specific aptamers 
Bi-specific aptamers displaying high affinities and simultaneous binding to both target 
proteins as well as suitable serum stability were finally applied in a functional ADCC assay. 
ADCC in this case denoted antibody- or aptamer- dependent cellular cytotoxicity in the cases 
of antibody positive control or evaluated bi-specific aptamers, respectively.  
 
ADCC assays were carried out using CLN0004-derived bsA3, 31, 4, 5, 7, 16, 18 (all with 
probably suitable linkers but relatively low c-Met affinities, Figure 34) and bsA12 and bsA13 
(showing higher c-Met affinities due to long linker sequences). Further, CLN0003-based bi-
specific aptamers bsA9, 10, 11, 15, 17, 20 and 22 were evaluated (sharing high c-Met 
affinities combined with varying linkers, Figures 33 and 34). bsA19, 21 and 32 were excluded 
due to lower affinity or less suitable linkers than related bsA20, 22 or 31, respectively. Initial 
evaluations were carried out with aptamer dilution series by applying peripheral blood 
mononuclear cells (PBMCs, chapter  4.4.4) to human gastric adenocarcinoma GTL-16 cells 
(chapter  3.1) in a ratio of 80:1 (chapter  4.4.6). Positive bi-specific aptamers were further 
analysed at 50 nM bsA with decreasing PBMC : target cell ratio. In addition, aptamer dilution 
series were carried out analogously to GLT-16 using human lung squamous cell carcinoma 
EBC-1 cells (chapter  3.1).  
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Figure 33: Functional ADCC assays of bi-specific aptamers on GTL-16 and EBC-1 cells. 
A, Specific GTL-16 cell lysis mediated by bi-specific aptamer bsA17 at a similar magnitude as cetuximab as 
positive control. Aptamer titration led to decrease of & lysis to background levels of non-binding negative 
control aptamer CLNC and reference with medium only. B, PBMC : target cell ratio reduction diminished 
specific GTL-16 cell lysis of both bsA17 and cetuximab at 50 nM. Note that the actual effector : target cell ratio 
was approximately 8:1 when applying 80:1 PBMC : target cells. C, bsA17 mediated concentration-dependent 
specific EBC-1 cell lysis as well analogously to GTL-16 target cells (A). D, Addition of 20-fold molar excess of 
antibody 3G8 resulted in a significant decrease of bsA17-mediated GTL-16 lysis due to inhibition of bsA17-
binding to CD16α. E, Affinity differences of 352 pM (bsA17) to 5 nM (bsA20) showed no influence on 
effectiveness of GTL-16 cell lysis, whereas longer linker sequences (approximately bsA17 with 49 Å, bsA22 
with 105 Å and bsA11 with 217 Å) led to a decrease of bsA-mediated GTL-16 cell lysis (F). Maximal lysis 
varied between individual experiments due to donor and CD16α allotype dependency. ADCC assays were 
performed 5 times with n = 4 (A), 3 times with n = 3 (B), 4 times with n = 4 (C), 3 times with n = 9 (D), 1 time 
with n = 9 (E), 3 times with n = 9 (F) and representative measurements are shown as calculated mean values, 
error bars indicate standard deviation.  
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Bi-specific aptamer bsA17 mediated cellular cytotoxicity to GTL-16 and EBC-1 cells with a 
similar magnitude to antibody positive control cetuximab (Figure 33, A and C). This effect 
was reduced by both aptamer or effector cell dilution (Figure 33, B). In addition, blocking of 
aptamer binding to CD16α by addition of competing antibody 3G8 in 20-fold excess led to a 
significant decrease of specific cell lysis, further supporting the proposed mode of action 
(Figure 33, D). The bsA17-related bi-specific aptamer bsA22 similarly mediated specific 
GTL-16 cell lysis that could be diminished by reduction of aptamer concentration or effector 
cell amount (Figure 34, A and B). CLN0004-derived bsA31, showing lower c-Met affinity 
(92 nM), induced weaker, but significant cytotoxicitiy at higher concentrations above 100 nM 
(Figure 34, C). Bi-specific aptamer bsA15 (similar to bsA17, but composed of medium 
affinity CLN0123 instead of CLN0020 as CD16α binding entity) mediated specific GTL-16 
lysis at comparable concentrations but to a lesser extent of 20 % (Figure 34, D).  
 
 
Figure 34: ADCC assays of bi-specific aptamers bsA22, bsA31 and bsA15. 
A, Bi-specific aptamer bsA22 induced specific tumour cell lysis in a concentration-dependent manner. bsA22 
was nearly as potent as cetuximab with significantly higher lysis than non-binding aptamer control CLNC or 
medium reference. B, At 50 nM fixed concentration, both bsA22- and cetuximab- mediated lysis was diminished 
by reduction of PBMC : target cell ratio. C, bsA31 with lower c-Met affinity induced weaker but significant lysis 
at higher concentrations. D, bsA15, composed of CLN0123 as lower affinity CD16α binding entity, mediated 
weak but significant cytotoxicity as well. Human gastric adenocarcinoma GTL-16 cells applied in all 
measurements. Mean values with standard deviation are shown. Assays were performed in triplicate (B) or n = 4 
– 5 (A, C, D) 4 times (A), 1 time (B), 2 times (C) and 1 time (D) and representative measurements are shown.  
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Direct comparison of bsA17 and bsA20 that only differed in c-Met affinity of 352 pM to 
5 nM, respectively, showed no difference of lysis effectiveness within this affinity range 
(Figure 33, E). However, the related construct bsA18, exhibiting 106 nM c-Met affinity, could 
not elicit cellular cytotoxicity (data not shown). Comparing similar constructs differing 
mostly in linker length only indicated putative linkers of approximately 50 – 100 Å (of bsA17 
and bsA22) were more suitable than longer linkers (217 Å of bsA11, all Figure 33, F). It must 
be noted that putative linker lengths were calculated based on crystal structures of other DNA 
aptamers (chapter  5.4.1), so these were estimations only. 
 
Although a precise EC50 determination was not feasible with mostly qualitative data obtained, 
the half effective dose of bsA17 and bsA22 was in the low two-digit nanomolar range of 1 –
 50 nM (Figure 33, A and C as well as Figure 34, A). 
 
Table 3 gives a concluding overview of reviewed bi-specific aptamers and all properties that 
have been characterised. 
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Table 3: Overview of all applied bi-specific aptamers with determined properties. 
Green coloured values indicate suitable, yellow acceptable and red insufficient properties. Putative linker lengths 
estimated as decribed in chapter  5.4.1. MS1 denotes -19ntCLN0020-24nt; MS2, -20ntCLN0004-23nt; MS3, 
-19ntCLN0020-31nt; n.d., not determined. For further information, please refer to respective chapters.  
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6 DISCUSSION 
6.1  Selection and characterisation 
CD16α specific DNA aptamers were selected in three different SELEX approaches (Figure 
13) yielding abundant unique sequences (Appendix, Table 6). After nine rounds of filter 
SELEX, the aptamer pool was enriched containing 86 % binding aptamers (Figure 16). 
Successful CD16β counterselection led to CD16α specific aptamers that did not bind CD16β 
at all, although CD16β shares 97 % sequence identity and protein quality was confirmed in 
PAGE and immunoprecipitation (chapter  5.1). Of the few CD16 aptamers characterised by 
epitope mapping, all bound in or near the Fc-binding domain of CD16. Furthermore, both 
CD16α and CD16β were functionally folded, but differed in gel migration pattern (Figure 9 
and Figure 12), possibly due to variation in glycosylation. CD16 isoform specificity of 
selected aptamers could be due to conformation-sensitive binding to epitopes that are 
influenced by the glycosylation pattern. This result supports the potential for aptamers as 
highly selective binding molecules. Although the specificity is surprising, it is in line with 
reported aptamers that show are highly specific (Jenison et al., 1994) and can differentiate, for 
example, between closely related tumour cell types (Shangguan et al., 2006). More 
importantly, the CD16α specificity could prevent decoy of therapeutically applied bi-specific 
aptamers by soluble CD16β vastly present in the blood (chapter  2.6), but ensure recruitment 
of suitable effector cells presenting mostly cell-bound CD16α. In comparison to therapeutic 
antibodies that are bound by both CD16α and CD16β isoforms, the CD16α specificity could 
increase the efficacy of therapeutic bi-specific aptamers.  
 
In addition, the selected CD16α aptamer CLN0020 exhibited high affinity to both CD16α 
V158 and F158 allotypes (Figure 20 and Figure 24), whereas CD16α affinity of Fc-portions 
of antibodies and the resulting therapeutic effect is dependent on the CD16α V158 instead of 
F158 polymorphism. The V/V homologue is associated with higher ADCC and improved 
clinical outcome than F/F alleles (Cartron et al., 2002; Taylor et al., 2008). Application of 
CLN0020 in bi-specific aptamers would thus reduce this difference and potentially broaden 
the cytolytic effect to all patients.  
 
Applying three additional rounds of CD16α hydrophobe plate selection (MTP SELEX) for 
competition elution with CD16 Fc-domain specific antibody 3G8 resulted in three unique 
sequences including CLN0030 with 6 nM affinity as well as two sequences that were also 
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found only in each of the cell SELEX approaches (Appendix, Table 6). In principle, MTP 
SELEX enriched binders should be specific for the Fc-binding domain of CD16α similar to 
antibodies, as the selection was driven with those aptamer initially bound to CD16α and 
replaced by 3G8. But since MTP SELEX derived aptamers did not bind to cellular CD16α, 
epitope specificity was not evaluated for these aptamers.  
 
Unexpectedly, aptamers that were periodical highly enriched in cell SELEX and showed high 
affinity to recombinant CD16α in dot blot assays mostly did not exhibit cellular binding to the 
same cells used during their selection when applied in biotinylated form in flow cytometric 
measurements (CLN0021, 28, 118 and 126, cf. Table 1 and Table 6). Similarly, most filter 
SELEX derived CD16α specific aptamers bound to recombinant CD16α-6His with high 
affinity, but not to cellular CD16α presented on recombinant Jurkat or NK cells. This could be 
due to disruption of their tertiary structure by either biotinylation or more likely the 
subsequent binding of comparatively large streptavidin-phycoerythrine conjugates for staining 
purposes. Since such aptamers probably would not have been suitable to serve as one entity in 
bi-specific constructs, optimisation of the detection method (e.g. switching to direct dye 
labelling) was not performed. On the other hand, six rounds of cell SELEX could have been 
to few to evolve high affinity cellular binding aptamers and additional selection rounds would 
have increased the number of positive binders. Nevertheless, cell SELEX yielded additional 
unique CD16α aptamers with sufficient affinity (CLN0118, CLN0123, CLN0126, Table 1) 
and even utilisation of differently preselected starting pools (of filter SELEX rounds 3 or 5, 
respectively) resulted in selection of different new aptamers. This illustrates on the one hand 
the positive influence of initial SELEX rounds on recombinant target protein under 
characterised conditions to produce a diverse but already pre-enriched library that enables 
well-directed selection of cell-specific aptamers (Björn Hock, personal communication). On 
the other hand, the importance of a selection design to be as close as possible to the desired 
binder application conditions is emphasised.  
 
Interestingly, the most prevalent aptamers did not always exhibit the highest affinity which 
was partly displayed by aptamers enriched very weakly and late during SELEX (e.g. 
CLN0030 with 6 nM CD16α affinity 2 % in MTP SELEX round 12, cf. Table 1 and Table 6, 
Appendix). Enrichment of aptamers during SELEX rounds using medium target protein 
concentrations could have also been due to intrinsic factors such as good compability for PCR 
amplification, while more stringent selection with decreased target protein but higher amounts 
of tRNA competitor could have yielded other binders with higher affinity. This implied a 
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mandatory characterisation of all aptamers that was carried out by testing the main 
representative of sequence families sharing 90 % sequence identity. In later stages, sequence 
variants of aptamer hits were analysed further for improved properties (CLN0004 in Figure 
28). Furthermore, temperature-dependent affinity variation was observed with most, but not 
all characterised aptamers (Figure 22). This indicates the need to characterise every aptamer 
hit and adjust subsequent assays accordingly. Selection and characterisation of potentially 
therapeutic aptamers were performed at 37 °C, and some aptamers exhibited less binding or 
lower affinites at 4 °C (Figure 22). In contrast, flow cytometry binding reactions are generally 
carried out at 4 °C for reduction of the cell metabolism to preserve an original cell surface 
composition as well as to reduce undesired antibody dissociation (Chao et al., 2006, step 15). 
Thus, flow cytometry was performed at ambient temperature, balancing both influences with 
the drawback of allowing undesired variations such as internalisation or autolysis of effector 
cells (e.g. 3G8 on NK cells in Figure 24, A).  
 
An additional CD16α rRfY SELEX with counterselection to CD16β yielded a still variable 
but already highly enriched pool of CD16α binders (Figure 19), again exhibiting no binding to 
the highly related CD16β (Figure 18, D). Dot blot derived affinities of 20 – 49 nM were 
comparable to selected DNA aptamers, but since no vast stability increase was assumed by 
pyrimidine 2’ fluoration only (Peng et al., 2007) and no tumour specific aptamers of this 
composition were accessible, rRfY CD16α specific aptamers were not applied further in this 
study. Nevertheless, if future research generates high affinity rRfY tumour specific aptamers, 
the sequences presented herein could be further characterised by flow cytometry and 
minimisation and finally applied in bi-specific approaches. 
 
Selected c-Met specific aptamers CLN0003 and CLN0004 exhibited desirable properties such 
as high affinity and clear cellular binding. In addition, both aptamers shared two sequence 
motifs (Figure 21) and recognised the same epitope on c-Met (Figure 27). Although binding 
to different epitopes on c-Met would have been interesting to examine (cf. Bluemel et al., 
2010), varying affinities and minimisation results enabled the construction of 24 different bi-
specific aptamers that permitted an evaluation of binding strength and linker length for 
aptamer function. This work represents the first description of DNA aptamers that show high 
specificity and affinity to c-Met.  
 
During aptamer characterisation, application of CD16α Fc-fusion proteins in dot blot assays 
generally yielded lower affinities in the direct comparison of V158 allotypes of Fc-CD16α to 
CD16α-6His (Figure 20). This effect could be due to sterical hindrance or slight 
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conformational changes induced by the Fc-fusion. Consequently, KD values were measured in 
dot blots by applying CD16α-6His only. Since the F158 allotype of CD16α was only available 
as Fc-fusion, comparisons of aptamer binding affinity to the different allotypes could be 
carried out qualitatively only. Dot blot binding curves with Fc-CD16α(V158) and Fc-
CD16α(F158) were compared directly and resulting KD values were used not as absolute 
values but as indicators of allotype specificity. Furthermore, shifts in dot blot derived binding 
curves and resulting KD values of independent measurements could be due to variation of 
ambient temperature affecting affinity (cf. Figure 22) or conformational changes of target 
proteins that would not affect the measurable applied protein concentration but reduce the 
actual bound protein portion and hence lead to a binding curve shift.  
 
Structure determination through crystallisation was not available and application of in silico 
structure prediction via the mfold tool (Zuker, 2003) was only used to narrow minimisation 
efforts that had to be confirmed in the lab (chapter  5.3.5, cf. Sayer et al., 2004). Predictions 
for CLN0020 structure were in accordance to minimisation results and defined a 34mer core 
structure essential for CD16α binding. Removal of only one base C20, predicted to participate 
in a stem structure, reduced binding properties drastically (cf. blue to red curve in Figure 28, 
B and Figure 26). However, similar predictions could not be retrieved for any other DNA 
aptamer, possibly due to energetically unstable sequences that become structured upon ligand 
binding only (Hermann et al., 2000). Sequence comparison of c-Met aptamers CLN0003 and 
CLN0004 revealed a putatively important base G61 in CLN0004 (Figure 21). Truncation of 
only this base led to a total loss of binding in dot blot assays (orange to red curves in Figure 
28, A). These results demonstrate that sequence analyses such as structure predictions via 
mfold and sequence comparisons may not be reliable in all cases but can be an important 
source of information that subsequently can be rapidly evaluated or confirmed in the 
laboratory (as clearly reported by, for example, Sayer et al., 2004).  
 
6.2  Bi-specific aptamers 
The design of bi-specific aptamers included the development of linkers which approximately 
match the distance between CDRs and the Fc binding domain in whole antibodies. Micking 
antibody architecture may improve the chance of enabling a similar cytotoxic effect. The 
definition of aptamer linker and core sequences, with the exception of -19ntCLN0020-31nt 
(chapter  5.3.5), were only based on affinity reduction observed in truncation studies (Figure 
28). Additionally, calculated linker lengths were based on measurements of nucleotide 
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distances in single stranded portions of DNA aptamer crystal structures and it was assumed 
that linker sequences did not interact with themselves or other parts of the binding entities. 
Hence, linker lengths represented an estimate and were utilised only for an approximate 
comparison of the distances bridged in antibodies to that in bi-specific aptamers.  
 
Upon characterisation through minimisation, c-Met specific aptamer CLN0004 with an initial 
affinity of 11 nM as a 84mer (Table 1) was truncated to a 41mer with 83 nM or a 64mer 
showing 3 nM affinity (-20ntCLN0004-19nt or -20ntCLN0004, respectively in Figure 28, D). 
When a minimised CD16α specific CLN0020 was linked 5’, resulting bi-specific aptamers 
exhibited lower CD16α affinities with 134 nM of bsA3 or bsA31 with 92 nM, respectively, 
while application of nearly full length CLN0004-5nt in bsA12 shared unaltered high affinity 
of 18 nM. This fact suggests steric hindrance of a second aptamer could have distorted 
CLN0004 and thus decreased c-Met affinity. A desired shorter linker was consequently only 
accessible at the cost of reduced affinity. In contrast, the c-Met specific aptamer CLN0003 
exhibited unaltered picomolar affinity only as full length aptamer in which flanking regions 
were important but not essential for affinity (Figure 28, C). This indicated that a longer 
sequence needed to be synthesised including a shorter, less characterised linker. This aptamer 
was therefore chosen as main tumour-specific entity. CLN0003-based bi-specific aptamers 
showed c-Met affinities of 157 pM (bsA9 with long linker) to 38 nM (bsA19 containing 
truncated CLN0003-24nt), while CLN0004-derived bi-specific aptamers had expectedly 
lower affinities (92 nM of bsA31 to 370 nM of bsA6 constructed from minimised 
-20ntCLN0004-19nt at the 5’ end of the bi-specific aptamer). Both approaches were tested in 
functional ADCC assays, since both affinity and defined linker length were potentially 
important features to be evaluated and optimised.  
 
Regarding the CD16α specific portion of bi-specific aptamers, CLN0123 generally showed a 
lower CD16α affinity and was only used for the construction of the two bi-specific aptamers 
bsA15 and bsA16. CLN0020 was mainly used as a minimised 41mer (-19ntCLN0020-24nt, 
Figure 28, E). A core sequence was well characterised (Figure 26) and this aptamer contained 
a 7 nt linker from the original full length sequence that retained the aptamers suitable original 
affinity of about 20 – 50 nM. Mostly, linkers were designed based on the sequences from 
corresponding full length aptamers, since minimisation studies had shown that these 
sequences were not essential and also did not interfere with high affinity binding as 
determined in dot blot assays. As a further nucleotide-based sequence, 15 dA linkers were 
used as described by Müller and colleagues (Muller et al., 2004). In addition, PEG linkers 
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could also be introduced directly during synthesis and were used to bridge a more precisely 
defined distance between the two aptamer binding moieties. 
 
Serum stabilities were analysed in ultra low IgG FCS (chapter  4.3.13) as this was a 
component of the ADCC medium applied in later functional assays. Although the serum was 
freshly thawed, stabilities measured in mouse or human serum may vary and remain to be 
determined as key characteristics for subsequent in vivo experiments. Measured stabilities of 
single and bi-specific aptamers of 6.4 – 20.3 h are in accordance with comparable studies of 
DNA aptamer degradation in human serum and plasma that reveal strongly differing 
stabilities varying from several minutes to 42 hours (Schmidt et al., 2004; Di Giusto et al., 
2004; Peng et al., 2007). Differences may reflect diverse applied methods, serum and plasma 
samples (Shaw et al., 1995; Di Giusto et al., 2004). But more important, nuclease degradation 
is also strongly dependent on the sequence (Choi et al., 2010) and properties such as a rigid 
structure or exposed termini (Di Giusto et al., 2006). It must be noted that analogous to the 
present work, most comparable studies evaluated residual intact aptamer bands of mono-
radiolabelled sequences in gel electrophoreses, but the determination of the functional half-
life by assessment of residual binding would be a more proper analysis method (similar to Di 
Giusto et al., 2004). Nevertheless, in addition to the proof of simultaneous binding in two 
different experimental setups (chapters  5.4.3.1 and  5.4.3.2), resulting serum stabilities 
provided clear evidence of the suitability of bi-specific aptamers for functional evaluation. 
 
6.3  Functional evaluation 
Properties of 16 bi-specific aptamers had been determined to be potentially suitable for 
recruitment of NK cells to c-Met positive tumour cells; therefore, their ability to mediate 
specific target cell lysis was evaluated in functional ADCC assays. Certain bi-specific 
aptamers elicited cellular cytotoxicity of a magnitude comparable to the therapeutically 
applied monoclonal antibody cetuximab (chapter  5.5). Since the ADCC mediating antibodies 
R13 and R28 (van der Horst et al., 2009) were reported only recently and were not available 
for comparative studies, cetuximab was used as positive antibody control in ADCC assays. 
Cetuximab targets the receptor tyrosine kinase EGFR and not c-Met, hence a quantitative 
comparison of antibody- and aptamer- dependent cellular cytotoxicity was not possible. 
Positive cetuximab-mediated target cell lysis was instead used as a qualitative indicator for a 
valid experimental setup including sufficient target cell viability and suitable NK cell 
reactivity. Literature-based, quantitative potency comparisons of bi-specific aptamers and 
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antibodies or further scFv-based bi-specific formats are discussed later in this section. 
Variation in total cell lyis at high aptamer or antibody concentrations was commonly observed 
in between single measurements. Specific lysis mediated by bi-specific aptamers varied from 
approximately 20 to 60 %. Cetuximab induced 30 – 100 % lysis (Figure 33 and Figure 34) 
which is comparable to reported maximal lysis of bi-specific scFv formats (Kellner et al., 
2008; Kugler et al., 2010; Singer et al., 2010) as well as therapeutical antibodies 
alemtuzumab (appr. 40 %), trastuzumab and rituximab (40 – 80 %) and optimised variants 
eliciting up to 100 % specific cell lysis (Figure 3 in Lazar et al., 2006). Variation of maximal 
lysis in between different measurements can be due to biological variance of target cell 
preparations, blood donors with varying effector cell reactivities and CD16α V/F158 
polymorphisms. PBMCs were applied in a ratio of 80:1 to target cells which translates to an 
effector to target cell ratio of approximately 8:1 assuming ~10 % of PBMCs are CD16α 
positive effector cells (Wallace and Smyth, 2005). Specific lysis may have been increased 
through the use of IL-2 or IL-21 activated and enriched NK cells (e.g. as reported by McCall 
et al., 1999) in a higher E:T ratio. Additionally, longer incubation could have further 
increased maximal lysis (Mack et al., 1995; Figure 2 in Brischwein et al., 2006). On the other 
hand, results were significant when applying PBMCs and the design of these ex vivo assays 
was chosen to be as unartificial as possible.  
 
The coupling of bi-specific aptamers was achieved by complete synthesis rather than 
hybridisation to obtain more uniform bi-specific aptamers. This advantage for potential 
therapeutic molecules outweighs the drawback that only aptamers of the same composition 
can be linked easily. Further use of polyethylene glycol linkers was not necessary due to 
positive results with pure oligonucleotide chains, but polyethylene glycol nevertheless shares 
the advantage of well characterised linker lengths, and is therefore a potentially applicable 
linker format. Linker lengths were chosen to vary from no linker in bsA2 to approximately 
357 Å (51 nt) in bsA12 to cover a broad range of bridged distances (Table 2). As the goal of 
bi-specific aptamers was to mimic antibody effector function, linker lengths resembling the 
approximate distance between the CDRs and the Fc binding domain of antibodies were 
expected to produce a similar cytotoxic effect. As discussed above (chapter  6.2), putative 
linker lengths were estimated from truncation studies. The two binding entities in bsA17 were 
separated by approximately 49 Å, while bsA22 span 105 Å and 217 Å were supposedly 
bridged in bsA11. In a more precise examination, CLN0003 minimisation indicated that the 5’ 
flanking region is important for binding but not essential: for example, the affinity of 
truncated -13ntCLN0003 was decreased in comparison to 91 pM but still high with 12 nM 
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(Figure 28, C). Therefore, bi-specific aptamers bsA15, bsA17 and bsA22 may comprise a 
lower affinity c-Met binding entity but potentially longer linker that more accurately 
resembles the distance in antibodies. In functional ADCC assays, these high affinity bi-
specific aptamers with linkers of around 65 Å, similar to the distance in antibodies mediated 
cytotoxicity. In accordance to these findings, effective bi-specific scFv molecules contain 
Gly-Ser-linkers bridging similar distances (e.g. 110 Å in Singer et al., 2010). In addition, 
decreased cytolytic efficacies were observed with increasing linker lengths (Figure 33, F) and 
linkers with putative separation distances over ~200 Å did not elicit significant cytotoxicity, 
regardless of high affinities to both target proteins (e.g. bsA9, bsA11 and bsA12, Table 3). 
This indicates the importance of the spatial distance for polarisation of NK cells and the 
formation of a lytic synapse (as evaluated in another way by Bluemel et al., 2010). Bi-specific 
aptamers bsA17 and bsA22 combined picomolar c-Met aptamer CLN0003 linked to CD16α 
aptamer CLN0020 with affinities of ~20 nM and induced strong cytotoxicity. In addition, 
application of medium affinity aptamers CLN0004 (in bsA31 binding with 92 nM to c-Met) 
or CLN0123 (yielding 173 nM affinity to CD16α in bsA15) resulted in weaker, but still 
distinct and concentration-dependent cytotoxicity (Figure 34). This illustrates the importance 
of suitable affinities for both binding entities in bi-specific aptamers but also further validates 
the functionality of the bi-specific aptamer approach. 
 
So far, ADCC to c-Met overexpressing tumour cells was only elicited by applying two 
antibodies synergistically (van der Horst et al., 2009). Other published c-Met antibody 
therapeutics comprise only Fab-fragments (Pacchiana et al., 2010) or E. coli produced 
monovalent antibodies (MetMAb, Jin et al., 2008) that do not induce cellular cytotoxicity. 
Dilution series of bi-specific aptamers bsA17 and bsA22 indicate a half-effective 
concentration in the 10 - 50 nM range (Figure 33 and Figure 34). This is comparable to 
antibody-mediated cytotoxicity to GTL-16 cells determined to be half maximal effective at 
60 nM concentrations when two synergistical antibodies are applied (van der Horst et al., 
2009). Approved therapeutic antibodies targeting other surface proteins have been optimised 
to elicit enhanced ADCC and exhibit EC50 values in a low ng/ml range translating to low 
picomolar concentrations (Lazar et al., 2006). Since ADCC is dependent on the target protein, 
its internalisation (Thie et al., in preparation) and to some extent even on the bound epitope 
on the target protein (as indicated by different target protein variants in Bluemel et al., 2010), 
targeting other tumour-associated surface proteins such as EGFR could potentially yield 
stronger aptamer-dependent cytotoxicity as well. CD16α targeting bi-specific constructs in 
scFv formats that are comparable to bi-specific aptamers described herein show half 
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maximum effective doses at low nanomolar (Kipriyanov et al., 2002) to three-digit picomolar 
concentrations (Bruenke et al., 2004; Kugler et al., 2010), while similar constructs as tri-
specific triplebodies (sctb) mediate ADCC with low picomolar EC50 values (Kellner et al., 
2008; Singer et al., 2010). Finally, CD3 specific T cell recruiting BiTEs (e.g. MT103 and 
MT110) and similar constructs exhibit half maximum effective doses below 1 ng/ml which 
equals low picomolar to femtomolar concentrations (Mack et al., 1995; Brischwein et al., 
2006). Due to target protein dependency of ADCC, direct comparison of bi-specific aptamers 
is only feasible to c-Met antibodies applied to GTL-16 cells that only synergistically show a 
potency similar to effective bi-specific aptamers alone (as discussed above and in van der 
Horst et al., 2009).  
 
Aptamer mediated cellular cytotoxicity was dependent on the concentration of bi-specific 
aptamers and the amount of applied effector cells. Blocking of aptamer binding to effector 
cells via the competing monoclonal antibody 3G8 reduced specific cell lysis which provided 
proof for the suggested mode of action. Specific cytotoxicity was demonstrated for 
independent human gastric and lung cancer cell lines and determined 3-6 times in independent 
experiments applying effector cell of different blood donors. Taken together, these results 
validate that bi-specific aptamers can mediate specific cellular cytotoxicity.  
 
6.4  Perspective 
The aim of the project presented herein was the specific re-localisation of NK cells to tumours 
by aptamers bi-specific for CD16α expressed on NK cells and tumour specific antigen c-Met 
to elicit “aptamer-dependent cellular cytotoxicity”. This was proven in functional cellular 
ADCC assays. Bi-specific aptamers exhibit affinities similar to certain BiTEs with three-digit 
picomolar to low nanomolar TSA binding (to c-Met, in comparison to 10-9 M affinity to 
CD19 in BiTE MT103, Baeuerle et al., 2003) and medium affinity ESA binding (15 - 197 nM 
to CD16α, in comparison to 10-7 M CD3 affinity in MT103, Baeuerle et al., 2003). These 
similar characteristics point out that bi-specific aptamers could induce serial killing of NK 
cells (cf. Hoffmann et al., 2005). Counterintuitively, a decreased CD3 affinity increased 
effective T cell targeting of BiTEs (Bortoletto et al., 2002). Therefore, facile adjustment of 
CD16α affinities of cytolytic-active bi-specific aptamers based on minimisation studies 
(chapter  5.3.7) could similarily enable optimisation of NK cell recruitment and potentially 
further increase the potency of bi-specific aptamers. However, as discussed above, the 
efficacy of BiTEs clearly superseeds that of first-generation bi-specific aptamers reported 
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herein. Re-localisation of CTLs instead of NK cells by targeting CD3 instead of CD16 could 
potentially increase the efficacy of bi-specific aptamers. Furthermore, targeting other tumour 
markers, the establishment of tri-specific aptamers sharing avidity as well as a precise fine 
tuning of linker lengths could enhance their potency. Additionally, the efficacy could be 
evaluated further by examining other c-Met tumour cell lines although positive results with 
two independent tumour types already provided clear evidence that the cytolytic effect is 
assignable to other c-Met overexpressing tumour cell lines as well.  
 
Future work could focus on in vivo evaluations using xenograft mouse models (chapter  2.8). 
Transgenic mouse models expressing human CD16 receptors could be used with human 
xenograft c-Met overexpressing tumours. Secondary effects through engagement of the 
murine immune system can not be excluded, although minimal binding of bi-specific 
aptamers to murine CD16 is anticipated (chapter  5.3.1). Despite this challenge, issues of 
serum stability and poor pharmacokinetics remain to be solved. Stability can be further 
improved by usage of modified nucleotides with substituted 2’ residues (chapter  2.4.1). 
Modifications can be inserted into the already selected DNA aptamers or via an additional 
SELEX, applying pools with the appropriate compositions. Suitable mRfY aptamers, sharing 
all essential characteristics with successfully employed DNA aptamer CLN0020, are already 
available (unpublished results). Renal clearance could be reduced by antibody-approved 
approaches as PEGylation (Pendergrast et al., 2005), HESylation, PASylation, polysialylation 
or other glycosylation (reviewed in Table I in Kontermann, 2009; and Constantinou et al., 
2010). FcRn-mediated recycling of antibodies (Roopenian and Akilesh, 2007) could be 
mimicked and converted into an aptamer-format as well. Aptamers binding to the neonatal Fc 
receptor FcRn at pH 6 but not at pH 7.4 (Ralf Günther, unpublished results) could be 
additionally linked and would enable half life extension by FcRn-mediated retention in 
monocytes and endothelial cells. Independently of these approaches, the molecular mass of 
bi-specific aptamers could be sufficient even without further coupling. The half-life of a PEG-
linked aptamer of a molecular mass of 47 kDa was determined to be 23 h in mice (Burmeister 
et al., 2005). An evaluation whether, for instance, bsA17 with a molecular mass of 39.1 kDa 
would yield a similarily suitable half-life would be a first step in further evaluation in vivo.  
 
Bi-specific aptamers, generated in this work to simultaneously bind to tumour and effector 
cells, represent a suitable starting concept for the development of stable, nucleotide based 
therapeutics to mediate lysis of c-Met positive tumours. Their application range could be 
broadened by facile exchange of the tumour-specific portion with further anti-tumour 
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aptamers targeting e.g. CD52, HER2/neu or EGFR as seen in current major antibody-based 
therapies (Table 1 in Das et al., 2009). Tumour-specific cell surface targets are often 
overexpressed receptors on which binding of therapeutics should either act by inhibiting or at 
least not activating through multimerisation. In contrast to antibodies, aptamers as single 
binding entities possess the property of binding tumour-specific surface receptors without the 
risk of activation (Pacchiana et al., 2010) but can serve as inhibitors (chapter  2.2 and below). 
Conferring a second function by linkage of CD16α specific aptamers to such nucleotide based 
inhibitors would broaden their functionality to multiple modes of action. Such constructs 
could mimic most eligible features of comparable therapeutic antibody approaches, but 
exceed them, for example, with uniform and cost-effective synthesis as well as no to low 
immunogenicity (White et al., 2000; Kaur et al., 2008).  
 
Internalisation was not evaluated for c-Met or CD16α specific aptamers. In case of possible 
internalisation upon high affinity binding, these aptamers could be used as well in further bi-
valent constructs for the delivery of cytotoxic substances. Other cancer target specific 
aptamers have been selected among others against MUC-1, PSMA, EGFR, CTL-A4, PDGF-R 
and VEGF as single binding entities only (Kaur et al., 2008; Table 2 in Das et al., 2009). 
Internalising target molecules were also addressed to specifically deliver fused payloads, e.g. 
as siRNA or cis-platin to target cells (Chu et al., 2006; Dhar et al., 2008; Zhou et al., 2009a). 
Most other linkage of aptamers aimed at an affinity increase by avidity (Santulli-Marotto et 
al., 2003; Muller et al., 2007; Kim et al., 2008). Müller and colleagues coupled aptamers to 
increase enzyme inhibition (Muller et al., 2008, and chapter  2.2). Furthermore, two copies of 
a receptor specific RNA aptamer were assembled on an olignucleotide-based scaffold to 
induce multimerisation of target receptors. This proved that linkage can convert single binders 
into receptor-activating aptamers (Dollins et al., 2008). In a similar approach, McNamara and 
co-workers hybridised two copies of an aptamer targeting a T cell receptor that induced co-
stimulation of these effector cells and led to tumour growth inhibition in mice (McNamara et 
al., 2008). To the author’s knowledge, the work presented herein describes for the first time a 
gain of tumour-effective function of two distinct binding entities by linkage into a bi-specific 
aptamer mediating tumour cell lysis.  
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8 APPENDIX 
8.1 Supporting information 
 
Table 4: Specifications of CD16 DNA SELEX. 
Target protein was CD16α-6His while CD16β-10His was applied for counterselection, tRNA served as 
unspecific competitor. PCR cycles needed to re-amplify a certain amount of aptamers were monitored and are 
highlighted. MTP, microtiter plate.  
 DNA filter SELEX 01.09  DNA filter SELEX 02.09 
Round 
DNA 
conc. 
(µM) 
Protein 
conc. 
(µM) 
Neg. 
sel. 
Counter 
sel. 
(µM) 
tRNA 
(mg/ml) 
No. of 
PCR 
cycles 
 
DNA 
conc. 
(µM) 
Protein 
conc. 
(µM) 
Neg. 
sel. 
Counter 
sel. 
(µM) 
tRNA 
(mg/ml) 
No. of 
PCR 
cycles 
              
1 1.66 1 none 0 0 10  1.66 1 none 0 0 10 
2 0.62 1 filter 0 0 15  0.83 0.96 filter 1 0 18 
3 1 1 filter 0 0 20  1 1 filter 1 0 20 
4 1 1 filter 0 0.1 17  0.75 1 filter 1 0 28 
5 1 0.8 filter 0 0.1 20  1 1 filter 1 0.1 20 
6 1 0.8 filter 0 0.1 10  1 0.8 filter 0.8 0.1 9 
7 0.62 0.6 filter 0 0.1 10  0.69 0.6 filter 0.6 0.1 11 
8 0.69 0.6 filter 0 0.1 7  0.96 0.6 filter 0.6 0.1 8 
9 0.55 0.6 filter 0 1 10  0.56 0.6 filter 0.6 1 10 
              
 DNA MTP SELEX 01.09  DNA MTP SELEX 02.09 
              
10 0.7 0.2 none 1 0 14  0.7 0.2 none 1 0 14 
11 0.5 0.2 none 1 0 21  0.6 0.2 none 1 0 18 
12 1 0.2 filter 0 1 11  1 0.6 filter 0 1 11 
 
Table 5: Specifications of CD16 DNA cell SELEX 
Aptamers were selected alternating against recombinant Jurkat CD16α V158 or F158 cells with counterselection 
with maternal Jurkat E6.1 cells from the second round on and at least as many cells as for positive selection. 
tRNA served as unspecific competitor. PCR cycles needed to re-amplify a certain amount of aptamers were 
monitored and are highlighted.  
 DNA cell SELEX 01.09  DNA cell SELEX 02.09 
Round 
DNA 
conc. 
(µM) 
Cells 
(x107) 
Allo-
type 
E6.1 
cells 
(x107) 
tRNA 
(mg/ml) 
No. of 
PCR 
cycles 
 
DNA 
conc. 
(µM) 
Cells 
(x107) 
Allo-
type 
E6.1 
cells 
(x107) 
tRNA 
(mg/ml) 
No. of 
PCR 
cycles 
              
4 1 0.36 V158 0 0 20        
5 1 0.75 F158 0.75 0 19        
6 1 0.2 V158 0.85 0.1 18  1 0.36 V158 0 0 20 
7 1 0.4 F158 0.75 0.1 15  1 0.75 F158 0.75 0 17 
8 1 0.3 V158 0.75 1 16  1 0.2 V158 0.85 0.1 16 
9 1 0.3 F158 0.3 1 16  1 0.4 F158 0.75 0.1 15 
10 
       1 0.3 V158 0.75 1 16 
11 
       1 0.3 F158 0.3 1 16 
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Table 6: Overview of the frequency of all selected CD16 DNA aptamers in all analysed pools. 
Filter and MTP SELEX pools 01.09 and 02.09 analysed jointly 
 
Frequency of aptamers in the respective SELEX pool (%) 
Code filter R3 filter R5 filter R9 MTP R12 cell 01.09 R7 
cell 
01.09 R9 
cell 
02.09 R9 
cell 02.09 
R11 
         
single seq. 100 79 14 39 18 3 19 6 
CLN0015 0 5 31 15 4 2 4 3 
CLN0016 0 0 10 3 0 0 0 0 
CLN0017 0 0 9 4 0 0 0 0 
CLN0018 0 0 10 4 0 0 0 0 
CLN0019 0 3 5 14 0 0 0 0 
CLN0020 0 0 4 0 0 0 8 2 
CLN0021 0 3 3 4 33 40 20 24 
CLN0022 0 4 6 1 38 39 21 2 
CLN0023 0 0 2 0 0 0 0 0 
CLN0024 0 4 3 0 0 0 0 0 
CLN0025 0 0 1 0 0 0 0 0 
CLN0026 0 2 1 0 0 0 0 0 
CLN0027 0 0 1 2 0 0 0 0 
CLN0028 0 0 0 6 4 6 0 2 
CLN0029 0 0 0 3 0 0 0 0 
CLN0030 0 0 0 2 0 0 0 0 
CLN0031 0 0 0 2 0 0 0 0 
CLN0032 0 0 0 1 0 0 4 3 
CLN0118 0 0 0 0 2 9 3 27 
CLN0119 0 0 0 0 0 0 4 1 
CLN0120 0 0 0 0 0 0 3 6 
CLN0121 0 0 0 0 0 0 2 2 
CLN0122 0 0 0 0 0 0 2 2 
CLN0123 0 0 0 0 0 1 2 2 
CLN0124 0 0 0 0 0 0 2 1 
CLN0125 0 0 0 0 0 0 2 0 
CLN0126 0 0 0 0 0 0 0 9 
CLN0127 0 0 0 0 0 0 1 3 
CLN0128 0 0 0 0 0 0 1 3 
 
8.2 Abbreviations 
A     Nucleotide adenosine 
aa    Amino acid 
ADCC    Antibody-dependent cellular cytotoxicity 
Amp     Ampicillin 
APS     Ammoniumpersulfate 
BID    BH3-interacting domain death agonist protein 
bp     Base pair  
BSA     Bovine serum albumin 
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C    Nucleotide Cytidine 
CAD    Caspase-activated deoxyribonuclease 
CD     Cluster of differentiation 
CD16    Fc γ receptor III 
CRP    C-reactive protein 
CTL    Cytotoxic T lymphocyte, T cell 
(k)Da     (kilo-)Dalton 
dH2O    Distilled water 
DNA     Deoxyribonucleic acid  
dNTPs    Desoxyribonucleotide triphosphate 
ECD    Extracellular domain 
FACS    Fluorescence-activated cell sorting 
FcγRIII    Fc γ receptor III or CD16 
FcR    Fc receptor 
FcRn    Neonatal Fc receptor 
FCS    Fetal calf serum 
G    Nucleotide Guanosine 
GM-CSF    Granulocyte-macrophage colony stimulating factor 
GPI    Glycosylphosphatidyl inositol 
HGF / SF   Hepatocyte growth factor / scatter factor 
HGFR / c-Met  HGF receptor 
His     Histidin 
HPLC    High performance liquid chromatography 
iCAD    Inhibitor of caspase-activated deoxyribonuclease 
ICAM-1    Intercellular adhesion molecule 1 
IEF    Isoelectrical focussing 
IFNγ     Interferon γ 
IgG    Immunoglobuline G 
IL-8/NAP-1    Interleukin 8 
IP-10     IFN induced protein 10 
ITAM    Immunoreceptor tyrosine-based activating motif 
ITIM    Immunoreceptor tyrosine-based inhibitory motif 
LB medium   Luria-Bertani medium 
LFA-1    Lymphocyte function-associated antigen 1 
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LTN/ATAC    Lymphotactin 
MCS     Multiple cloning site 
MDC     Macrophage-derived chemokine  
MIG     Monokine induced IFNγ 
MIP-1α/β    Macrophage-inflammatory protein 1 
NC    Nitrocellulose 
NK cells   Natural killer cells 
nt    nucleotide, length of single stranded oligonucleotide chain 
OD     Optical density  
PAGE     Polyacrylamide gel electrophoresis 
PBMCs   Peripheral blood mononuclear cells (MNCs) 
PCR    Polymerase chain reaction 
PE    R-phycoerythrin 
PI     Propidiumiodid 
pI    Isoelectrical point 
PVDF    Polyvinylidene fluoride 
RANTES    Regulated on activation, normal T cell expressed and secreted 
RNA    Ribonucleic acid 
RT    Room temperature, ambient temperature  
RTK    Receptor tyrosine kinase 
rpm     Revolutions per minute  
SA-PE    Streptavidin-R-phycoerythrin conjugate 
sctb    Single chain triabody 
SELEX   Systematic evolution of ligands by exponential enrichment 
SDS     Sodium dodecylsulfate 
T    Nucleotide Thymidine 
tBID    Truncated BH3-interacting domain death agonist protein 
TEMED    N,N,N,N’-Tetramethylendiamine 
TNFα     Tumor necrosis factor α 
Tris     Tris(hydroxymethyl)aminomethane 
v/v    Volume per volume 
w/v    Weight per volumen 
ZAP-70   Z-associated protein of 70 kDa 
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